<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>y50447exv2w1.htm
<DESCRIPTION>EX-2.1: AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">EXECUTION VERSION
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 3px double #000000; font-size: 1px">&nbsp;</DIV>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Dated as of February&nbsp;25, 2008</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>among</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Galderma Laboratories, Inc.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Galderma Acquisition Inc.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CollaGenex Pharmaceuticals, Inc.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 3px double #000000; font-size: 1px">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE I THE OFFER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Offer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Actions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Directors of the Company</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Stockholders Meeting</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Offer Documents; Schedule 14D-9; Proxy Statement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE II THE MERGER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Merger</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Closing</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effective Time</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effects of the Merger</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Incorporation and Bylaws of the Surviving Corporation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Directors and Officers of the Surviving Corporation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.7</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conversion of Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.8</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exchange of Certificates</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Appraisal Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Options</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization, Standing and Corporate Power</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Capitalization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authority; Noncontravention; Voting Requirements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Approvals</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company SEC Documents; Financial Statements; Undisclosed Liabilities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Absence of Certain Changes</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.7</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Legal Proceedings</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.8</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance With Laws; Permits; Regulatory Compliance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Information Supplied</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Matters</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.11</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employee Benefits and Labor Matters</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.12</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contracts</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.13</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Environmental Matters</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.14</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Intellectual Property</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.15</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Products and Operations; Manufacturing</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.16</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.17</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Real Property</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.18</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Financial Advisor</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.19</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers and Other Advisors</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.20</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Other Representations or Warranties</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization and Standing</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authority; Noncontravention</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Approvals</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Information Supplied</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ownership and Operations of Purchaser</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Capital Resources</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.7</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Legal Proceedings</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.8</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers and Other Advisors</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ownership of Company Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Reliance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE V ADDITIONAL COVENANTS AND AGREEMENTS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conduct of Business</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Solicitations</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Efforts to Consummate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Public Announcements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Information; Confidentiality</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notification of Certain Matters</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.7</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification and Insurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.8</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fees and Expenses</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rule 16b-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employee Matters</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.11</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delisting</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.12</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Takeover Laws</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.13</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Stockholder Litigation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.14</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchase of Shares of Series D-1 Preferred Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE VI CONDITIONS TO THE MERGER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 6.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Each Party&#146;s Obligation to Effect the Merger</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE VII TERMINATION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 7.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 7.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Termination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 7.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination Fees</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">ARTICLE VIII MISCELLANEOUS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Survival of Representations, Warranties and Agreements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment or Supplement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Extension of Time, Waiver, Etc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assignment</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement; No Third-Party Beneficiaries</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.7</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law; Jurisdiction; Waiver of Jury Trial</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.8</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Specific Enforcement; Remedies</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.11</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Definitions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58
</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 8.12</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Interpretation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Annex A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions of the Offer<BR>
Annex B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred Stockholder Agreement

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This AGREEMENT AND PLAN OF MERGER, dated as of February&nbsp;25, 2008 (this &#147;<U>Agreement</U>&#148;),
is among Galderma Laboratories, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), Galderma
Acquisition Inc., a Delaware corporation and a wholly owned Subsidiary of Parent
(&#147;<U>Purchaser</U>&#148;), and CollaGenex Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;). Certain terms used in this Agreement without definition shall have their
meanings as defined in <U>Section&nbsp;8.11</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the respective Boards of Directors of Parent, Purchaser and the Company each deems it
advisable that Parent acquire the Company on the terms and subject to the conditions provided for
in this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, in furtherance thereof it is proposed that such acquisition be accomplished by
(a)&nbsp;Purchaser commencing a tender offer to purchase all of the shares of common stock, $0.01 par
value, of the Company (&#147;<U>Company Common Stock</U>&#148;) issued and outstanding (each, a
&#147;<U>Share</U>&#148; and, collectively, the &#147;<U>Shares</U>&#148;), for $16.60 per Share (such amount or any
greater amount per Share paid pursuant to the Offer being hereinafter referred to as the &#147;<U>Offer
Price</U>&#148;), subject to any required withholding of Taxes, net to the sellers in cash, on the terms
and subject to the conditions provided for in this Agreement (such cash tender offer, as it may be
amended from time to time as permitted by this Agreement, the &#147;<U>Offer</U>&#148;), and (b)&nbsp;following
the consummation of the Offer, the merger of Purchaser with and into the Company, with the Company
being the surviving corporation, in accordance with the General Corporation Law of the State of
Delaware (the &#147;<U>DGCL</U>&#148;), pursuant to which (i)&nbsp;the Shares (other than certain Shares as
provided in <U>Section&nbsp;2.7(b)</U> and Dissenting Shares) will be converted into the right to
receive the Offer Price and (ii)&nbsp;the outstanding shares (each, a &#147;<U>Series&nbsp;D-1 Share</U>&#148; and,
collectively, the &#147;<U>Series&nbsp;D-1 Shares</U>&#148;) of the Series&nbsp;D-1 Cumulative Convertible Preferred
Stock, $0.01 par value, of the Company (the &#147;<U>Series&nbsp;D-1 Preferred Stock</U>&#148;) (other than
certain Series&nbsp;D-1 Shares as provided in <U>Section&nbsp;2.7(b)</U> and Dissenting Shares) will be
converted into the right to receive an amount of cash equal to the product of the number of shares
of Company Common Stock into which such Series&nbsp;D-1 Shares are convertible pursuant to and in
accordance with Section&nbsp;A.5 of the Certificate of Designation, Preferences and Rights of the Series
D-1 Cumulative Convertible Preferred Stock, dated as of December&nbsp;19, 2005 (the &#147;<U>Series&nbsp;D-1
Preferred Stock Certificate of Designation</U>&#148;) multiplied by the Offer Price, subject to any
required withholding of Taxes, on the terms and subject to the conditions provided for in this
Agreement (the &#147;<U>Merger</U>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the respective Boards of Directors of the Company, Parent (on its own behalf and as
the sole direct or indirect stockholder of Purchaser), and Purchaser have approved this Agreement
and resolved that the transactions contemplated by this Agreement are advisable and in the best
interests of their respective stockholders, including the consummation of the Offer and the Merger,
upon the terms and subject to the conditions set forth in this Agreement and in accordance with the
relevant provisions of the DGCL;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company Board has resolved to recommend that the holders of Company Common Stock
(the &#147;<U>Company Stockholders</U>&#148;) accept
the Offer, tender their shares of Company Common Stock in the Offer, and, to the extent
required by applicable Law, approve
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Merger and adopt this Agreement and the transactions
contemplated by this Agreement (including the Offer and the Merger), in each case, upon the terms
and subject to the conditions set forth in this Agreement; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, concurrently with the execution of this Agreement, Parent, Purchaser and holders
(collectively, the &#147;<U>Company Preferred Stockholders</U>&#148;) of 90% or more of the Series&nbsp;D-1
Shares have entered into a preferred stock purchase and voting agreement, dated as of the date of
this Agreement (the &#147;<U>Preferred Stockholder Agreement</U>&#148;), pursuant to which each Company
Preferred Stockholder has agreed to, among other things, sell, convey, transfer, assign and deliver
to Purchaser all of such Company Preferred Stockholder&#146;s Series&nbsp;D-1 Shares immediately following
the time Purchaser purchases Shares in the Offer, a copy of which Preferred Stockholder Agreement
is attached as <U>Annex B</U> hereto;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements
contained in this Agreement, and intending to be legally bound hereby, Parent, Purchaser and the
Company hereby agree as follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>The Offer</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.1 <U>The Offer</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Provided that this Agreement shall not have been terminated in accordance with
<U>Article&nbsp;VII</U> and none of the events or circumstances set forth in clause (iii)&nbsp;of <U>Annex
A</U> hereto shall have occurred and be existing (and shall not have been waived by Purchaser),
Purchaser shall (and Parent shall cause Purchaser to) commence (within the meaning of Rule&nbsp;14d-2
under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder (the &#147;<U>Exchange Act</U>&#148;)) the Offer to purchase all of the Shares at the Offer Price
as promptly as reasonably practicable, but in no event later than ten (10)&nbsp;Business Days, after the
date of this Agreement; <U>provided</U>, <U>however</U>, that such ten (10)&nbsp;Business Day deadline
to commence the Offer will be extended to such date as the Company is ready to file the Schedule
14D-9 on the same date as the commencement of the Offer. The obligation of Purchaser to accept for
payment and pay for Shares tendered pursuant to the Offer shall be subject only to (x)&nbsp;the
satisfaction of the condition that at the expiration of the Offer there be validly tendered in
accordance with the terms of the Offer and not withdrawn that number of Shares which, when taken
together with Shares (if any) then owned by Parent or any of its Subsidiaries, represents more than
50% of the Shares then outstanding determined on a fully-diluted basis (on a &#147;fully-diluted basis&#148;
meaning the number of Shares then issued and outstanding <I>plus </I>all shares of Company Common Stock
which the Company may be required to issue as of such date pursuant to options, warrants,
convertible securities (other than the shares of Series&nbsp;D-1 Preferred Stock owned, beneficially or
of record, as of the date hereof, by the Company Preferred Stockholders) or similar obligations
regardless of the conversion or exercise price, the vesting schedule or other terms and conditions
thereof) (the &#147;<U>Minimum Condition</U>&#148;), and (y)&nbsp;the satisfaction (or waiver by Purchaser) of
the other conditions
set forth in <U>Annex A</U> hereto. Purchaser expressly reserves the right to waive any of
such conditions (other than the Minimum Condition), to increase the price per Share payable in the
Offer and to make any other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">changes in the terms of the Offer; <U>provided</U>, <U>however</U>,
that no change may be made without the prior written consent of the Company which decreases the
price per Share payable in the Offer, changes the form of consideration payable in the Offer,
reduces the maximum number of Shares sought to be purchased in the Offer, imposes conditions to the
Offer in addition to, or modifies or amends, the conditions set forth in <U>Annex A</U> hereto,
waives the Minimum Condition or makes any other changes in the terms of the Offer that are in any
manner adverse to the holders of Shares or, except as provided below, extends the expiration date
of the Offer. Notwithstanding the foregoing, subject to the right of the parties to terminate this
Agreement in accordance with <U>Section&nbsp;7.1</U>, Purchaser may, and at the request of the Company
shall, extend the Offer (i)&nbsp;beyond the initial scheduled expiration date, which shall be twenty
(20)&nbsp;business days (as defined in Rule&nbsp;14d-1 under the Exchange Act) following the date of
commencement of the Offer, or any subsequent scheduled expiration date, if, at the scheduled
expiration of the Offer, any of the conditions to Purchaser&#146;s obligation to accept for payment and
to pay for Shares tendered shall not be satisfied or, to the extent permitted by this Agreement,
waived and (ii)&nbsp;for any period required by any rule, regulation or interpretation of the U.S.
Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) or the staff thereof applicable to the
Offer; <U>provided</U> that Purchaser shall not be required to extend the Offer to a date later
than the Outside Date. Each extension of the Offer pursuant to clause (i)&nbsp;of the preceding
sentence shall not exceed ten (10)&nbsp;Business Days (or such longer period as the Company and
Purchaser may agree in writing in any particular instance) or such fewer number of days that
Purchaser reasonably believes are necessary to cause the conditions of the Offer set forth in
<U>Annex A</U> hereto to be satisfied. Subject to the terms of this Agreement and the
satisfaction or earlier waiver of all the conditions of the Offer set forth in <U>Annex A</U>
hereto as of any expiration date of the Offer, Purchaser shall (and Parent shall cause Purchaser
to) accept for payment and pay for all Shares validly tendered and not withdrawn pursuant to the
Offer promptly after it is permitted to do so under applicable Laws (but in no event later than two
(2)&nbsp;Business Days after such expiration date of the Offer). In addition, if, at the expiration
date of the Offer, all of the conditions to the Offer have been satisfied (or, to the extent
permitted by this Agreement, waived by Purchaser) but the number of Shares validly tendered and not
withdrawn pursuant to the Offer, when taken together with Shares, if any, then owned by Parent and
its Subsidiaries, constitutes less than 90% of the Shares then outstanding, determined on a
fully-diluted basis (as defined in <U>Section&nbsp;1.1(a)</U>), Purchaser may, or at the Company&#146;s
request (subject to applicable Laws) shall, provide for one or more &#147;subsequent offering periods&#148;
(as contemplated by Rule&nbsp;14d-11 under the Exchange Act) for at least three (3)&nbsp;but not more than
twenty (20)&nbsp;Business Days following the Purchase Date, in which event Purchaser shall (and Parent
shall cause Purchaser to) (A)&nbsp;give the required notice of such subsequent offering period and
(B)&nbsp;immediately accept and promptly pay for all Shares tendered during the &#147;initial offering
period&#148; and immediately accept and promptly pay for all Shares tendered during any &#147;subsequent
offering period,&#148; in each case in accordance with Rule&nbsp;14d-11 under the Exchange Act. On or prior
to the date that Purchaser becomes obligated to pay for Shares pursuant to the Offer, Parent shall
provide or cause to be provided to Purchaser the funds necessary to pay for all Shares that
Purchaser becomes so obligated to pay for pursuant to the Offer. The Offer Price shall, subject to
any required withholding of Taxes, be net to the sellers in cash, upon the terms and subject to
the conditions of the Offer. The Company agrees that no shares of Company Common Stock held
by the Company or any of its Subsidiaries will be tendered in the Offer.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As promptly as practicable on the date of commencement of the Offer, Parent and Purchaser
shall file with the SEC a Tender Offer Statement on Schedule&nbsp;TO (together with all amendments,
supplements and exhibits thereto, the &#147;<U>Schedule&nbsp;TO</U>&#148;) with respect to the Offer. The
Schedule&nbsp;TO shall contain or incorporate by reference an offer to purchase and forms of the related
letter of transmittal and all other ancillary Offer documents (collectively, together with all
amendments, supplements and exhibits thereto, the &#147;<U>Offer Documents</U>&#148;). Parent and Purchaser
shall cause the Offer Documents to be disseminated to the holders of the Shares as and to the
extent required by applicable federal securities Laws and rules and regulations promulgated
thereunder. Parent and Purchaser, on the one hand, and the Company, on the other hand, shall
promptly correct any information provided by them for use in the Offer Documents if and to the
extent that it shall be or shall have become false or misleading in any material respect, and
Parent and Purchaser shall cause the Offer Documents as so corrected to be filed with the SEC and
disseminated to holders of the Shares, in each case, as and to the extent required by applicable
federal securities Laws and rules and regulations promulgated thereunder. The Company and its
counsel shall be given a reasonable opportunity to review and comment upon the Offer Documents
before they are filed with the SEC and disseminated to holders of Shares. In addition, Parent and
Purchaser shall provide the Company and its counsel with any comments that Parent or Purchaser or
their counsel may receive from time to time from the SEC or its staff with respect to the Offer
Documents promptly after the receipt of such comments, consult with the Company and its counsel
prior to responding to any such comments and provide the Company with copies of all such responses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Purchaser shall be entitled to deduct and withhold from the consideration otherwise
payable pursuant to the Offer (or in connection with any subsequent offering period) any such
amounts as are required to be deducted and withheld with respect to the making of such payment
under the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), or under any provision of
state, local or foreign Tax Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.2 <U>Company Actions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As promptly as practicable on the date of commencement of the Offer, the Company shall
file with the SEC a Solicitation/Recommendation Statement on Schedule&nbsp;14D-9 (together with all
amendments, supplements and exhibits thereto, the &#147;<U>Schedule&nbsp;14D-9</U>&#148;) which, subject to
<U>Section&nbsp;5.2</U>, shall contain the Company Recommendation. The Company shall cause the
Schedule&nbsp;14D-9 to be disseminated to holders of the Shares as and to the extent required by
applicable federal securities Laws and rules and regulations promulgated thereunder. The Company,
on the one hand, and each of Parent and Purchaser, on the other hand, shall promptly correct any
information provided by it for use in the Schedule&nbsp;14D-9 if and to the extent that it shall be or
shall have become false or misleading in any material respect, and the Company shall cause the
Schedule&nbsp;14D-9 as so corrected to be filed with the SEC and disseminated to holders of the Shares,
in each case, as and to the extent required by applicable federal securities Laws and rules and
regulations promulgated thereunder. Parent and its counsel shall be given a reasonable opportunity
to review and comment upon the Schedule&nbsp;14D-9 before it is filed with the SEC and disseminated to
holders of Shares. In addition, the Company shall provide Parent and its counsel with any comments
that the Company or its counsel may receive from time to time from the SEC or its staff with
respect to
the Schedule&nbsp;14D-9 promptly after the receipt of such comments,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">consult with Parent and its
counsel prior to responding to any such comments and provide Parent with copies of all such
responses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall promptly furnish Purchaser with mailing labels containing the names and
addresses of all record holders of Shares and with security position listings of Shares held in
stock depositories, each as of a recent date, together with all other available listings and
computer files containing names, addresses and security position listings of record holders and
beneficial owners of Shares. The Company shall furnish Purchaser with such additional information,
including updated listings and computer files of stockholders, mailing labels and security position
listings, and such other assistance as Parent, Purchaser or their agents may reasonably require in
communicating the Offer to the record and beneficial holders of Shares. Subject to the
requirements of applicable Laws, and except for such steps as are necessary to disseminate the
Offer Documents and any other documents necessary to consummate the Offer or the Merger, Parent and
Purchaser shall hold in confidence the information contained in such labels, listings and files,
shall use such information solely in connection with the Offer and the Merger, and, if this
Agreement is terminated in accordance with <U>Section&nbsp;7.1</U> or if the Offer is otherwise
terminated, shall promptly deliver or cause to be delivered to the Company all copies of such
information, labels, listings and files then in their possession or in the possession of their
agents or representatives.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company grants to Parent and Purchaser an irrevocable option (the &#147;<U>Merger
Option</U>&#148;) to purchase up to that number of newly issued shares of Company Common Stock (the
&#147;<U>Merger Option Shares</U>&#148;) equal to the number of shares of Company Common Stock that, when
added to the number of shares of Company Common Stock owned by Parent and Purchaser immediately
following consummation of the Offer, shall constitute one share more than 90% of the shares of
Company Common Stock then outstanding on a fully-diluted basis (after giving effect to the issuance
of the Merger Option Shares) for consideration per Merger Option Share equal to the Offer Price;
<U>provided</U>, <U>however</U>, that the obligation of the Company to deliver Merger Option
Shares upon the exercise of the Merger Option is subject to the condition that no judgment,
injunction, order or decree shall prohibit the exercise of the Merger Option or the delivery of the
Merger Option Shares in respect of such exercise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Merger Option shall be exercisable only after the purchase of and payment for shares
of Company Common Stock pursuant to the Offer by Parent or Purchaser as a result of which Parent
and Purchaser own beneficially at least 80% of the outstanding shares of Company Common Stock on a
fully-diluted basis. The Merger Option shall not be exercisable to the extent that the number of
shares of Company Common Stock subject thereto exceeds (x)&nbsp;the number of authorized shares of
Company Common Stock available for issuance or (y)&nbsp;the number of shares of Company Common Stock
that may be issued to Parent and Purchaser without obtaining stockholder approval under the rules
of NASDAQ.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;In the event that Parent or Purchaser wish to exercise the Merger Option, Purchaser shall
give the Company one (1)&nbsp;Business Day&#146;s prior written notice specifying the number of shares of
Company Common Stock that are owned by Parent and Purchaser immediately following consummation of
the Offer and specifying a place and a time for the
closing of the purchase. The Company shall, as soon as practicable following receipt of such
notice, deliver written notice to Purchaser specifying the number of Merger Option Shares. At
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the
closing of the purchase of the Merger Option Shares, Parent or Purchaser shall pay to the Company
an amount equal to the product of (i)&nbsp;the number of shares of Company Common Stock purchased
pursuant to the Merger Option, multiplied by (ii)&nbsp;the Offer Price, which amount shall be paid in
cash (by wire transfer or cashier&#146;s check) or, at the election of Parent or Purchaser, by delivery
of a promissory note having full recourse to Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Parent and Purchaser acknowledge that the Merger Option Shares which Parent and Purchaser
may acquire upon exercise of the Merger Option will not be registered under the Securities Act and
will be issued in reliance upon an exemption thereunder for transactions not involving a public
offering. Parent and Purchaser represent and warrant to the Company that Purchaser is, or will be
upon the purchase of the Merger Option Shares, an &#147;accredited investor&#148;, as defined in Rule&nbsp;501 of
Regulation&nbsp;D under the Securities Act. Parent and Purchaser agree that the Merger Option and the
Merger Option Shares to be acquired upon exercise of the Merger Option are being and will be
acquired by Purchaser for the purpose of investment and not with a view to, or for resale in
connection with, any distribution thereof (within the meaning of the Securities Act).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.3 <U>Directors of the Company</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Upon the purchase of Shares pursuant to the Offer and for so long thereafter as Parent and
its Subsidiaries own in the aggregate more than 50% of the outstanding Shares (the &#147;<U>Board
Representation Period</U>&#148;), determined on a fully-diluted basis (as defined in
<U>Section&nbsp;1.1(a)</U>), Parent shall be entitled to designate for appointment or election to the
Company Board, upon written notice to the Company, such number of directors, rounded up to the next
whole number, as is equal to the product obtained by multiplying the total number of directors on
the Company Board (after giving effect to the directors designated by Parent pursuant to this
sentence) by the percentage that the number of Shares so owned by Parent and its Subsidiaries bears
to the total number of Shares then outstanding. In furtherance thereof, the Company shall, upon
request of Parent, use its reasonable best efforts, subject to compliance with applicable
securities Laws and applicable rules of the NASDAQ Global Market (&#147;<U>NASDAQ</U>&#148;), to promptly
cause Parent&#146;s designees (and any replacement designees in the event that any designee shall no
longer be on the Company Board) to be so appointed or elected to the Company Board and, in
furtherance thereof, to the extent necessary, use its reasonable best efforts to increase the size
of the Company Board or obtain the resignation of such number of its directors as is necessary to
give effect to the foregoing provision. During the Board Representation Period, subject to
<U>Section&nbsp;1.3(c)</U>, the Company will cause individuals designated by Parent to constitute such
number of members of each committee of the Company Board, rounded up to the next whole number, that
represents the same percentage as such individuals represent on the Company Board, other than any
committee established to take action under this Agreement which committee shall be composed only of
Independent Directors. Notwithstanding the foregoing, until the Effective Time, the Company Board
shall have at least two (2)&nbsp;directors who are directors of the Company on the date of this
Agreement and who are not officers of the Company or any of its Subsidiaries (&#147;<U>Independent
Directors</U>&#148;); <U>provided</U> for the avoidance of doubt, the director elected by the holders
of the Series&nbsp;D-1 Preferred Stock,
pursuant to Section&nbsp;A.8 of the Series&nbsp;D-1 Preferred Stock Certificate of Designation may
constitute an Independent Director for purposes of this <U>Section&nbsp;1.3(a)</U>; and
<U>provided</U>, <U>further</U>, that if the number of Independent Directors shall be reduced
below two (2)&nbsp;for any reason whatsoever (or if immediately following
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">consummation of the Offer
there are not at least two (2)&nbsp;then-existing directors of the Company who are (A)&nbsp;Qualified Persons
and (B)&nbsp;willing to serve as Independent Directors), then the number of Independent Directors
required hereunder shall be one (1), unless the remaining Independent Director is able to identify
a person who is not then an officer or Affiliate of the Company, Parent or any of their respective
Subsidiaries (any such person being referred to herein as a &#147;<U>Qualified Person</U>&#148;; it being
understood that, for purposes of this definition, a person that would otherwise not be considered
an Affiliate of the Company shall not be deemed an Affiliate of the Company solely because he or
she is a director of the Company), willing to serve as an Independent Director, in which case such
remaining Independent Director shall be entitled to designate any such Qualified Person to fill
such vacancy, and such designated Qualified Person shall be deemed to be an Independent Director
for purposes of this Agreement, or if no Independent Directors then remain, the other directors
shall be required to designate two (2)&nbsp;Qualified Persons to fill such vacancies, and such persons
shall be deemed to be Independent Directors for purposes of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall promptly take all actions required pursuant to Section&nbsp;14(f) of the
Exchange Act and Rule&nbsp;14f-l promulgated thereunder in order to fulfill its obligations under
<U>Section&nbsp;1.3(a)</U>, including mailing to the Company&#146;s stockholders the information required by
such Section&nbsp;14(f) and Rule&nbsp;14f-1 (which the Company shall mail together with the Schedule&nbsp;14D-9 if
it receives from Parent and Purchaser the information below on a basis timely to permit such
mailing) as is necessary to fulfill the Company&#146;s obligations under <U>Section&nbsp;1.3(a)</U>. The
Company&#146;s obligation to appoint Parent&#146;s designees to the Company Board pursuant to
<U>Section&nbsp;1.3(a)</U> shall be subject to compliance with Section&nbsp;14(f) of the Exchange Act and
Rule&nbsp;14f-1 promulgated thereunder and to Parent&#146;s compliance with its obligations under the
following sentence. Parent and Purchaser shall supply the Company such information with respect to
Parent and Purchaser and their nominees, officers, directors and Affiliates required by such
Section&nbsp;14(f) and Rule&nbsp;14f-1 as is necessary in connection with the appointment of any of Parent&#146;s
designees under <U>Section&nbsp;1.3(a)</U>, and Parent and Purchaser shall be solely responsible for
the accuracy and completeness of such information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Following the election or appointment of Parent&#146;s designees pursuant to
<U>Section&nbsp;1.3(a)</U> and prior to the Effective Time, the approval by affirmative vote or written
consent of a majority of the Independent Directors then in office (or, if there shall be only one
(1)&nbsp;Independent Director then in office, the Independent Director) (the &#147;<U>Independent Director
Approval</U>&#148;) shall be required to authorize (and such authorization shall constitute the
authorization of the Company Board and no other action on the part of the Company, including any
action by any other committee thereof or any other director of the Company, shall, unless otherwise
required by applicable Law, be required or permitted to authorize) (i)&nbsp;any amendment or termination
of this Agreement by the Company, (ii)&nbsp;any extension by the Company of time for performance of any
obligation or action under this Agreement by Parent or Purchaser, (iii)&nbsp;any waiver, exercise or
enforcement of any of the Company&#146;s rights under this Agreement, (iv)&nbsp;any other action by the
Company which could adversely affect the interests of the stockholders of the Company (other than
Parent or any of its Affiliates) or (v)&nbsp;any amendment of the Company Charter Documents. The
Independent
Directors shall have the authority to retain such counsel and other advisors at the expense of
the Company as are reasonably appropriate to the exercise of their duties in connection with this
Agreement, subject to approval by the Company of the terms of such retention, which approval shall
not be unreasonably withheld, conditioned or delayed. In
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">addition, the Independent Directors shall
have the authority to institute any action, on behalf of the Company, to enforce performance of
this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.4 <U>Stockholders Meeting</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As promptly as practicable following the acceptance for payment of Shares by Parent or
Purchaser or any of their Affiliates pursuant to and in accordance with the terms of the Offer on
the Purchase Date (the &#147;<U>Acceptance Time</U>&#148;) (or, if later, following the termination of the
subsequent offering period, if any), if required by applicable Law in order to consummate the
Merger, the Company, acting through the Company Board, shall, in accordance with applicable Law and
the Company Charter Documents:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;duly call, give notice of, convene and hold an annual or special meeting of the Company
Stockholders and the holders of Series&nbsp;D-1 Preferred Stock (the &#147;<U>Series&nbsp;D-1 Holders</U>&#148;) for
the purposes of considering and taking action upon the adoption of this Agreement (the &#147;<U>Company
Stockholders Meeting</U>&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;in consultation with Parent, prepare and file with the SEC a preliminary proxy or
information statement relating to the Merger and this Agreement and obtain and furnish the
information required by the SEC to be included therein and, after consultation with Parent, respond
promptly to any comments made by the SEC with respect to the preliminary proxy or information
statement and cause a definitive proxy or information statement (together with all amendments,
supplements and exhibits thereto, the &#147;<U>Proxy Statement</U>&#148;) to be mailed to the Company
Stockholders and the Series&nbsp;D-1 Holders at the earliest practicable date; <U>provided</U> that no
amendments or supplements to the Proxy Statement shall be made by the Company without consultation
with Parent. Parent shall provide the Company with such information with respect to Parent and its
Affiliates as shall be required to be included in the Proxy Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding the provisions of <U>Section&nbsp;1.4(a)</U>, in the event that Parent,
Purchaser and any of Parent&#146;s other Subsidiaries shall acquire in the aggregate at least 90% of the
outstanding shares of each class of capital stock of the Company pursuant to the Offer or
otherwise, the parties hereto shall, subject to <U>Article&nbsp;VI</U>, take all necessary and
appropriate action to cause the Merger to become effective as soon as practicable after such
acquisition, without a meeting of stockholders of the Company, in accordance with Section&nbsp;253 of
the DGCL.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Parent shall vote, or cause to be voted, all of the shares of capital stock of the Company
acquired in the Offer or pursuant to the Preferred Stockholder Agreement or otherwise then owned by
it, Purchaser or any of Parent&#146;s other Subsidiaries in favor of the adoption of this Agreement at
the Company Stockholders Meeting or in order to take the actions required by
<U>Section&nbsp;1.4(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.5 <U>Offer Documents; Schedule&nbsp;14D-9; Proxy Statement</U>. Without limiting any
other provision of this Agreement, whenever any party hereto becomes aware of any event or change
which is required to be set forth in an amendment or supplement to the Offer Documents, the
Schedule&nbsp;14D-9 and/or the Proxy Statement, such party shall promptly inform the other parties
thereof and each of the parties shall cooperate in the preparation, filing with the SEC and (as and
to the extent required by applicable federal securities Laws and rules and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">regulations promulgated
thereunder) dissemination to the Company&#146;s stockholders of such amendment or supplement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>The Merger</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.1 <U>The Merger</U>. Upon the terms and subject to the conditions set forth in
this Agreement, and in accordance with the DGCL, at the Effective Time Purchaser shall be merged
with and into the Company, and the separate corporate existence of Purchaser shall thereupon cease,
and the Company shall be the surviving corporation in the Merger (the &#147;<U>Surviving
Corporation</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.2 <U>Closing</U>. The closing of the Merger (the &#147;<U>Closing</U>&#148;) shall take
place at 10:00&nbsp;a.m. (New York time) on a date to be specified by the parties (the &#147;<U>Closing
Date</U>&#148;), which date shall be no later than the second (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP>)&nbsp;Business Day after
satisfaction or waiver of the conditions set forth in <U>Article&nbsp;VI</U> (other than those
conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction
or waiver of those conditions at such time), at the offices of Debevoise &#038; Plimpton LLP, 919 Third
Avenue, New York, New York 10022, unless another time, date or place is agreed to in writing by the
parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.3 <U>Effective Time</U>. Subject to the provisions of this Agreement, as soon as
practicable on the Closing Date, the parties shall file with the Secretary of State of the State of
Delaware a certificate of merger (or, if applicable, a certificate of ownership and merger)
executed in accordance with the relevant provisions of the DGCL (the &#147;<U>Certificate of
Merger</U>&#148;). The Merger shall become effective upon the filing of the Certificate of Merger or at
such later time as is agreed to by the parties hereto and specified in the Certificate of Merger
(the time at which the Merger becomes effective is herein referred to as the &#147;<U>Effective
Time</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.4 <U>Effects of the Merger</U>. The Merger shall have the effects set forth in the
DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective
Time, all the properties, rights, privileges, powers and franchises of the Company and Purchaser
shall vest in the Surviving Corporation, and all debts, liabilities and duties of the Company and
Purchaser shall become the debts, liabilities and duties of the Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.5 <U>Certificate of Incorporation and Bylaws of the Surviving Corporation</U>. The
certificate of incorporation and bylaws of Purchaser, as in effect immediately prior to the
Effective Time, shall be the certificate of incorporation and bylaws of the Surviving Corporation
until thereafter amended as provided therein or by applicable Law (but subject to
<U>Section&nbsp;5.7</U>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.6 <U>Directors and Officers of the Surviving Corporation</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The directors of Purchaser immediately prior to the Effective Time shall be the directors
of the Surviving Corporation immediately following the Effective Time, until their respective
successors are duly elected or appointed and qualified or their earlier death, resignation or
removal in accordance with the certificate of incorporation and bylaws of the Surviving
Corporation.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The officers of Purchaser immediately prior to the Effective Time shall be the officers of
the Surviving Corporation until their respective successors are duly appointed and qualified or
their earlier death, resignation or removal in accordance with the certificate of incorporation and
bylaws of the Surviving Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.7 <U>Conversion of Securities</U>. At the Effective Time, by virtue of the Merger
and without any action on the part of the holders of any securities of Purchaser or the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each issued and outstanding share of capital stock of Purchaser shall be converted into
and become one (1)&nbsp;validly issued, fully paid and nonassessable share of common stock, par value
$0.01 per share, of the Surviving Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Any shares of Company Common Stock that are owned by the Company as treasury stock and any
Shares or Series&nbsp;D-1 Shares owned by Parent, Purchaser, any other Subsidiary of Parent or a
Subsidiary of the Company shall be automatically canceled and shall cease to exist and no
consideration shall be delivered in exchange therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each (i)&nbsp;Share (other than (x)&nbsp;Shares to be canceled in accordance with
<U>Section&nbsp;2.7(b)</U> and (y)&nbsp;any Dissenting Shares), shall be converted into the right to receive
an amount of cash equal to the Offer Price payable upon surrender, in the manner provided in this
Agreement, to the holder of the certificate formerly representing such Share, without interest and
(ii)&nbsp;Series&nbsp;D-1 Share (other than (x)&nbsp;Series&nbsp;D-1 Shares to be canceled in accordance with
<U>Section&nbsp;2.7(b)</U> and (y)&nbsp;any Dissenting Shares) shall be converted into the right to receive
an amount of cash equal to the product of the number of shares of Company Common Stock into which
such Series&nbsp;D-1 Shares are convertible pursuant to and in accordance with Section&nbsp;A.5 of the Series
D-1 Preferred Stock Certificate of Designation multiplied by the Offer Price payable upon
surrender, in the manner provided in this Agreement, to the holder of the certificate formerly
representing such Series&nbsp;D-1 Share, without interest (collectively, the &#147;<U>Merger
Consideration</U>&#148;). All such Shares and Series&nbsp;D-1 Shares, when so converted, shall no longer be
outstanding and shall automatically be canceled and shall cease to exist, and each holder of a
certificate which immediately prior to the Effective Time represented any such Shares or such
Series&nbsp;D-1 Shares shall cease to have any rights with respect thereto, except the right to receive
the Merger Consideration therefor upon the surrender of such certificate in accordance with this
Agreement, without interest.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Merger Consideration shall be adjusted to reflect fully the effect of any
reclassification, stock split, reverse split, stock dividend (including any dividend or
distribution of securities convertible into Shares), reorganization, recapitalization or other like
change with respect to Shares, occurring (or for which a record date is established) after the
date of this Agreement and prior to the Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.8 <U>Exchange of Certificates</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Paying Agent</U>. Prior to the Effective Time, Parent shall designate a bank or trust
company reasonably acceptable to the Company to act as agent for the holders of Shares and the
holders of Series&nbsp;D-1 Shares in connection with the Merger (the &#147;<U>Paying Agent</U>&#148;) to
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">receive,
on terms reasonably acceptable to the Company, for the benefit of holders of Shares and the holders
of Series&nbsp;D-1 Shares, the aggregate Merger Consideration to which holders of Shares and holders of
Series&nbsp;D-1 Shares shall become entitled pursuant to <U>Section&nbsp;2.7(c)</U>. Parent shall deposit
such aggregate Merger Consideration with the Paying Agent at or prior to the Effective Time. Such
aggregate Merger Consideration deposited with the Paying Agent shall, pending its disbursement to
such holders, be invested by the Paying Agent in (i)&nbsp;direct obligations of the United States of
America, (ii)&nbsp;obligations for which the full faith and credit of the United States of America is
pledged to provide for the payment of principal and interest, (iii)&nbsp;commercial paper rated the
highest quality by either Moody&#146;s Investors Service, Inc. or Standard and Poor&#146;s Ratings Services
or (iv)&nbsp;money market funds investing solely in a combination of the foregoing. Any interest and
other income resulting from such investments shall be the property of, and shall be paid to,
Parent. Parent shall promptly replace any funds deposited with the Paying Agent lost through any
investment made pursuant to this paragraph.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exchange Procedures</U>. Promptly after the Effective Time (but in no event more than
three (3)&nbsp;Business Days thereafter), the Surviving Corporation shall cause the Paying Agent to mail
to each holder of record of a certificate or certificates (or evidence of shares in book-entry
form), which immediately prior to the Effective Time represented outstanding Shares (the
&#147;<U>Certificates</U>&#148;), whose shares were converted pursuant to <U>Section&nbsp;2.7(c)</U> into the
right to receive the Merger Consideration and to each holder of record of a certificate or
certificates (or evidence of shares in book-entry form), which immediately prior to the Effective
Time represented outstanding Series&nbsp;D-1 Shares (the &#147;<U>Series&nbsp;D-1 Certificates</U>&#148;), whose
shares were converted pursuant to <U>Section&nbsp;2.7(c)</U> into the right to receive the Merger
Consideration, (i)&nbsp;a letter of transmittal (which shall specify that delivery shall be effected,
and risk of loss and title to the Certificates and the Series&nbsp;D-1 Certificates shall pass, only
upon delivery of the Certificates and the Series&nbsp;D-1 Certificates to the Paying Agent, and which
shall be in such form and shall have such other customary provisions (including customary
provisions with respect to delivery of an &#147;agent&#146;s message&#148; with respect to shares held in
book-entry form) as Parent may reasonably specify) and (ii)&nbsp;instructions for use in effecting the
surrender of the Certificates and the Series&nbsp;D-1 Certificates in exchange for payment of the Merger
Consideration with respect thereto. Upon surrender of a Certificate or a Series&nbsp;D-1 Certificate
for cancellation to the Paying Agent, together with such letter of transmittal, duly completed and
validly executed in accordance with the instructions (and such other customary documents as may
reasonably be required by the Paying Agent), the holder of such Certificate or such Series&nbsp;D-1
Certificate, as applicable, shall be entitled to receive in exchange therefor the Merger
Consideration (less any applicable excise and withholding Taxes in accordance with
<U>Section&nbsp;2.8(g)</U>), without interest, for each Share formerly represented by such Certificate
or each Series&nbsp;D-1 Share formerly represented by such Series&nbsp;D-1 Certificate, as applicable, and
the Certificate or Series&nbsp;D-1 Certificate so surrendered shall forthwith be canceled. If payment
of the Merger Consideration
is to be made to a Person other than the Person in whose name the surrendered Certificate or
Series&nbsp;D-1 Certificate is registered, it shall be a condition of payment that (x)&nbsp;the Certificate
or Series&nbsp;D-1 Certificate so surrendered shall be properly endorsed or shall otherwise be in proper
form for transfer and (y)&nbsp;the Person requesting such payment shall have paid any transfer and other
Taxes required by reason of the payment of the Merger Consideration to a Person other than the
registered holder of such Certificate or Series&nbsp;D-1 Certificate surrendered or shall have
established to the reasonable satisfaction of the Surviving Corporation that such Tax either has
been paid or is not applicable. Until surrendered as contemplated by this <U>Section&nbsp;2.8</U>,
each
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Certificate and Series&nbsp;D-1 Certificate shall be deemed at any time after the Effective Time to
represent only the right to receive the Merger Consideration with respect thereto as contemplated
by this <U>Article&nbsp;II</U>, without interest.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Transfer Books; No Further Ownership Rights in Company Stock</U>. The Merger
Consideration paid in respect of Shares or Series&nbsp;D-1 Shares upon the surrender for exchange of
Certificates or Series&nbsp;D-1 Certificates, as applicable, in accordance with the terms of this
<U>Article&nbsp;II</U> shall be deemed to have been paid in full satisfaction of all rights pertaining
to the Shares previously represented by such Certificates or the Series&nbsp;D-1 Shares previously
represented by such Series&nbsp;D-1 Certificate, as applicable, and at the close of business on the day
on which the Effective Time occurs, the stock transfer books of the Company shall be closed and
thereafter there shall be no further registration of transfers on the stock transfer books of the
Surviving Corporation of the Shares or the Series&nbsp;D-1 Shares that were outstanding immediately
prior to the Effective Time. From and after the Effective Time, the holders of Certificates that
evidenced ownership of Shares outstanding immediately prior to the Effective Time and holders of
Series&nbsp;D-1 Certificates that evidenced ownership of Series&nbsp;D-1 Shares outstanding immediately prior
to the Effective Time shall cease to have any rights with respect to such shares, except as
otherwise provided for herein or by applicable Law. Subject to the last sentence of
<U>Section&nbsp;2.8(e)</U>, if, at any time after the Effective Time, Certificates or Series&nbsp;D-1
Certificates are presented to the Surviving Corporation for any reason, they shall be canceled and
exchanged as provided in this <U>Article&nbsp;II</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Lost, Stolen or Destroyed Certificates</U>. If any Certificate or Series&nbsp;D-1
Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact
by the Person claiming such Certificate or such Series&nbsp;D-1 Certificate, as applicable, to be lost,
stolen or destroyed and, if required by the Surviving Corporation, the posting by such Person of a
bond, in such reasonable amount as Parent may direct, as indemnity against any claim that may be
made against it with respect to such Certificate or such Series&nbsp;D-1 Certificate, the Paying Agent
will pay, in exchange for such lost, stolen or destroyed Certificate or Series&nbsp;D-1 Certificate, the
applicable Merger Consideration to be paid in respect of the shares formerly represented thereby,
as contemplated by this <U>Article&nbsp;II</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Termination of Fund</U>. At any time following six (6)&nbsp;months after the Closing Date,
the Surviving Corporation shall be entitled to require the Paying Agent to deliver to it any funds
(including any interest received with respect thereto) that had been made available to the Paying
Agent and which have not been disbursed to holders of Certificates or holders of Series&nbsp;D-1
Certificates, and thereafter such holders shall be entitled to look only to the Surviving
Corporation (subject to abandoned property, escheat or other similar Laws) as general creditors
thereof with respect to the payment of any Merger Consideration that may be payable upon surrender
of any Certificates or Series&nbsp;D-1 Certificates held by such holders, as determined pursuant to this
Agreement, without any interest thereon. Any amounts remaining unclaimed by such holders at such
time at which such amounts would otherwise escheat to or become property of any Governmental
Authority shall become, to the extent permitted by applicable Law, the property of Parent free and
clear of all claims or interests of any Person previously entitled thereto.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>No Liability</U>. Notwithstanding any provision of this Agreement to the contrary,
none of the parties hereto, the Surviving Corporation or the Paying Agent shall be liable to any
Person for Merger Consideration delivered to a public official pursuant to any applicable abandoned
property, escheat or similar Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Withholding Taxes</U>. Parent, Purchaser, the Surviving Corporation and the Paying
Agent shall be entitled to deduct and withhold from the consideration otherwise payable to a holder
of Shares, Company Options or Series&nbsp;D-1 Shares pursuant to this Agreement such amounts as may be
required to be deducted and withheld with respect to the making of such payment under the Code, or
under any provision of state, local or foreign Tax Law. To the extent amounts are so withheld and
paid over to the appropriate taxing authority, the withheld amounts shall be treated for all
purposes of this Agreement as having been paid to the holder of the Shares, Company Options or
Series&nbsp;D-1 Shares in respect of which such deduction and withholding was made.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.9 <U>Appraisal Rights</U>. Notwithstanding anything in this Agreement to the
contrary, Shares and Series&nbsp;D-1 Shares that are issued and outstanding immediately prior to the
Effective Time and which are held by a stockholder who did not vote in favor of the Merger (or
consent thereto in writing) and who is entitled to demand and properly demands appraisal of such
shares pursuant to, and who complies in all respects with, the provisions of Section&nbsp;262 of the
DGCL (each, a &#147;<U>Dissenting Stockholder</U>&#148;), shall not be converted into or be exchangeable for
the right to receive the Merger Consideration therefor (the &#147;<U>Dissenting Shares</U>&#148;), but
instead such Dissenting Stockholder shall be entitled to payment of the fair value of such
Dissenting Shares in accordance with the provisions of Section&nbsp;262 of the DGCL (and at the
Effective Time, such Dissenting Shares shall no longer be outstanding and shall automatically be
canceled and shall cease to exist, and such Dissenting Stockholder shall cease to have any rights
with respect thereto, except the right to receive the fair value of such Dissenting Shares in
accordance with the provisions of Section&nbsp;262 of the DGCL), unless and until such Dissenting
Stockholder shall have failed to perfect or shall have effectively withdrawn or lost rights to
appraisal under the DGCL. If any Dissenting Stockholder shall have failed to perfect or shall have
effectively withdrawn or lost such right, such Dissenting Stockholder&#146;s Shares shall thereupon be
treated as if they had been converted into and become exchangeable for the right to receive, as of
the Effective Time, the Merger Consideration for each such Share or Series&nbsp;D-1 Share, in accordance
with <U>Section&nbsp;2.7(c)</U>, without any interest thereon. The Company shall give Parent
(i)&nbsp;prompt notice of any written demands for appraisal of any Shares or Series&nbsp;D-1 Shares,
attempted withdrawals of such demands and any other instruments served pursuant to the DGCL and
received by the Company relating to stockholders&#146; rights of appraisal, and (ii)&nbsp;the opportunity to
participate in all negotiations and proceedings with respect to demands for appraisal under the
DGCL. Prior to the Effective Time, the Company shall not, without the prior written consent of
Parent or as otherwise required by an order, decree, ruling or injunction of a court of competent
jurisdiction, make any payment with respect to, or settle or compromise or offer to settle or
compromise, any such demand, or agree to do any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.10 <U>Company Options</U>. Prior to the Purchase Date, the Company shall take all
actions necessary to provide that each Company Option outstanding immediately prior to the
Effective Time (whether or not then vested or exercisable) shall be terminated and converted at
the Effective Time into the right to receive, in full satisfaction of such Company Option, a
cash
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">amount equal to the Option Consideration (if any) for each share of Company Common Stock then
subject to the Company Option. The Option Consideration shall be paid within five (5)&nbsp;Business
Days following the Effective Time. Notwithstanding the foregoing, Parent and the Company shall be
entitled to deduct and withhold from the Option Consideration otherwise payable such amounts as may
be required to be deducted and withheld with respect to the making of such payment under the Code,
or any provision of state, local or foreign Tax Law. For purposes of this Agreement, &#147;<U>Option
Consideration</U>&#148; means, with respect to any share of Company Common Stock issuable under a
particular Company Option, an amount equal to the excess, if any, of (i)&nbsp;the Offer Price over
(ii)&nbsp;the exercise price payable in respect of such share of Company Common Stock issuable under
such Company Option rounded down to the nearest cent. As of the Effective Time, any Option with an
exercise price equal to or greater than the Offer Price shall be canceled without consideration and
be of no further force or effect. The Company Board (or, if appropriate, any committee thereof
administering the Company Stock Plans) shall adopt such resolutions or take such other actions as
may be required to effect the foregoing. Any Company Options held by any director of the Company
that do not vest and are thereby cancelled as a result of such director&#146;s resignation pursuant to
the provisions of <U>Section&nbsp;1.3(a)</U> shall nevertheless be deemed to be outstanding for
purposes of the payments to be made in respect of Company Options outstanding immediately prior to
the Effective Time (whether or not then vested or exercisable) pursuant to this <U>Section
2.10</U>.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Representations and Warranties of the Company</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and warrants to Parent and Purchaser that except as set forth in the
letter delivered by the Company to Parent simultaneously with the execution of this Agreement (the
&#147;<U>Company Disclosure Letter</U>&#148;) or the Company SEC Documents filed prior to the date of this
Agreement (the &#147;<U>Filed Company SEC Documents</U>&#148;) (excluding all exhibits, annexes and
schedules thereto and documents incorporated by reference therein or any risk factors or
forward-looking statements and any other disclosures therein to the extent they are predictive or
forward-looking in nature) (it being understood that any matter set forth in the Company Disclosure
Letter or in such Filed Company SEC Documents shall be deemed disclosed for all sections and
subsections of this Agreement only to the extent that the applicability of such disclosure to such
section or subsection is readily apparent):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.1 <U>Organization, Standing and Corporate Power</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company is a corporation duly organized, validly existing and in good standing under
the Laws of the State of Delaware and has all requisite corporate power and authority necessary to
own or lease all of its properties and assets and to carry on its business as it is now being
conducted. The Company is duly licensed or qualified to do business and is in good standing in
each jurisdiction in which the nature of the business conducted by it or the character or location
of the properties and assets owned or leased or held under license by it makes such licensing or
qualification necessary, except where the failure to be so licensed, qualified or in good standing would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect. For purposes of this Agreement, &#147;<U>Company
Material Adverse Effect</U>&#148; shall mean any change, event, occurrence, state of facts or
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">development which has a material adverse effect on (1)&nbsp;the business, results of operations or
financial condition of the Company and its Subsidiaries taken as a whole or (2)&nbsp;the ability of the
Company to perform its obligations under this Agreement or to consummate the transactions
contemplated by this Agreement by the Outside Date; <U>provided</U> that with respect to clause
(1)&nbsp;above, Company Material Adverse Effect shall not include any changes, events, occurrences,
state of facts or developments, to the extent arising out of or resulting from (i)&nbsp;changes after
the date of this Agreement in conditions generally in the United States or global economy or in the
capital or financial markets, including changes in interest or exchange rates, (ii)&nbsp;changes after
the date of this Agreement in general legal, regulatory, political, economic or business conditions
or changes in generally accepted accounting principles that, in either case, generally affect the
industry in which the Company and its Subsidiaries conduct business, (iii)&nbsp;the negotiation,
execution, announcement or performance of this Agreement or the consummation of the Transactions,
including the impact thereof on relationships, contractual or otherwise, with customers, suppliers,
distributors, partners, collaborators or employees, (iv)&nbsp;acts of war, sabotage or terrorism, or any
escalation or worsening of any such acts of war, sabotage or terrorism threatened or underway as of
the date of this Agreement, (v)&nbsp;storms, earthquakes or other natural disasters, (vi)&nbsp;the initiation
of any litigation by any stockholder of the Company relating to this Agreement, the Offer or the
Merger, (vii)&nbsp;any decline in the market price, or change in trading volume, of the Company Common
Stock or any failure of the Company to meet publicly announced revenue or earnings projections;
<U>provided</U> that the underlying changes, events, occurrences, state of facts or developments
that caused or contributed to any such decline, change or failure may otherwise be taken into
consideration in determining whether a Company Material Adverse Effect has occurred, (viii)&nbsp;any
delay after the date of this Agreement in any of the Company&#146;s ongoing research programs resulting
from any adverse changes, developments, circumstances, events or occurrences, or (ix)&nbsp;any action
taken by the Company or any of its Subsidiaries which is expressly required by this Agreement or
that has been expressly consented to by Parent under the terms of this Agreement, except in each of
cases (i), (ii), (iii), (iv), (v), (vi)&nbsp;and (vii), to the extent that such changes affect the
Company and its Subsidiaries in a disproportionate manner relative to other participants in the
businesses and industries in which the Company and its Subsidiaries operate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the Company&#146;s Subsidiaries is a corporation or other organization duly organized,
validly existing and in good standing under the Laws of the jurisdiction of its organization. Each
of the Company&#146;s Subsidiaries is duly licensed or qualified to do business and is in good standing
in each jurisdiction in which the nature of the business conducted by it or the character or
location of the properties and assets owned or leased or held under license by it makes such
licensing or qualification necessary, except where the failure to be so licensed, qualified or in
good standing would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect. <U>Section&nbsp;3.1(b) of the Company Disclosure Letter</U> sets forth a true
and complete list of each Subsidiary of the Company (including its name and form of organization,
its jurisdiction of incorporation or organization and the number and type of outstanding equity
securities and a list of the holders of such securities). All the outstanding shares of capital
stock, voting securities or other equity interests of each Subsidiary of the Company (except for directors&#146; qualifying shares or the like) are duly authorized, have been
validly issued, are fully paid, nonassessable and free of preemptive rights, and are owned by the
Company or another wholly-owned Subsidiary of the Company free and clear of all liens, pledges,
security interests and transfer restrictions, except for such transfer restrictions of general
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">applicability as may be provided under the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder (the &#147;<U>Securities Act</U>&#148;), and other applicable securities
Laws and rules and regulations promulgated thereunder. There are no (i)&nbsp;outstanding options or
other rights of any kind which obligate the Company or any of its Subsidiaries to issue or deliver
any shares of capital stock, voting securities or other equity interests of any such Subsidiary or
any securities or obligations convertible into or exchangeable into or exercisable for any shares
of capital stock, voting securities or other equity interest of a Subsidiary of the Company,
(ii)&nbsp;outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or
otherwise acquire any securities or obligations convertible into or exchangeable into or
exercisable for any shares of capital stock, voting securities or other equity interests of a
Subsidiary of the Company; or (iii)&nbsp;other options, calls, warrants or other rights, agreements,
arrangements or commitments of any character relating to the issued or unissued capital stock of
any Subsidiary to which the Company or any of its Subsidiaries is a party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company has made available to Parent complete and correct copies of the certificate of
incorporation and bylaws (or other comparable organizational documents) of the Company and each of
its Subsidiaries, in each case as amended through the date of this Agreement (the &#147;<U>Company
Charter Documents</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company does not control directly or indirectly or own, directly or indirectly, any
capital stock of, or other voting securities or equity or similar interests in, or investment in or
have any obligation to invest in, any corporation, partnership, limited liability company, joint
venture, trust or other business association or entity or Person which is not a Subsidiary of the
Company listed on <U>Section&nbsp;3.1(b) of the Company Disclosure Letter</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.2 <U>Capitalization</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The authorized capital stock of the Company consists of: (i)&nbsp;75,000,000 shares of Company
Common Stock and (ii)&nbsp;5,000,000 shares of preferred stock, par value $0.01 per share (&#147;<U>Company
Preferred Stock</U>&#148;) of which, (x)&nbsp;200,000 shares are designated as Series&nbsp;D-1 Preferred Stock and
(y)&nbsp;150,000 shares are designated as Series&nbsp;A Participating Preferred Stock and were reserved for
issuance in accordance with the Company Rights Agreement, pursuant to which the Company had issued
rights (&#147;<U>Company Rights</U>&#148;) to purchase shares of such Series&nbsp;A Participating Preferred Stock
and which Company Rights expired pursuant to the terms of the Company Rights Agreement on September
26, 2007. At the close of business on February&nbsp;22, 2008, (i)&nbsp;21,576,533 shares of Company Common
Stock were issued and outstanding, (ii)&nbsp;200,000 shares of Series&nbsp;D-1 Preferred Stock were issued
and outstanding, (iii)&nbsp; 3,568,658 shares of Company Common Stock were subject to outstanding
Company Options, (iv)&nbsp;2,352,941 shares of Company Common Stock were reserved for issuance upon
conversion of the Series&nbsp;D-1 Preferred Stock, (v)&nbsp;no shares of Company Common Stock were held by
the Company in its treasury, (vi)&nbsp;no shares of Company Preferred Stock were held by the Company in
its treasury and (vii)&nbsp;no shares or Series&nbsp;A Participating Preferred Stock were outstanding. All
outstanding shares of Company Common Stock, and all shares of Company Common Stock reserved for
issuance upon exercise of the Company Options or upon conversion of the Series&nbsp;D-1 Preferred Stock,
have been duly authorized and all outstanding shares of Company Common Stock are, and all shares of
Company Common Stock reserved for issuance upon exercise of the Company Options or upon conversion
of the Series&nbsp;D-1 Preferred Stock, both in accordance with their
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respective terms, will upon
issuance be, validly issued, fully paid, nonassessable and free of preemptive rights. All shares
of Company Preferred Stock have been duly authorized and all outstanding shares of Series&nbsp;D-1
Preferred Stock are validly issued, fully paid, nonassesable and free of preemptive rights.
<U>Section&nbsp;3.2(a) of the Company Disclosure Letter</U> sets forth a correct and complete list, as
of February&nbsp;25, 2008, of the outstanding Company Options, the number of shares of Company Common
Stock underlying such Company Options, the holders, exercise prices, dates of grant, vesting
schedules and expiration dates thereof and the Company Stock Plan (if any) under which such Company
Option was granted. Since February&nbsp;22, 2008, the Company has not issued, or reserved for issuance,
any shares of its capital stock or any securities convertible into or exchangeable or exercisable
for any shares of its capital stock, other than or pursuant to the Company Options referred to
above that are outstanding as of the date of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in <U>Section&nbsp;3.2(a)</U>, as of the date of this Agreement, (A)&nbsp;there
are no outstanding options, stock appreciation rights or other rights of any kind which obligate
the Company or any of its Subsidiaries to issue or deliver any shares of capital stock, voting
securities or other equity interests of the Company or any securities or obligations convertible
into or exchangeable into or exercisable for any shares of capital stock, voting securities or
other equity interests of the Company (collectively, (&#147;<U>Company Securities</U>&#148;); (B)&nbsp;there are
no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or
otherwise acquire any Company Securities; and (C)&nbsp;there are no other options, calls, warrants or
other rights, agreements, arrangements or commitments of any character relating to the issued or
unissued capital stock of the Company to which the Company or any of its Subsidiaries is a party.
No Subsidiary of the Company owns any shares of Company Common Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except as disclosed in <U>Section&nbsp;3.2(c) of the Company Disclosure Letter</U>, the
Company and its Subsidiaries have no outstanding indebtedness for borrowed money and there are no
outstanding guarantees by the Company or any of its Subsidiaries of indebtedness for borrowed money
of any other Person. There are no bonds, debentures, notes or other indebtedness of the Company or
any of its Subsidiaries having the right to vote (or convertible into or exchangeable for
securities having the right to vote) on any matters on which stockholders of the Company or any
such Subsidiary may vote.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.3 <U>Authority; Noncontravention; Voting Requirements</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company has all necessary corporate power and authority to execute and deliver this
Agreement and, subject to obtaining the Company Stockholder Approval as contemplated by
<U>Section&nbsp;1.4</U>, to perform its obligations hereunder and to consummate the Transactions. The
execution, delivery and performance by the Company of this Agreement, and the consummation by it of
the Transactions, have been duly authorized and approved by all necessary corporate action on the part of the Company (including by the Company Board), and
except for obtaining the Company Stockholder Approval (to the extent required by the DGCL), no
other corporate action or proceedings on the part of the Company or any of its stockholders are
necessary to authorize the execution, delivery and performance by the Company of this Agreement and
the consummation by it of the Transactions. This Agreement has been duly executed and delivered by
the Company and, assuming due authorization, execution and delivery
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hereof by the other parties
hereto, constitutes a legal, valid and binding obligation of the Company, enforceable against the
Company in accordance with its terms, except that such enforceability (i)&nbsp;may be limited by
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar Laws of
general application affecting or relating to the enforcement of creditors&#146; rights generally and
(ii)&nbsp;is subject to general principles of equity, whether considered in a proceeding at Law or in
equity (the &#147;<U>Bankruptcy and Equity Exception</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company approves of and consents to the Offer, and represents and warrants that the
Company Board, at a meeting duly called and held, has, subject to the terms and conditions set
forth in this Agreement, unanimously (i)&nbsp;approved this Agreement, and deemed this Agreement and the
Transactions advisable, fair to and in the best interests of the Company Stockholders;
(ii)&nbsp;approved this Agreement and the Transactions, including the Offer and the Merger, in all
respects, and such approval constitutes approval of this Agreement and the Transactions and the
Tender Agreement for purposes of Section&nbsp;203 of the DGCL (assuming the accuracy of Parent&#146;s
representation and warranty contained in <U>Section&nbsp;4.9</U>) and for purposes of any other state
takeover Law or state Law that purports to limit or restrict business combinations or the ability
to acquire or vote shares; and (iii)&nbsp;resolved to recommend that the Company Stockholders accept the
Offer, tender their shares of Company Common Stock in the Offer, and, to the extent required by
applicable Law, approve the Merger and adopt this Agreement (the &#147;<U>Company Recommendation</U>&#148;).
The Company hereby consents to the inclusion of such approval and the Company Recommendation in
the Offer Documents, subject to <U>Section&nbsp;5.2(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the execution and delivery of this Agreement by the Company nor the consummation
by the Company of the Transactions, nor compliance by the Company with any of the terms or
provisions hereof, will (i)&nbsp;conflict with or result in any violation or breach of (with or without
notice or lapse of time, or both) any provision of the Company Charter Documents or (ii)&nbsp;assuming
that the authorizations, consents and approvals referred to in <U>Section&nbsp;3.4</U> and the Company
Stockholder Approval (to the extent required by the DGCL) are obtained and the filings referred to
in <U>Section&nbsp;3.4</U> are made, (x)&nbsp;violate any Law, judgment, writ or injunction of any
Governmental Authority applicable to the Company or any of its Subsidiaries or (y)&nbsp;conflict with or
result in any violation or breach of, or default (with or without notice or lapse of time, or both)
under or give rise to a right of, or result in, termination, modification, cancellation, recapture
or acceleration of any obligation or to the loss of a benefit, or result in the creation of any
lien in or upon or with respect to, any of the properties (including Intellectual Property) or
other assets of the Company or any of its Subsidiaries, under any of the terms, conditions or
provisions of any loan or credit agreement, debenture, note, bond, mortgage, indenture, deed of
trust, lease, contract or other agreement (each, a &#147;<U>Contract</U>&#148;) to which the Company or any
of its Subsidiaries is a party, except, in the case of this clause (ii),
for such violations or defaults as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except as set forth in <U>Section&nbsp;3.3(d) of the Company Disclosure Letter</U>, the
affirmative vote (in person or by proxy) by the holders of at least a majority in voting power of
the outstanding shares of Company Common Stock and Series&nbsp;D-1 Preferred Stock (voting on an
as-converted basis) voting together as a single class, at the Company Stockholders Meeting, or any
adjournment or postponement of the Company Stockholders Meeting, in favor of the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">adoption of this
Agreement are the only votes or approvals of the holders of any class or series of the Company&#146;s
capital stock or any of its Subsidiaries&#146; capital stock or other securities which are necessary to
adopt this Agreement and approve the Transactions (to the extent required by applicable Law to
approve the Merger) (the &#147;<U>Company Stockholder Approval</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.4 <U>Governmental Approvals</U>. Except for (i)&nbsp;the filing with the SEC of the
Schedule&nbsp;14D-9 and, if necessary, of the Proxy Statement in definitive form, and other filings
required under, and compliance with other applicable requirements of, the Exchange Act, state
securities or &#147;blue sky&#148; laws and the rules and regulations of NASDAQ, (ii)&nbsp;the filing of the
Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL and
(iii)&nbsp;filings required under, and compliance with other applicable requirements of, the HSR Act, no
consents or approvals of, or filings, declarations or registrations with, any Governmental
Authority are necessary for the execution and delivery of this Agreement by the Company and the
consummation by the Company of the Transactions, other than such consents, approvals, filings,
declarations or registrations that, if not obtained, made or given, would not, individually or in
the aggregate, reasonably be expected to have a Company Material Adverse Effect or to impair in any
material respect the ability of the Company to perform its obligations hereunder or prevent or
materially delay consummation of the Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.5 <U>Company SEC Documents; Financial Statements; Undisclosed Liabilities</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company has filed all required statements, prospectuses, forms, reports, schedules and
other documents with the SEC, together with all certifications required pursuant to the
Sarbanes-Oxley Act of 2002 (including its rules and regulations, &#147;<U>SOX</U>&#148;), from and after
January&nbsp;1, 2005 (collectively, and in each case including all exhibits and schedules thereto and
documents incorporated by reference therein, the &#147;<U>Company SEC Documents</U>&#148;). As of their
respective effective dates (in the case of Company SEC Documents that are registration statements
filed pursuant to the requirements of the Securities Act) and as of their respective SEC filing
dates (in the case of all other documents), the Company SEC Documents and all documents filed from
and after December&nbsp;31, 2004 by the Company with the SEC on a voluntary basis on Current Reports on
Form 8-K (the &#147;<U>Company Current Reports</U>&#148;) complied in all material respects with applicable
Law, including the Exchange Act, the Securities Act and SOX, as the case may be, and none of the
Company SEC Documents or the Company Current Reports as of such respective dates contained any
untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. No Subsidiary of the
Company is, or has at any time since December&nbsp;31, 2004 been, subject to the reporting
requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The consolidated financial statements of the Company included in the Company SEC Documents
(the &#147;<U>Company Financial Statements</U>&#148;) have been prepared in accordance with GAAP (except, in
the case of unaudited interim statements, as indicated in the notes thereto) applied on a
consistent basis during the periods involved (except as may be indicated in the notes thereto) and
fairly present in all material respects the consolidated financial position of the Company and its
consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations
and cash flows for the periods then ended (subject, in the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">case of unaudited interim statements, to
normal year-end audit adjustments which were not and would not, individually or in the aggregate,
reasonably be expected to be material). The books and records of the Company and each of its
Subsidiaries have been, and are being, maintained in all material respects in accordance with
applicable legal and accounting requirements, and the Company Financial Statements are consistent
in all material respects with such books and records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except as disclosed in <U>Section&nbsp;3.5(c) of the Company Disclosure Letter</U>, neither
the Company nor any of its Subsidiaries has any liabilities of any nature, whether accrued,
contingent or otherwise (&#147;<U>Liabilities</U>&#148;), except Liabilities (i)&nbsp;reflected in or reserved
against on the most recent financial statements of the Company and included in the Company SEC
Documents filed with the SEC prior to the date of this Agreement, (ii)&nbsp;incurred in the ordinary
course of business, (iii)&nbsp;that have been discharged or paid in full in the ordinary course of
business, (iv)&nbsp;that are expressly contemplated by this Agreement or (v)&nbsp;as would not, individually
or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company and its Subsidiaries have designed and maintain a system of internal controls
over financial reporting (as defined in Rules&nbsp;13a-15(f) and 15d-15(f) of the Exchange Act)
sufficient to provide reasonable assurances regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP. The Company
(i)&nbsp;has designed and maintains &#147;disclosure controls and procedures&#148; (as defined in Rules&nbsp;13a-15(e)
and 15d-15(e) of the Exchange Act) to ensure that information required to be disclosed by the
Company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the SEC&#146;s rules and forms and is
accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions
regarding required disclosure and to make the certifications required pursuant to Section&nbsp;302 and
906 of SOX, and (ii)&nbsp;has disclosed, based on its most recent evaluation of such disclosure controls
and procedures prior to the date of this Agreement, to the Company&#146;s auditors and the audit
committee of the Company Board (A)&nbsp;any &#147;significant deficiencies&#148; and &#147;material weaknesses&#148; in the
design or operation of &#147;internal controls over financial reporting&#148; that are reasonably likely to
adversely affect in any material respect the Company&#146;s ability to record, process, summarize and
report financial information and (B)&nbsp;any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&#146;s internal controls over financial
reporting. For purposes of this Agreement, the terms &#147;significant deficiency&#148; and &#147;material
weakness&#148; shall have the meanings assigned to them by the Public Company Accounting Oversight Board
in Auditing Standard No.&nbsp;2, as in effect on the date of this Agreement, and the term &#147;internal controls over financial
reporting&#148; shall have the meaning assigned to it by Rule&nbsp;13a-15(f).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Each of the principal executive officer of the Company and the principal financial officer
of the Company (or each former principal executive officer of the Company and each former principal
financial officer of the Company, as applicable) has made all certifications required by Rule
13a-14 or 15d-14 under the Exchange Act and Sections&nbsp;302 and 906 of SOX with respect to the Company
SEC Documents, and the statements contained in such certifications were complete and correct on the
date such certifications were made. For purposes of this Agreement, &#147;principal executive officer&#148;
and &#147;principal financial officer&#148; shall have the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">meanings given to such terms in SOX. Neither the
Company nor any of its Subsidiaries has outstanding (nor has arranged or modified since the
enactment of SOX) any &#147;extensions of credit&#148; (within the meaning of Section&nbsp;402 of SOX ) to
directors or executive officers (as defined in Rule&nbsp;3b-7 under the Exchange Act) of the Company or
any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except as set forth in <U>Section&nbsp;3.5(f) of the Company Disclosure Letter</U>, since
December&nbsp;31, 2004 through the date of this Agreement, (i)&nbsp;neither the Company nor any of its
Subsidiaries, nor any director or executive officer of the Company or any of its Subsidiaries has,
and, to the Knowledge of the Company, no other officer, employee or accountant of the Company or
any of its Subsidiaries has, received any material complaint, allegation, assertion or claim, in
writing (or, to the Knowledge of the Company, orally) regarding the accounting or auditing
practices, procedures, methodologies or methods of the Company or any of its Subsidiaries or their
respective internal accounting controls, including any material complaint, allegation, assertion or
claim that the Company or any of its Subsidiaries has engaged in questionable accounting or
auditing practices, and (ii)&nbsp;no attorney representing the Company or any of its Subsidiaries,
whether or not employed by the Company or any of its Subsidiaries, has reported evidence of a
material violation of securities Laws, breach of fiduciary duty or similar violation by the Company
or any of its officers, directors, employees or agents to the Company Board or any committee
thereof or to any director or officer of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.6 <U>Absence of Certain Changes</U>. Except as disclosed in <U>Section&nbsp;3.6 of the
Company Disclosure Letter</U> or in the Company SEC Documents, from December&nbsp;31, 2006 until the
date of this Agreement (a)&nbsp;each of the Company and its Subsidiaries has carried on and operated its
businesses in all material respects in the ordinary course of business, (b)&nbsp;there have not been any
events, changes or occurrences that have had, or would, individually or in the aggregate,
reasonably be expected to have, a Company Material Adverse Effect, (c)&nbsp;there has not been any
material damage, destruction or loss, whether or not covered by insurance, and (d)&nbsp;no action,
event, occurrence or transaction has taken place, and neither the Company nor any of its
Subsidiaries has taken any action, that would have been prohibited by <U>Section&nbsp;5.1(a)</U>
without the consent of Parent if this Agreement had been in effect at the time thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.7 <U>Legal Proceedings</U>. As of the date of this Agreement, there is no pending
or, to the Knowledge of the Company, threatened Action or Proceeding against or relating to the
Company or any of its Subsidiaries or any of the executive officers or directors of the Company in
their capacity as such, nor is the Company, any of its Subsidiaries, or any of their respective
properties or assets subject to any injunction, order, judgment, settlement, award, ruling or
decree imposed upon the Company or any of its Subsidiaries, in each case, by or before
any Governmental Authority, except, in each case, for those that would not, individually or in
the aggregate, reasonably be expected to have a Company Material Adverse Effect. Since December
31, 2006, there has not been made or, to the Knowledge of the Company, threatened, any material
product liability or other material product-related claims by any third party arising from the
sale, distribution or manufacturing of products by the Company or any of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.8 <U>Compliance With Laws; Permits; Regulatory Compliance</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company and its Subsidiaries are, and have been since January&nbsp;1, 2006, in compliance
with all laws, statutes, ordinances, codes, rules, regulations, decrees and
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">orders of Governmental
Authorities (collectively, &#147;<U>Laws</U>&#148;) applicable to the Company or any of its Subsidiaries,
except for such non-compliance as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect. The Company and each of its Subsidiaries hold
all licenses, franchises, permits, certificates, approvals, consents, clearances and authorizations
from Governmental Authorities necessary for the lawful conduct of their respective businesses
(collectively, &#147;<U>Permits</U>&#148;), and there is no Action or Proceeding pending, or to the
Knowledge of the Company threatened, regarding any of the Permits, except where the failure to hold
the same or such Actions or Proceedings regarding the same would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect. The Company and its
Subsidiaries are in compliance with the terms of all Permits, except for such non-compliance as
would not, individually or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To the Knowledge of the Company (including for this purpose the members of the Audit
Committee of the Company Board), there are no formal or informal Governmental Authority inquiries
or investigations or internal investigations or whistle-blower
complaints pending or threatened, in each case regarding accounting or disclosure practices of
the Company or any of its Subsidiaries, compliance by the Company or any of its Subsidiaries with
any Law or any malfeasance by any officer of the Company or any of its Subsidiaries, other than
ordinary course inquiries, investigations or complaints not material to the Company and its
Subsidiaries, taken as a whole.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Since January&nbsp;1, 2006, neither the Company nor any of its Subsidiaries has received a
written notice that the Food and Drug Administration (&#147;<U>FDA</U>&#148;) or any other Governmental
Authority which has jurisdiction over the operations of the Company and any of its Subsidiaries has
commenced, or threatened to commence, any regulatory Action or Proceeding relating to any alleged
violation of Law with respect to any of the Company&#146;s or its Subsidiaries&#146; products, except where
such action would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;To the Knowledge of the Company, each of the products of the Company and its Subsidiaries
that is subject to the jurisdiction of the Food, Drug and Cosmetic Act of 1938, as amended (the
&#147;<U>FDCA</U>&#148;), the Public Health Service Act, as amended (the &#147;<U>PHSA</U>&#148;), the Controlled
Substances Act, as amended (the &#147;<U>CSA</U>&#148;), and the regulations promulgated thereunder or
similar Laws in any foreign jurisdiction, is in compliance in all material respects with all
applicable requirements under the FDCA, the PHSA, the CSA and the regulations promulgated
thereunder or similar Laws in any foreign jurisdiction, including but not limited to those
requirements applicable to the development, manufacture, storage, testing, labeling or packaging,
marketing, promotion or distribution of such product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;All preclinical and clinical studies conducted by, or, to the Knowledge of the Company, on
behalf of, the Company or its Subsidiaries since January&nbsp;1, 2005 have been and are being conducted
in compliance with the FDA&#146;s Good Laboratory Practice and Good Clinical Practice requirements,
including regulations under 21 C.F.R. Parts 50, 54, 56, 58, 312 and applicable guidance documents,
as amended from time to time, the Animal Welfare Act, and all applicable similar requirements in
other jurisdictions, all requirements related to protection of human subjects and, to the extent it
would not reasonably be expected to result in a material
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">liability to the Company or its
Subsidiaries, the provisions governing the privacy of patient medical records under the Health
Insurance Portability and Accountability Act of 1996 and the implementing regulations of the United
States Department of Health and Human Services. The Company and its Subsidiaries have not received
any written notices, correspondence or other communication from the FDA or any other Governmental
Authority, or any institutional review board, requiring the termination, suspension or material
modification of any preclinical or clinical trials conducted by, or on behalf of, the Company or
its Subsidiaries, or in which the Company or its Subsidiaries have participated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except as set forth on <U>Section&nbsp;3.8(f) of the Company Disclosure Letter</U>, neither
the Company nor its Subsidiaries have received any notice, letters or other correspondence from the
FDA or any other Governmental Authority or Person (i)&nbsp;contesting the pre-market clearance or
approval of, the clinical or non-clinical testing of, the uses of or the labeling, promotion or
distribution of its products or (ii)&nbsp;otherwise alleging any violation of Laws by the Company. The
Company and its Subsidiaries are in substantial compliance with all applicable FDA requirements,
including, but not limited to, registration and listing requirements
set forth in 21 U.S.C. &#167; 360 and 21 C.F.R. Part&nbsp;207 and all other similar Laws, except where
such noncompliance would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect. To the Knowledge of the Company, no communication, filing or
submission to any Governmental Authority with regard to the Company&#146;s or any of its Subsidiaries&#146;
products that is or is intended to be the basis for any approval contains any material omission or
any materially false information. The Company and its Subsidiaries are in substantial compliance
with all Laws applicable to the maintenance, compilation and filing of reports, including, but not
limited to, periodic or annual, or other reports, with regards to its products. The Company and
each of its Subsidiaries has filed with the applicable Governmental Authorities all applicable
adverse event or product safety reports required to be filed in relation to its products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;All manufacturing operations of products by the Company and its Subsidiaries and, to the
Knowledge of the Company, for the benefit of the Company and its Subsidiaries have been and are
being, to the extent required by applicable Law, conducted in material compliance with the FDA
regulations, Good Manufacturing Practices, including C.F.R. Parts 210 and 211 and applicable
guidance documents, as amended from time to time, and all applicable similar requirements in
countries where such compliance is required.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Except as set forth on <U>Section&nbsp;3.8(h) of the Company Disclosure Letter</U>, none of
the Company&#146;s or its Subsidiaries&#146; products or product candidates has been recalled, withdrawn,
suspended or discontinued (whether voluntarily or otherwise) at the request of the FDA or any other
Governmental Authority, nor has the Company or any of its Subsidiaries received any notice from the
FDA or any other Governmental Authority that it has commenced, or threatened to initiate, any
action to withdraw approval, place sales or marketing restrictions on or request the recall of any
of the Company&#146;s or its Subsidiaries&#146; products, or that it has commenced or threatened to initiate
any action to enjoin or place restrictions on the production of any of the Company&#146;s or its
Subsidiaries&#146; products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Neither the Company nor its Subsidiaries, nor, to the Knowledge of the Company, any of
their respective directors, officers, agents or employees (in their capacities as
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such) has engaged
in any conduct that has resulted in or would reasonably be expected to result in any material
violation of the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), or the False Claims Act,
31 U.S.C. &#167; 3729, or any similar Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;To the Knowledge of the Company, no officer, employee or agent of the Company (in their
capacities as such) has made an untrue statement of a material fact or fraudulent statement to the
FDA or any other Governmental Authority, failed to disclose a material fact required to be
disclosed to the FDA or any other Governmental Authority, or committed an act, made a statement, or
failed to make a statement that, at the time such disclosure was made, would reasonably be expected
to provide a basis for the FDA or any other Governmental Authority to invoke its policy respecting
&#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#148; set forth in 56 Fed.
Reg. 46191 (September&nbsp;10, 1991) or any similar policy. To the Knowledge of the Company, neither
the Company nor its Subsidiaries has used in any capacity the services of any individual or entity
debarred under 21 U.S.C. &#167; 335a(a) or any similar Laws in connection with a product of the Company
or its Subsidiaries, and neither the Company nor any of its Subsidiaries, nor, to the Knowledge of
the Company, any
of their respective directors, officers, agents or employees (in their capacities as such),
has engaged in any conduct that has resulted, or would reasonably be expected to result, in
debarment under 21 U.S.C. &#167; 335a(a) or any similar Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.9 <U>Information Supplied</U>. Subject to the accuracy of the representations and
warranties of Parent and Purchaser set forth in <U>Section&nbsp;4.4</U>, neither the Schedule&nbsp;14D-9 nor
any information supplied (or to be supplied) in writing by or on behalf of the Company specifically
for inclusion or incorporation by reference in the Offer Documents will, at the respective times
the Schedule&nbsp;14D-9, the Offer Documents, or any amendments or supplements thereto are filed with
the SEC or at the time they are first published, sent or given to the holders of Company Common
Stock, as the case may be, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements made
therein, in light of the circumstances under which they are made, not misleading. The Proxy
Statement (if any) will not, on the date it is first mailed to the holders of Company Common Stock,
contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they are made, not misleading, and will not, at the time of the Company Stockholders
Meeting (if such a meeting is held), omit to state any material fact necessary to correct any
statement in any earlier communication from the Company with respect to the Company Stockholders
Meeting which shall have become false or misleading in any material respect. The Proxy Statement
(if any) and the Schedule&nbsp;14D-9 will comply as to form in all material respects with the applicable
requirements of the Exchange Act. Notwithstanding the foregoing, the Company makes no
representation or warranty with respect to information supplied by or on behalf of Parent or
Purchaser for inclusion or incorporation by reference in any of the foregoing documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.10 <U>Tax Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of the Company and its Subsidiaries has timely filed, or has caused to be timely
filed on its behalf (taking into account any extension of time within which to file), all material
Tax Returns required to be filed by it, and all such filed Tax Returns are correct and
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">complete in
all material respects. All material Taxes of the Company and its Subsidiaries (whether or not
shown to be due on such Tax Returns) have been timely paid. No material deficiency with respect to
Taxes has been proposed, asserted or assessed against the Company or any of its Subsidiaries which
have not been fully paid or adequately reserved in the Company SEC Documents. No audit or other
administrative or court proceedings are pending with any Governmental Authority with respect to
Taxes of the Company or any of its Subsidiaries, and no written notice thereof has been received.
There are no agreements in effect to extend the period of limitations for assessment or collection
of any Tax for which the Company or any of its Subsidiaries may be liable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the Company nor any of its Subsidiaries (i)&nbsp;is a party to or bound by any Tax
allocation or Tax sharing agreement (other than any such agreement solely between or among the
Company and any of its Subsidiaries), (ii)&nbsp;has received notice in writing of any claim made by a
Governmental Authority in a jurisdiction where it does not file a Tax Return that it is or may be
subject to taxation by such jurisdiction, (iii)&nbsp;has participated in a &#147;listed transaction&#148; (as
defined in Treasury Regulation&nbsp;Section&nbsp;1.6011-4), (iv)&nbsp;has received or applied
for a Tax ruling or entered into a closing agreement pursuant to Section&nbsp;7121 of the Code (or
any predecessor provision or any similar provision of state, local or foreign law, or (v)&nbsp;has
constituted either a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; in a distribution of
stock qualifying or intended to qualify for tax-free treatment under Section&nbsp;355 of the Code in the
two (2)&nbsp;years prior to the date of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the Company nor any of its Subsidiaries (i)&nbsp;is or has been a member of an
affiliated group filing a consolidated federal income Tax Return (other than a group the common
parent of which was the Company) or (ii)&nbsp;has any liability for the Taxes of any Person (other than
the Company or any of its Subsidiaries) under United States Treasury Regulation &#167;1.1502-6 (or any
similar provision of state, local, or foreign Law), as a transferee or successor, by Contract, or
otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;There are no material liens for Taxes upon any property or other assets of the Company or
any of its Subsidiaries, except liens for Taxes not yet due and payable and liens for Taxes that
are being contested in good faith by appropriate proceedings.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;All material Taxes required to be withheld, collected or deposited by or with respect to
the Company and each of its Subsidiaries have been timely withheld, collected or deposited, as the
case may be, and to the extent required, such Taxes have been paid to the relevant Tax authority or
other Governmental Authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Company had net operating loss carryforwards for U.S. federal income Tax purposes as
of December&nbsp;31, 2006 of approximately $105&nbsp;million.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;For purposes of this Agreement: (i) &#147;<U>Taxes</U>&#148; shall mean (x)&nbsp;all federal, state,
local or foreign taxes, charges, fees, imposts, levies or other assessments, including all net
income, gross receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits,
inventory, capital stock, license, withholding, payroll, employment, social security, unemployment,
excise, severance, stamp, occupation, property and estimated taxes, customs duties, fees,
assessments and charges of any kind whatsoever, (y)&nbsp;all interest, penalties, fines,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">additions to
tax or additional amounts imposed by any Governmental Authority in connection with any item
described in clause (x), and (z)&nbsp;any transferee liability in respect of any items described in
clauses (x)&nbsp;and/or (y)&nbsp;payable by reason of Contract, assumption, transferee liability, operation
of Law, Treasury Regulation &#167; 1.1502-6(a) (or any predecessor or successor thereof of any analogous
or similar provision under Law) or otherwise, and (ii) &#147;<U>Tax Returns</U>&#148; shall mean any return,
report, claim for refund, estimate, information return or statement or other similar document
relating to or required to be filed with any Governmental Authority with respect to Taxes,
including any schedule or attachment thereto, and including any amendment thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;This <U>Section&nbsp;3.10</U> contains the sole and exclusive representations and warranties
of the Company with respect to Tax matters.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.11 <U>Employee Benefits and Labor Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Section&nbsp;3.11(a) of the Company Disclosure Letter</U> lists each material Company Plan.
The Company has made available to Parent correct and complete copies of (i)
each Company Plan and any amendments thereto (or if the Company Plan is not a written Company
Plan, a description of the Company Plan), (ii)&nbsp;the most recent annual reports on Form&nbsp;5500 required
to be filed with the Internal Revenue Service (the &#147;<U>IRS</U>&#148;) with respect to each Company Plan
(if any such report was required), (iii)&nbsp;the most recent summary plan description for each Company
Plan for which such summary plan description is required, (iv)&nbsp;any related trust, agreement,
insurance contract or other funding vehicle, (v)&nbsp;the two most recent annual financial reports, if
any, (vi)&nbsp;any reports or summaries required under ERISA or the Code and (vii)&nbsp;the most recent
determination letter received from the IRS with respect to each Company Plan intended to qualify
under Section&nbsp;401 of the Code. Each Company Plan that is a Company Stock Plan is marked with an
asterisk (*) in <U>Section&nbsp;3.11(a) of the Company Disclosure Letter</U>. Each Company Plan
maintained, contributed to or required to be contributed to by the Company or any of its
Subsidiaries has been administered in accordance with its terms in all material respects. The
Company, its Subsidiaries and all the Company Plans are all in material compliance with the
applicable provisions of ERISA, the Code and all other applicable Laws. Each Company Plan that is
intended to be Tax qualified under Section 401(a) of the Code has received a favorable
determination letter from the IRS, and, to the Knowledge of the Company, there are no existing
circumstances or any events that could reasonably be expected to adversely affect the qualified
status of any such plan. There has been no amendment to, announcement by the Company or any
Subsidiary relating to, or change in employee participation or coverage under, any Company Plan
that would increase materially the expense of maintaining such plan above the level of the expense
incurred therefor for the most recent fiscal year, except as required by applicable Law or as
provided in <U>Section&nbsp;3.11(a) of the Company Disclosure Letter</U>. Neither the Company nor any
of its Subsidiaries maintains or, within the past six (6)&nbsp;years, has contributed or has been
obligated to contribute to an &#147;employee benefit plan&#148; subject to Title IV of ERISA, a multiemployer
plan, as defined in Section&nbsp;3(37) of ERISA, or an &#147;employee benefit plan&#148; subject to Sections&nbsp;4063
or 4064 of ERISA.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the Company, any Subsidiary, any Company Plan, any trust created thereunder, nor,
to the Knowledge of the Company, any trustee or third-party administrator of the foregoing, has
engaged in a transaction in connection with which the Company or any Subsidiary, any Company Plan,
any such trust, or any trustee or administrator
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the foregoing, or any party dealing with any
Company Plan or any such trust could be subject to either a civil penalty assessed pursuant to
Section&nbsp;409 or 502(i) of ERISA or a tax imposed pursuant to Section&nbsp;4975 or 4976 of the Code, other
than penalties or taxes that, would not, individually or in the aggregate, reasonably be expected
to be material.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except as disclosed in <U>Section&nbsp;3.11(c) of the Company Disclosure Letter</U> or the
Company SEC Documents, no Company Plan provides medical, surgical, hospitalization, death or
similar benefits (whether or not insured) for employees or former employees of the Company or any
Subsidiary for periods extending beyond their retirement or other termination of service, other
than (i)&nbsp;coverage mandated by applicable Law, (ii)&nbsp;death benefits under any pension plan, or (iii)
benefits the full costs of which are borne by the current or former employee (or his beneficiary).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company acknowledges that certain payments have been made or are to be made and
certain benefits have been granted or are to be granted according to employment compensation,
severance and other arrangements or agreements or pursuant to the terms of this
Agreement (collectively, the &#147;<U>Company Compensation Arrangements</U>&#148;) to certain holders
of Company Common Stock and other securities of the Company (the &#147;<U>Covered Stockholders</U>&#148;).
Amounts payable under the Company Compensation Arrangements (i)&nbsp;were or are being paid or granted
as compensation for past services performed, future services to be performed or future services to
be refrained from performing, by the Covered Stockholders (and matters incidental thereto) and (ii)
are not calculated based on the number of shares of Company Common Stock to be tendered in the
Offer by the applicable Covered Stockholder. In connection therewith, the Compensation Committee
of the Company Board has adopted resolutions, substantially in the form set forth in <U>Section
3.11(d) of the Company Disclosure Letter</U>, approving the Company Compensation Arrangements, in
accordance with the &#147;safe harbor&#148; requirements of Rule&nbsp;14d-10(d)(2) under the Exchange Act and the
instructions thereto, to the extent required (collectively the &#147;<U>14d-10 Approvals</U>&#148;). The
Company Board has determined that each of the members of the Compensation Committee of the Company
Board is &#147;independent&#148; as defined in the rules of NASDAQ.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company and each of its Subsidiaries is in material compliance with all applicable
Laws respecting labor, employment, fair employment practices, terms and conditions of employment,
workers&#146; compensation, occupational safety and health requirements, plant closings, wages and
hours, withholding of taxes, employment discrimination, disability rights or benefits, equal
opportunity, affirmative action, labor relations, employee leave issues and unemployment insurance
and related matters. To the Knowledge of the Company, all individuals who provide services to the
Company or any Subsidiary have at all times been accurately classified by the Company or such
Subsidiary with respect to such services as an employee or a non-employee. Except as disclosed in
<U>Section&nbsp;3.11(e) of the Company Disclosure Letter</U> and except for instances that could not
reasonably be expected to, individually or in the aggregate, result in a Company Material Adverse
Effect: (i)&nbsp;there is no pending or, to the Knowledge of the Company, threatened labor strike,
slowdown or stoppage against or affecting the Company or any Subsidiary of the Company and (ii)
neither the Company nor any Subsidiary has received notice of (A)&nbsp;any unfair labor practice charge
or complaint pending before the National Labor Relations Board or any other Governmental Authority
against it, (B)&nbsp;any charge or complaint against it pending before the Equal Employment Opportunity
Commission or any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other Governmental Authority responsible for the prevention of unlawful
employment practices, or (C)&nbsp;any complaint or lawsuit against the Company or any Subsidiary
concerning employees or former employees of the Company or any Subsidiary alleging employment
discrimination or violations of occupational safety and health requirements pending before a court
of competent jurisdiction. Neither the Company nor any of its Subsidiaries is a party to a
collective bargaining agreement, and no labor union has been certified to represent any employee of
the Company or any of its Subsidiaries or, to the Knowledge of the Company, has applied to
represent or is attempting to organize so as to represent such employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except as disclosed in <U>Section&nbsp;3.11(f) of the Company Disclosure Letter</U>, other
than routine claims for benefits, there are no pending, or to the Knowledge of the Company,
threatened or anticipated claims by or on behalf of (i)&nbsp;any Company Plan, by any employee or
beneficiary covered under any Company Plan, or otherwise involving any Company Plan or (ii)&nbsp;any
current or former employee of the Company or any Subsidiary relating to his or her employment,
termination of employment, compensation or employee benefits.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;No officer, employee, director, consultant or other service provider of the Company or any
of its Subsidiaries is entitled to receive any Tax gross-up, indemnity or similar payment from the
Company or any of its Subsidiaries as a result of the imposition of any income Tax or excise Tax
under Section&nbsp;409A of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Section&nbsp;3.11(h) of the Company Disclosure Letter</U> lists each (i)&nbsp;severance or
employment agreement with directors, officers or employees of or consultants to the Company or any
of its Subsidiaries and (ii)&nbsp;severance program or policy of the Company or any of its Subsidiaries
with or relating to its employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Except as contemplated in <U>Section&nbsp;2.10</U> or as set forth in <U>Section&nbsp;3.11(i) of
the Company Disclosure Letter</U>, neither the Offer, the execution of this Agreement or the
consummation of the transactions contemplated by this Agreement will, either alone or in
conjunction with another event, (i)&nbsp;entitle any current or former employee, consultant, officer or
director of the Company or any of Subsidiary to severance pay or any other payment, (ii)&nbsp;result in
any payment becoming due, accelerate the time of payment or vesting, or increase the amount of
compensation due to any such employee, consultant, officer or director, (iii)&nbsp;result in any
forgiveness of indebtedness, trigger any funding obligation under any Company Plan or impose any
restrictions or limitations on the Company&#146;s rights to administer, amend or terminate any Company
Plan, or (iv)&nbsp;result in any payment (whether in cash or property or the vesting of property) to any
&#147;disqualified individual&#148; (as such term is defined in Treasury Regulation&nbsp;Section&nbsp;1.280G-1) that
could reasonably be construed, individually or in combination with any other such payment, to
constitute an &#147;excess parachute payment&#148; (as defined in Section&nbsp;280G(b)(1) of the Code). Except as
set forth in <U>Section&nbsp;3.11(i) of the Company Disclosure Letter</U>, no person is entitled to
receive any additional payment (including any tax gross up or other payment) from the Company or
any Subsidiary or any other person as a result of the imposition of the excise tax required by
Section 4999(a) of the Code.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.12 <U>Contracts</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except for this Agreement, <U>Section&nbsp;3.12(a) of the Company Disclosure Letter</U> sets
forth a correct and complete list, and the Company has made available to Parent correct and
complete copies, of all Contracts (including all material amendments, modifications, extensions or
renewals with respect thereto, but excluding all names, terms and conditions that have been
redacted in compliance with the terms of each such Contract or with applicable Laws governing the
sharing of information) to which the Company or any of its Subsidiaries is a party as of the date
of this Agreement (collectively, the &#147;<U>Company Contracts</U>&#148;):
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) that are required to be filed as an exhibit to any report of the Company
filed pursuant to the Exchange Act of the type described in Item&nbsp;601(b)(10) of
Regulation&nbsp;S-K promulgated by the SEC;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) that contain a covenant restricting the ability of the Company or any of
its Subsidiaries (x)&nbsp;to compete in any business or with any Person or in any
geographic area, (y)&nbsp;to sell to or purchase from any other Person or (z)&nbsp;to hire or
solicit for employment any individuals or groups of individuals;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) that contain change-of-control provisions relating to the Company or any
of its Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) with respect to the employment of any directors, executive officers or
other senior officers of the Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) with any Affiliate of the Company (other than any of its Subsidiaries and
other than employment or compensation-related Contracts);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) which substantially relates to (A)&nbsp;the granting to the Company or any of
its Subsidiaries of any IP License in or to any material Company Intellectual
Property owned by a third party, or (B)&nbsp;the granting by the Company or any of its
Subsidiaries of any IP License to a third party in or to any material Company
Intellectual Property, in each of clause (A)&nbsp;and (B)&nbsp;above, excluding &#147;click-wrap&#148;
or &#147;shrink-wrap&#148; agreements, agreements contained in or pertaining to
&#147;off-the-shelf&#148; Software, or the terms of use or service for any web site;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) relating to any joint venture, partnership or other similar arrangement
involving co-investment with a third party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) with a Governmental Authority (other than ordinary course Contracts with
Governmental Authorities as a customer) which impose any material obligation or
restriction on the Company or any of its Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) relating to any indebtedness for borrowed money of the Company or any of
its Subsidiaries is outstanding or may be incurred or pursuant to which the Company
or any of its Subsidiaries has guaranteed any indebtedness for borrowed money of any
other Person (other than the Company or any of its Subsidiaries and excluding trade
payables arising in the ordinary course of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">business) or that is a mortgage, security
agreement, capital lease or similar agreements that creates a lien on any material
asset of the Company or any of its Subsidiaries, in each case involving annual
payments of more than $75,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) that is a service contract, equipment lease or arrangement (other than
purchase orders entered into in the ordinary course of business) with respect to the
receipt of goods and services involving payments by the Company or any of its
Subsidiaries of more than $75,000 in the aggregate over the term of such contract;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) pursuant to which the Company, any of its Subsidiaries or any other party
thereto has material continuing obligations, rights or interests relating to the
research, development, clinical trial, distribution, supply, manufacture, testing,
design, marketing or co-promotion of, or collaboration with respect to, any products
or product candidates of the Company or any of its Subsidiaries, including material
manufacture or supply services or material Contracts with contract research
organizations for clinical trials-related services; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) relating to the future disposition or acquisition of any material assets
or properties, other than dispositions or acquisitions in the ordinary course of
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Company Contract is valid and binding on the Company and each of its Subsidiaries
which is party thereto and, to the Knowledge of the Company, each other party thereto, and is in
full force and effect, and the Company and each of its Subsidiaries has performed all obligations
required to be performed by them prior to the date of this Agreement under each Company Contract
and, to the Knowledge of the Company, each other party to each Company Contract has performed all
obligations required to be performed by it prior to the date of this Agreement under such Company
Contract, except for such failures to be in compliance by the Company, any of its Subsidiaries or
such other party as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.13 <U>Environmental Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company and each of its Subsidiaries is in compliance with (i)&nbsp;all applicable federal,
state, local and foreign Laws, judicial decisions, rules, judgments, codes, injunctions, permits
and binding government agreements concerning pollution or protection of the environment or human
health as it relates to exposure to pollution, including without limitation all those relating to
the presence, use, production, generation, handling, transportation, treatment, storage, disposal,
distribution, labeling, testing, processing, discharge, release, threatened release, control or
cleanup of any Hazardous Materials, substances or wastes, as such requirements are enacted and in
effect on the date of this Agreement (&#147;<U>Environmental Laws</U>&#148;), and (ii)&nbsp;any Permits required
under applicable Environmental Laws for the current operations of the Company and each of its
Subsidiaries, except for any such instances of non-compliance that would not, individually or in
the aggregate, reasonably be expected to have a Company Material Adverse Effect.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as disclosed in <U>Section&nbsp;3.13(b) of the Company Disclosure Letter</U> or except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i)&nbsp;neither the Company nor any of its Subsidiaries has received any written
notice, notification, demand, request for information, citation, summons, complaint or order, and
no action, claim, suit, proceeding or review or investigation is pending or, to the Knowledge of
the Company, threatened by any Person against the Company or any of its Subsidiaries, with respect
to any matters relating to or arising out of any Environmental Law; and (ii)&nbsp;none of the Company or
its Subsidiaries has Released Hazardous Materials at any of its currently or formerly owned, leased
or operated properties or facilities in a manner that has subjected the Company or any of its
Subsidiaries to a remedial obligation under Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;This <U>Section&nbsp;3.13</U> contains the sole and exclusive representations and warranties
of the Company with respect to any environmental matters, including without limitation any arising
under any Environmental Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.14 <U>Intellectual Property</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As used herein: (i) &#147;<U>Intellectual Property</U>&#148; means all U.S. and foreign (A)
trademarks, service marks, trade names, Internet domain names, corporate names, designs, logos,
trade dress, slogans and other source identifiers, together with goodwill, registrations and
applications for registration relating to the foregoing (&#147;<U>Trademarks</U>&#148;), (B)&nbsp;patents and
patent applications, invention disclosure statements, invention registrations of any type and any
and all divisions, continuations, continuations-in-part, reissues, reexaminations and extensions
thereof, any counterparts claiming priority therefrom and like statutory rights
(&#147;<U>Patents</U>&#148;), (C)&nbsp;copyrightable works, registered and unregistered copyrights (including
those in Software) and registrations and applications to register the same, (D)&nbsp;confidential and
proprietary information, including confidential technology, know-how, inventions, trade secrets,
processes, formulae, algorithms, specifications, models and methodologies and (E)&nbsp;databases and
compilations, including any and all electronic data and electronic collections of data; (ii)
&#147;<U>IP Licenses</U>&#148; means any license or sublicense rights in or to any Intellectual Property;
(iii) &#147;<U>Software</U>&#148; means all computer programs, including any and all software
implementations of algorithms, models and methodologies whether in source code or object code form,
and all documentation, including user manuals and training materials, related to any of the
foregoing; (iv) &#147;<U>Licenses In</U>&#148; means all licenses, sublicenses and other agreements pursuant
to which the Company or any of its Subsidiaries is authorized to use any third party Intellectual
Property that is material to the business of the Company or any of its Company Subsidiaries; (v)
&#147;<U>Licenses Out</U>&#148; means all licenses, sublicenses and other agreements pursuant to which the
Company or any of its Subsidiaries authorizes any third party to use any Company Intellectual
Property and (vi) &#147;<U>Company Intellectual Property</U>&#148; means Intellectual Property that is owned
or exclusively licensed by the Company or any of its Subsidiaries and used in the Company&#146;s or its
Subsidiaries&#146; business, as currently conducted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as would not, individually or in the aggregate, be reasonably expected to be
materially adverse to the Company and its Subsidiaries taken as a whole, to the Knowledge of the
Company, either the Company or one of its Subsidiaries owns or possesses appropriate licenses or
other legal rights to use, sell or license all Company Intellectual Property.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the Knowledge of
the Company, except as set forth on <U>Section&nbsp;3.14(b) of the Company Disclosure Letter</U>, the
Company and its Subsidiaries own or have the rights to use, free and clear of any liens, but
subject to any existing licenses or other grants of rights to third parties, all material
Intellectual Property as is necessary and sufficient to conduct the Company&#146;s and its Subsidiaries&#146;
respective businesses as currently conducted and for the manufacture, use and sale of the products
currently marketed and the products currently in clinical development by the Company and its
Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except as would not, individually or in the aggregate, be reasonably expected to be
materially adverse to the Company and its Subsidiaries taken as a whole, and except as set forth in
<U>Section&nbsp;3.14(c) of the Company Disclosure Letter</U>, (i)&nbsp;each of the Company Intellectual
Property is, to the Knowledge of the Company, valid, subsisting and enforceable, (ii)&nbsp;none of the
Company Intellectual Property has been or is subject to an adverse judgment, injunction, order,
decree or agreement restricting its use or the assignment or license thereof by
the Company, (iii)&nbsp;to the Knowledge of the Company, no Patent included in the Company
Intellectual Property is currently involved in any interference, reissue, reexamination or
opposition proceeding, (iv)&nbsp;no Trademark included in the Company Intellectual Property is or has
been or is currently involved in any opposition, concurrent use, cancellation, invalidity or other
similar proceeding, (v)&nbsp;no Trademark included in the Company Intellectual Property is subject to a
consent agreement or coexistence agreement, and (vi)&nbsp;neither the Company nor any of its
Subsidiaries has agreed to, or is otherwise bound by, any covenant not to use or register, or to
permit any other Person to use or to register, any of the Company Intellectual Property or has
agreed to, or is otherwise bound by, any covenant not to sue for infringement, misuse, dilution or
other violation of any of the Company Intellectual Property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except as would not, individually or in the aggregate, be reasonably expected to be
materially adverse to the Company and its Subsidiaries taken as a whole
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) as of the date of this Agreement, there are no pending or, to the Knowledge
of the Company, threatened claims by any Person alleging infringement,
misappropriation, dilution or violation by the Company or any of its Subsidiaries of
any Intellectual Property of any Person and, to the Knowledge of the Company, the
conduct of the businesses of the Company and its Subsidiaries and the manufacture,
use and sale of the products currently marketed and the products currently in
clinical development by the Company and its Subsidiaries does not infringe,
misappropriate, or otherwise violate any Intellectual Property rights of any Person;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) as of the date of this Agreement, neither the Company nor any of its
Subsidiaries has made any claim of an infringement, misappropriation, dilution or
other violation by another Person of rights to or in connection with the Company
Intellectual Property or the products marketed and the products currently in
development by the Company and its Subsidiaries and, to the Knowledge of the
Company, no Person is infringing, misappropriating, diluting or violating any
Company Intellectual Property;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) no settlement agreements, consents, orders, forbearances to sue or
similar obligations to which the Company or any of its Subsidiaries is a party limit
or restrict any rights of the Company or any of its Subsidiaries in and to any
Company Intellectual Property;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) subject to third party licenses, no Person (other than the Company or its
Subsidiaries), including any current or former employee or consultant of the Company
or its Subsidiaries, has any proprietary, commercial or other interest in any of the
Company Intellectual Property, including goodwill associated therewith;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) neither the Company nor any of its Subsidiaries has licensed or sublicensed
its rights in any Company Intellectual Property, or received or been granted any
such rights (except pursuant to &#147;click-wrap&#148; or &#147;shrink-wrap&#148; agreements, agreements
contained in or pertaining to &#147;off-the-shelf&#148; Software, or
the terms of use or service for any website), other than pursuant to the IP
Licenses;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) for the Company&#146;s and its Subsidiaries&#146; products that are currently
marketed, all material Licenses In and material Licenses Out are in full force and
effect and have not terminated or expired, and there are no material disputes or
Actions or Proceedings pending or to the Knowledge of the Company threatened
regarding the same;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) neither the Company nor any of its Subsidiaries is and, to the Knowledge
of the Company, no other party is in breach or violation of, or default under, in
any material respect, any material Licenses In or material Licenses Out, and to the
Company&#146;s Knowledge, no event has occurred or circumstances exist that may
reasonably be expected to (with notice, a lapse of time or both) constitute or
result in such a default; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) neither the execution and delivery of this Agreement, the performance of
the Company of its obligations hereunder nor the consummation of the Offer, the
Merger or the other Transactions will result in the loss or impairment of any rights
of the Company or any of its Subsidiaries to own or use any of the Company
Intellectual Property or obligate the Company or any of its Subsidiaries to pay any
royalties or other amounts to any third party in excess of the amounts that would
have been payable by them absent such execution and delivery, performance or
consummation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company and its Subsidiaries have made commercially reasonable decisions with respect
to the filing, prosecution and maintenance of all Intellectual Property owned or exclusively
licensed by the Company or any of its Subsidiaries. Except where the failure to do so would not
reasonably be expected to be, individually or in the aggregate, materially adverse to the Company
and its Subsidiaries taken as a whole, any filing, registration, issuance, maintenance and renewal
fees in connection with the Company Intellectual Property have been filed in a timely manner with
the relevant Governmental Authority.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.15 <U>Products and Operations; Manufacturing</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The operations and commercial products of the Company and its Subsidiaries have at all
times conformed in all material respects to a compliance program that utilizes internal controls
and promotional guidelines to provide reasonable assurance of adherence to Laws applicable to a
pharmaceutical manufacturer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To the Knowledge of the Company, except as set forth in <U>Section&nbsp;3.15(b) of the Company
Disclosure Letter</U> no (i)&nbsp;supplier of a raw material or active ingredient required for the
manufacture of a product of the Company or any of its Subsidiaries or (ii)&nbsp;manufacturer of a
product of the Company or any of its Subsidiaries for which there is not a permissible replacement
obtainable under commercially reasonable terms, including timing of such replacement to ensure
uninterrupted supply of a finished product in quantities consistent with past practice, has
indicated that it will not continue to supply such raw material or manufacture
such product, as the case may be, on terms consistent with those pursuant to which such raw
material is supplied or such product is manufactured, as the case may be, as of the date of this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.16 <U>Insurance</U>. The Company has made available to Parent copies of all
binders of material insurance policies maintained by the Company and its Subsidiaries, including
fire and casualty, general liability, product liability, business interruption, directors and
officers and other professional liability policies. All such insurance policies are in full force
and effect. There is no material claim pending under any policies or Contracts of insurance
maintained by the Company or any of its Subsidiaries as to which coverage has been questioned,
denied or disputed by the issuers of such policies or Contracts. All premiums due and payable to
date under all such policies and Contracts have been paid and neither the Company nor any of its
Subsidiaries are is in breach or default, and neither the Company nor any of its Subsidiaries has
taken any action or failed to take any action which (including with respect to the transactions
contemplated by this Agreement), with notice or lapse or time or both, would constitute such a
breach or default, or permit a termination or modification of any of such policies and Contracts,
except for such failures to pay, perform or otherwise be in compliance which would not,
individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.17 <U>Real Property</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Neither the Company nor any of its Subsidiaries owns any real property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Section&nbsp;3.17(b) of the Company Disclosure Letter</U> sets forth a complete and
accurate list as of the date of this Agreement of all real property leased, subleased or licensed,
or otherwise occupied (whether as a tenant, subtenant or pursuant to other occupancy arrangements),
by the Company or any of its Subsidiaries (collectively &#147;<U>Company Leases</U>&#148;), together with
the location of the premises. As of the date of this Agreement, except as would not, individually
or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i)&nbsp;each
Company Lease is in full force and effect and constitutes the valid and legally binding obligation
of the Company or its Subsidiaries, enforceable in accordance with its terms, subject to the
Bankruptcy and Equity Exception, and (ii)&nbsp;neither the Company nor any of
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">its Subsidiaries nor, to
the Company&#146;s Knowledge, any other party to any Company Lease is in default in any material respect
under any of the Company Leases, and, to the Company&#146;s Knowledge, no event has occurred or
circumstances exist that may (with notice, a lapse of time or both) constitute or result in such a
default. Neither the Company nor any of its Subsidiaries leases, subleases or licenses any real
property to any Person other than the Company and its Subsidiaries. The Company has made available
to the Parent complete and accurate copies of all Company Leases.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;As of the date of this Agreement, except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect, or as set forth in <U>Section
3.17(c) of the Company Disclosure Letter</U>, the Company and/or its Subsidiaries have valid
leasehold estates in all real property leased, subleased or licensed, or otherwise occupied
pursuant to the Company Leases (&#147;<U>Leased Real Property</U>&#148;), in each case, free and clear of
all liens. With respect to all Leased Real Property, all
buildings, improvements and fixtures and equipment located thereon and used in the business of
the Company (x)&nbsp;are in all material respects in reasonably good condition and repair (ordinary wear
and tear excepted) and are sufficient for the operation of the business of the Company; and (y)&nbsp;are
in material compliance with zoning and other applicable land use regulations for their current
uses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.18 <U>Opinion of Financial Advisor</U>. The Company Board has received the opinion
of Cowen and Company, LLC to the effect that, as of the date of this Agreement, and subject to the
various assumptions and qualifications set forth therein, the consideration to be received by the
holders of Company Common Stock, other than Parent and its Affiliates, in the Offer and the Merger
is fair, from a financial point of view, to such holders. A copy of such opinion has been, or will
promptly be, delivered to Parent. As of the date of this Agreement, such opinion has not been
withdrawn or revoked or otherwise modified in any material respect, and the Company has received
the consent of Cowen and Company, LLC to include such opinion in the Schedule&nbsp;14D-9 and the Proxy
Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.19 <U>Brokers and Other Advisors</U>. Except for Cowen and Company, LLC, the fees
and expenses of which will be paid by the Company, no broker, investment banker, financial advisor,
agent or other Person is entitled to any broker&#146;s, finder&#146;s, financial advisor&#146;s, agent&#146;s or other
similar fee or commission, or the reimbursement of expenses, in connection with the Transactions
based upon arrangements made by or on behalf of the Company or any of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.20 <U>No Other Representations or Warranties</U>. Except for the representations
and warranties made by the Company in this Agreement, neither the Company nor any other Person
makes any representation or warranty with respect to the Company or its Subsidiaries or their
respective businesses, operations, assets, liabilities, condition (financial or otherwise) or
prospects, notwithstanding the delivery or disclosure to Parent or any of its Affiliates or
Representatives of any documentation, forecasts or other information with respect to any one or
more of the foregoing.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Representations and Warranties of Parent and Purchaser</U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Parent and Purchaser represent and warrant to the Company that:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.1 <U>Organization and Standing</U>. Parent is a corporation duly organized,
validly existing and in good standing under the Laws of the State of Delaware and Purchaser is a
corporation validly existing and in good standing under the Laws of the State of Delaware. Parent
is duly licensed or qualified to do business and is in good standing in each jurisdiction in which
the nature of the business conducted by it or the character or location of the properties and
assets owned or leased or held under license by it makes such licensing or qualification necessary,
except where the failure to be so licensed, qualified or in good standing would not, individually
or in the aggregate, reasonably be expected to impair in any material respect the ability of Parent
to perform its obligations hereunder or prevent or materially delay consummation of the
Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.2 <U>Authority; Noncontravention</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of Parent and Purchaser has all necessary corporate power and authority to execute
and deliver this Agreement, to perform their respective obligations hereunder and to consummate the
Transactions. The execution, delivery and performance by Parent and Purchaser of this Agreement,
and the consummation by Parent and Purchaser of the Transactions, have been duly authorized and
approved by their respective Boards of Directors and adopted by Parent as the sole stockholder of
Purchaser, and no other corporate action on the part of Parent or any of its stockholders or
Purchaser is necessary to authorize the execution, delivery and performance by Parent and Purchaser
of this Agreement and the consummation by them of the Transactions. This Agreement has been duly
executed and delivered by Parent and Purchaser and, assuming due authorization, execution and
delivery hereof by the Company, constitutes a legal, valid and binding obligation of each of Parent
and Purchaser, enforceable against each of them in accordance with its terms, subject to the
Bankruptcy and Equity Exception.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the execution and delivery of this Agreement by Parent and Purchaser, nor the
consummation by Parent or Purchaser of the Transactions, nor compliance by Parent or Purchaser with
any of the terms or provisions hereof, will (i)&nbsp;conflict with or violate any provision of the
certificate of incorporation or bylaws of Parent or Purchaser or (ii)&nbsp;assuming that the
authorizations, consents and approvals referred to in <U>Section&nbsp;4.3</U> are obtained and the
filings referred to in <U>Section&nbsp;4.3</U> are made, (x)&nbsp;violate any Law, judgment, writ or
injunction of any Governmental Authority applicable to Parent or any of its Subsidiaries, or
(y)&nbsp;violate or constitute a default under any of the terms, conditions or provisions of any
Contract to which Parent, Purchaser or any of their respective Subsidiaries is a party, except, in
the case of this clause (ii), for such violations or defaults as would not, individually or in the
aggregate, reasonably be expected to impair the ability of Parent or Purchaser to perform its
obligations hereunder or prevent or materially delay consummation of the Transactions.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.3 <U>Governmental Approvals</U>. Except for (i)&nbsp;the filing with the SEC of the
Offer Documents and other filings required under, and compliance with other applicable requirements
of, the Exchange Act and the rules of NASDAQ, (ii)&nbsp;the filing of the Certificate of Merger with the
Secretary of State of the State of Delaware pursuant to the DGCL, and (iii)&nbsp;filings required under,
and compliance with other applicable requirements of, the HSR Act, no consents or approvals of, or
filings, declarations or registrations with, any Governmental Authority are necessary for the
execution, delivery and performance of this Agreement by Parent and Purchaser or the consummation
by Parent and Purchaser of the Transactions, other than such other consents, approvals, filings,
declarations or registrations that, if not obtained, made or given, would not, individually or in
the aggregate, reasonably be expected to impair in any material respect the ability of Parent or
Purchaser to perform its obligations hereunder or prevent or materially delay consummation of the
Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.4 <U>Information Supplied</U>. Subject to the accuracy of the representations and
warranties of the Company set forth in <U>Section&nbsp;3.9</U>, neither the Offer Documents nor any
information supplied (or to be supplied) in writing by or on behalf of Parent or Purchaser
specifically for inclusion or incorporation by reference in the Schedule&nbsp;14D-9 will, at the
respective times the Offer Documents, the Schedule&nbsp;14D-9, or any amendments or supplements
thereto, are filed with the SEC or at the time they are first published, sent or given to the
holders of Company Common Stock, or at the expiration of the Offer, as the case may be, contain any
untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in the light of the
circumstances under which they are made, not misleading. The information supplied by Parent for
inclusion or incorporation by reference in the Proxy Statement (if any) will not, on the date it is
first mailed to the holders of Company Common Stock, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under which they are made, not
misleading, and will not, at the time of the Company Stockholders Meeting (if such a meeting is
held), omit to state any material fact necessary to correct any statement in any earlier
communication with respect to the Company Stockholders Meeting which shall have become false or
misleading in any material respect. The Offer Documents will comply as to form in all material
respects with the applicable requirements of the Exchange Act. Notwithstanding the foregoing,
Parent and Purchaser make no representation or warranty with respect to any information supplied by
or on behalf of the Company for inclusion or incorporation by reference in any of the foregoing
documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.5 <U>Ownership and Operations of Purchaser</U>. Parent owns beneficially and of
record all of the outstanding capital stock of Purchaser. Purchaser was formed solely for the
purpose of engaging in the Transactions, has engaged in no other business activities and has
conducted its operations only as contemplated hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.6 <U>Capital Resources</U>. Parent and Purchaser collectively have or will have at
the dates that Purchaser becomes obligated to accept for payment and pay for Shares pursuant to the
Offer, and at the Effective Time, sufficient cash resources available to pay (i)&nbsp;for the Shares
that Purchaser becomes so obligated to accept for payment and pay for pursuant to the Offer,
(ii)&nbsp;for the shares of Series&nbsp;D-1 Preferred Stock that Purchaser becomes obligated to pay for
pursuant to the Preferred Stockholder Agreement, (iii)&nbsp;the aggregate Merger Consideration
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">pursuant
to the Merger, (iv)&nbsp;the aggregate Option Consideration, and (v)&nbsp;all fees and expenses payable by
them in connection with the Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.7 <U>Legal Proceedings</U>. As of the date of this Agreement, there is no pending
or, to the Knowledge of Parent, threatened Action or Proceeding against or relating to Parent or
any of its Subsidiaries, nor is there any injunction, order, judgment, ruling or decree imposed
upon Parent or any of its Subsidiaries, in each case, by or before any Governmental Authority, that
would, individually or in the aggregate, reasonably be expected to impair in any material respect
the ability of Parent to perform its obligations hereunder or prevent or materially delay
consummation of the Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.8 <U>Brokers and Other Advisors</U>. Except for Credit Suisse Securities (Europe)
Limited, the fees and expenses of which will be paid by Parent, no broker, investment banker,
financial advisor, agent or other Person is entitled to any broker&#146;s, finder&#146;s, financial
advisor&#146;s, agent&#146;s or other similar fee or commission, or the reimbursement of expenses, in
connection with the Transactions based upon arrangements made by or on behalf of Parent or any of
its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.9 <U>Ownership of Company Common Stock</U>. Neither Parent nor any of its
Affiliates beneficially owns (as defined in Rule&nbsp;13d-3 of the Exchange Act) any Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.10 <U>No Reliance</U>. Notwithstanding anything contained in this Agreement to the
contrary, (a)&nbsp;neither the Company nor any Person on behalf of the Company is making any
representations or warranties whatsoever, express or implied, beyond those expressly made by the
Company in this Agreement, and (b)&nbsp;neither Parent nor Purchaser has been induced by, or relied
upon, any representations, warranties or statements (written or oral), whether express or implied,
made by any Person, that are not expressly set forth in this Agreement. Without limiting the
generality of the foregoing, each of Parent and Purchaser acknowledges that, except as expressly
set forth in this Agreement, no representations or warranties are made with respect to any
projections, forecasts, estimates, budgets or information as to prospects with respect to the
Company and its Subsidiaries that may have been made available to Parent, Purchaser or any of their
respective representatives.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Additional Covenants and Agreements</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.1 <U>Conduct of Business</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as expressly contemplated or permitted by this Agreement or as required by
applicable Law or as set forth in <U>Section&nbsp;5.1(a) of the Company Disclosure Letter</U>, during
the period from the date of this Agreement until the Effective Time, unless Parent otherwise
consents (which consent shall not be unreasonably withheld, conditioned or delayed), the Company
shall, and shall cause each of its Subsidiaries to, (x)&nbsp;conduct its business in the ordinary course
and in conformity with past practice and (y)&nbsp;use its reasonable best efforts to (A)&nbsp;preserve
substantially intact its business organization, its customer and supplier relationships and its
goodwill, and (B)&nbsp;retain its officers and key employees, and, without limiting the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">generality of
the foregoing, the Company shall not, and shall not permit any of its Subsidiaries to:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (A)&nbsp;issue, deliver, sell or grant, pledge or otherwise encumber or subject
to any lien any shares of its capital stock, or any securities or rights convertible
into, exchangeable or exercisable for, or evidencing the right to subscribe for any
shares of its capital stock, or any rights, warrants or options to purchase any
shares of its capital stock, or any securities or rights convertible into,
exchangeable or exercisable for, or evidencing the right to subscribe for, any
shares of its capital stock; <U>provided</U> that the Company may issue shares of
Company Common Stock upon the exercise of Company Options or the conversion of any
shares of Series&nbsp;D-1 Preferred Stock that are outstanding on the date of this
Agreement, (B)&nbsp;redeem, purchase or otherwise acquire any of its outstanding shares
of capital stock, or any rights, warrants or options to acquire any shares of its
capital stock, except in accordance with or pursuant to written commitments in
effect as of the date of this Agreement, (C)&nbsp;other than in accordance with the
Series&nbsp;D-1 Preferred Stock Certificate of Designation, declare, set aside for
payment or pay any dividend on, or make any other
distribution in respect of, any shares of its capital stock, (D)&nbsp;split,
combine, subdivide or reclassify any shares of its capital stock or (E)&nbsp;enter into
any agreement, understanding or arrangement with respect to the sale, voting,
registration or repurchase of its capital stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) (A)&nbsp;incur any new indebtedness for borrowed money or guarantee any such
indebtedness, (B)&nbsp;make any loans, advances or capital contributions to, or
investments in, any Person other than the Company or any of its Subsidiaries or in
the ordinary course of business or (C)&nbsp;repurchase or prepay any indebtedness for
borrowed money, except as required by the terms of such indebtedness or for payments
made in the ordinary course of business;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) sell, transfer or encumber any of its properties or assets, except
(A)&nbsp;sales, leases, rentals and licenses in the ordinary course of business,
(B)&nbsp;pursuant to Contracts in force at the date of this Agreement or entered into
after the date of this Agreement to the extent permitted by the terms of this
Agreement, (C)&nbsp;dispositions of obsolete or worthless assets or (D)&nbsp;transfers among
the Company and its Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) make capital expenditures in excess of $500,000 in the aggregate for the
Company and its Subsidiaries taken as a whole, except to the extent provided for in
the capital budget set forth in <U>Section&nbsp;5.1(a)(iv) of the Company Disclosure
Letter</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) directly or indirectly acquire (A)&nbsp;by merging, consolidating with,
purchasing a material portion of the assets of, by making an investment in or
capital contribution to, or by any other manner, any Person or division, business or
equity interest of any Person or (B)&nbsp;any assets, rights, or properties except
(1)&nbsp;for capital expenditures (which shall be governed by clause (iv)&nbsp;above), (2)&nbsp;for
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">purchases of inventory, raw materials or supplies, or services in the ordinary
course of business consistent with past practice and (3)&nbsp;pursuant to Contracts in
effect as of the date of this Agreement or entered into after such date in
compliance with this <U>Section&nbsp;5.1</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) increase the compensation of any of their directors, officers or
employees, other than (A)&nbsp;as required pursuant to applicable Law or the terms of a
Company Plan in effect on the date of this Agreement or entered into after the date
of this Agreement to the extent permitted by the terms of this Agreement and
(B)&nbsp;increases in salaries, wages and benefits of employees (other than directors,
executive officers or employees who earn more than $100,000 in annual base salary)
made in the ordinary course of business consistent with past practice;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) (A)&nbsp;grant or pay to any current or former director, officer, employee or
consultant of the Company or any Subsidiaries any cash compensation or other benefit
not provided for under any Company Plan (other than the payment of customary cash
compensation in the ordinary course of business consistent with past practice) in
existence on the date of this Agreement
or entered into after such date in compliance with this <U>Section&nbsp;5.1</U>,
(B)&nbsp;adopt any new employee benefit plan or arrangement or amend, modify or terminate
any existing Company Plan to increase the benefits thereunder, in each case for the
benefit of any current or former director, officer, employee or consultant of the
Company or any Subsidiary, other than as required by applicable Tax qualification
requirements, (C)&nbsp;make any new equity awards to any director, employee or consultant
of the Company or any of its Subsidiaries, (D)&nbsp;take any action to accelerate the
vesting or payment, or fund or in any other way secure the payment, compensation or
benefits under, any Company Plan to the extent not required by the terms of this
Agreement or such Company Plan as in effect on the date of this Agreement or
(E)&nbsp;enter into or amend any collective bargaining agreements; <U>provided</U>,
<U>however</U>, that nothing in this <U>Section&nbsp;5.1(a)(vii)</U> shall prevent the
Company or its Subsidiaries from hiring new employees as non-officers or
non-directors of the Company in the ordinary course of business consistent with past
practice so long as the amount of salaries, wages, bonuses and benefits provided to
such new employees shall be in the ordinary course of business consistent with past
practice;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) make, change or resolve any material election concerning Taxes or settle
or compromise any material Tax liability, file any material amended Tax Return, or
surrender any claim for a material refund of Taxes;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) make any changes in financial or Tax accounting methods, principles or
practices (or change an annual accounting period), except insofar as may be required
by a change in GAAP or applicable Law;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) amend the Company Charter Documents or create any new Subsidiaries;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) adopt a plan or agreement of complete or partial liquidation or
dissolution;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) adopt or enter into any collective bargaining agreement or other labor
union Contract applicable to the employees of the Company or any Subsidiary of the
Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) permit any insurance policy naming the Company or any of its
Subsidiaries as a beneficiary or a loss payable payee to lapse, be canceled or
expire unless a new policy with substantially identical coverage is in effect as of
the date of lapse, cancellation or expiration;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) enter into any new line of business that is material to the Company and
the Subsidiaries of the Company, taken as a whole;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) (A)&nbsp;enter into, terminate, materially modify, renew or waive any material
provision of any Contract that is or would be a Company Contract, if it had been
entered into prior to the date of this Agreement or (B)&nbsp;enter into, terminate,
materially modify, renew or waive any material provision under any
Contract (other than a Company Contract, which shall be governed by clause (A)
above) (i)&nbsp;that would reasonably be expected to materially delay or prevent the
consummation of the Merger or any of the Transactions or (ii)&nbsp;that has a term of two
(2)&nbsp;years or more and that involves payment of $50,000 or more per year by or to the
Company or any of its Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) withdraw or modify, in any manner adverse to Parent, or permit the
withdrawal or such adverse modification of, the 14d-10 Approvals;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii) waive, release, assign, initiate, pay, discharge, settle or compromise
any pending or threatened claim, action, litigation, arbitration or proceeding other
than (A)&nbsp;in the ordinary course of business consistent with past practice, (B)&nbsp;for
solely money damages not in excess of $25,000 individually or $50,000 in the
aggregate and (C)&nbsp;as would not be reasonably likely to have any adverse impact on
any other pending or potential claims, actions, litigation, arbitration or
proceedings;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xviii) engage in any discounting, rebate, promotional or other special
incentive arrangements with respect to the sale of any of the Company&#146;s or its
Subsidiaries&#146; finished products other than (A)&nbsp;in the ordinary course of business
consistent with past practice and (B)&nbsp;as would not be reasonably likely to result in
a material increase in the volume of such finished product in the Company&#146;s or its
Subsidiaries&#146; wholesale and retail distribution channel; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xix) authorize any of or commit, resolve or agree to take any of the foregoing
actions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;During the period from the date of this Agreement until the Effective Time, Parent shall
not, and shall not permit any of its Subsidiaries to, take, or agree or commit to
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">take, any action that would reasonably be expected to (i)&nbsp;impose any material delay in the obtaining of, or
significantly increase the risk of not obtaining, any authorizations, consents, orders,
declarations or approvals of any Governmental Authority necessary to consummate the Transactions or
the expiration or termination of any applicable waiting period, (ii)&nbsp;significantly increase the
risk of any Governmental Authority entering an order prohibiting the consummation of the
Transactions or (iii)&nbsp;otherwise prevent or materially delay the consummation of the Transactions.
Without limiting the generality of the foregoing, Parent agrees that, during the period from the
date of this Agreement until the Effective Time, Parent shall not, and shall not permit any of its
Subsidiaries to, acquire or agree to acquire by merging or consolidating with, or by purchasing a
substantial portion of the assets of or equity in, or by any other manner, any Person or portion
thereof, or otherwise acquire or agree to acquire any assets or rights, if the entering into of a
definitive agreement relating to or the consummation of such acquisition, merger or consolidation
would reasonably be expected to have any of the effects described in clauses (i)&nbsp;through
(iii)&nbsp;above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.2 <U>No Solicitations</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall not, nor shall it authorize or permit any of its Subsidiaries, any of
its or their respective directors, officers or employees or any investment banker, financial
advisor, attorney, accountant or other advisor, agent or representative retained by the Company or
any Subsidiary in connection with the Transactions (collectively, &#147;<U>Representatives</U>&#148;) to,
directly or indirectly through another Person, (i)&nbsp;solicit, initiate, or knowingly encourage or
facilitate (including by way of furnishing information) any inquiries or the making, submission or
announcement of any proposal or offer that constitutes or is reasonably likely to lead to a
Takeover Proposal, or (ii)&nbsp;other than informing Persons of the provisions contained in this
<U>Section&nbsp;5.2</U>, enter into, continue or participate in any discussions or negotiations
regarding any Takeover Proposal, or furnish any information concerning the Company and its
Subsidiaries to any Person in connection with any Takeover Proposal, or otherwise cooperate with or
take any other action to knowingly facilitate any effort or attempt to make or implement a Takeover
Proposal. Notwithstanding anything in this <U>Section&nbsp;5.2</U> to the contrary, at any time prior
to the Acceptance Time, the Company may, upon a good faith determination by the Company Board
(after receiving the advice of its outside counsel) that failure to take such action would be
reasonably likely to result in a failure of the Company Board to comply with its fiduciary duties
to the Company Stockholders under applicable Law, and after giving Parent prompt written notice of
such determination, in response to an unsolicited <I>bona fide </I>written Takeover Proposal made after
the date of this Agreement that the Company Board determines in good faith (after receiving advice
of its outside counsel and a financial advisor of nationally recognized reputation) constitutes or
is reasonably likely to result in a Superior Proposal, (A)&nbsp;furnish information with respect to the
Company and its Subsidiaries to the Person making such Takeover Proposal (and its Representatives)
pursuant to a confidentiality agreement containing terms and conditions no more favorable to and no
less restrictive of such Person than those contained in the Confidentiality Agreement are to
Parent, except that such confidentiality agreement between the Company and such Person shall not
contain any provisions that would prevent the Company from complying with its obligations to
provide the required disclosure to Parent pursuant to this <U>Section&nbsp;5.2</U> and shall permit
such Person to make a Takeover Proposal; <U>provided</U> that all such information (to the extent
that such written information that has not been previously provided or made available to Parent) is
promptly, and in no event later than twenty-
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">four (24)&nbsp;hours after delivery to such Person, provided
or made available to Parent, and (B)&nbsp;participate in discussions or negotiations with the Person
making such Takeover Proposal (and its Representatives) regarding such Takeover Proposal. Upon
execution of this Agreement, the Company shall, and shall cause its Subsidiaries and its and their
respective Representatives to, immediately cease and cause to be terminated all existing
discussions or negotiations with any Person previously conducted with respect to any Takeover
Proposal, and will request, to the extent permitted under the applicable confidentiality agreement,
the prompt return of any confidential information previously furnished to such Persons that has not
been previously returned to the Company. Any violation of the restrictions set forth in this
<U>Section&nbsp;5.2</U> by any Representative of the Company or its Subsidiaries shall be deemed to be
a breach of this <U>Section&nbsp;5.2</U> by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as expressly permitted by this <U>Section&nbsp;5.2(b)</U>, the Company Board shall not
(i)(A)&nbsp;withdraw, modify or qualify, in a manner adverse to Parent, the Company Recommendation or
(B)&nbsp;adopt, recommend or propose publicly to adopt or recommend, to the
Company Stockholders a Takeover Proposal (any action described in this clause (i)&nbsp;being
referred to as a &#147;<U>Company Adverse Recommendation Change</U>&#148;) (it being understood and agreed
that (x)&nbsp;any &#147;stop, look and listen&#148; communication by the Company Board to the Company Stockholders
pursuant to Rule&nbsp;14d-9(f) of the Exchange Act shall not constitute a Company Adverse Recommendation
Change and (y)&nbsp;any change or development relating to any clinical trial of one or more products or
product candidates of the Company or its Subsidiaries or any determination or communication by the
FDA or any other Governmental Authority relating thereto will not be a basis for a Company Adverse
Recommendation Change), or (ii)&nbsp;authorize the Company or any of its Subsidiaries to enter into any
letter of intent, memorandum of understanding, agreement in principle or merger, acquisition or
similar agreement with respect to, or that is intended to or could reasonably be expected to lead
to, any Takeover Proposal (other than a confidentiality agreement referred to in
<U>Section&nbsp;5.2(a)</U>) (each, a &#147;<U>Company Acquisition Agreement</U>&#148;). Notwithstanding the
foregoing, at any time prior to the Acceptance Time and subject to the proviso of this sentence:
(x)&nbsp;the Company Board may make a Company Adverse Recommendation Change, upon a good faith
determination by the Company Board (after receiving the advice of its outside counsel) that failure
to take such action would be reasonably likely to result in a failure of the Company Board to
comply with its fiduciary duties to the Company Stockholders under applicable Law, and (y)&nbsp;if the
Company Board receives a Takeover Proposal that the Company Board reasonably determines (after
receiving the advice of its outside counsel and a financial advisor of nationally recognized
reputation) constitutes a Superior Proposal, and that was unsolicited after the date of this
Agreement and did not otherwise result from a material breach of this <U>Section&nbsp;5.2</U>, the
Company or its Subsidiaries may enter into a Company Acquisition Agreement with respect to such
Superior Proposal if the Company shall have complied with the provisions of the following sentence
and, immediately prior to entering into such Company Acquisition Agreement, terminates this
Agreement pursuant to <U>Section&nbsp;7.1(d)(ii)</U> and paid the Termination Fee and Expense Payment
pursuant to <U>Section&nbsp;7.3(a)</U>; <U>provided</U>, <U>however</U>, that the Company shall not
be entitled to exercise its right to make a Company Adverse Recommendation Change, terminate this
Agreement pursuant to <U>Section&nbsp;7.1(d)(ii)</U> or enter into any Company Acquisition Agreement
unless: (1)&nbsp;the Company has provided to Parent five (5)&nbsp;Business Days prior written notice (an
&#147;<U>Alternative Transaction Notice</U>&#148;), which Alternative Transaction Notice shall specify that
the Company Board is prepared to make a Company Adverse Recommendation Change, terminate this
Agreement pursuant to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Section&nbsp;7.1(d)(ii)</U> or enter into any Company Acquisition Agreement
unless: (1)&nbsp;the Company has provided to Parent five (5)&nbsp;Business Days prior written notice (an
&#147;<U>Alternative Transaction Notice</U>&#148;), which Alternative Transaction Notice shall specify that
the Company Board is prepared to make a Company Adverse Recommendation Change, terminate this
Agreement pursuant to <U>Section&nbsp;7.1(d)(ii)</U> and/or enter into any Company Acquisition
Agreement, as applicable, and, in the case of a Takeover Proposal that the Company Board has
determined constitutes a Superior Proposal, shall attach the most current version of any written
agreement relating to such Takeover Proposal and advising Parent that the Company Board has
determined that such Takeover Proposal is a Superior Proposal and that the Company Board intends to
enter into an agreement providing for such Superior Proposal, (2)&nbsp;during such five (5)&nbsp;Business Day
period, if requested by Parent, the Company has engaged in good-faith negotiations with Parent to
amend this Agreement in such a manner that the Takeover Proposal that was determined to constitute
a Superior Proposal no longer is a Superior Proposal and (3)&nbsp;at 5:00 p.m., New York time, at the
end of the fifth (5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>)&nbsp;Business Day following the date of receipt of the Alternative
Transaction Notice (or, in the event that the Takeover Proposal has been materially revised or
modified, at 5:00 p.m., New York time, on the fifth (5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>)&nbsp;Business Day following the
date of receipt of notice of such material revision or modification, if later), such
Takeover Proposal has not been withdrawn and continues to constitute a Superior Proposal
(taking into account all changes to the terms of this Agreement agreed to by Parent). It is
understood and agreed that an Alternative Transaction Notice shall be required for a Company
Adverse Recommendation Change, regardless of whether it was made in response to or as a result of a
Superior Proposal.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In addition to the obligations of the Company set forth in <U>Sections&nbsp;5.2(a)</U> and
<U>5.2(b)</U>, the Company shall promptly (and in any event within twenty-four (24)&nbsp;hours after
learning of the relevant information) advise Parent in writing of its receipt of any Takeover
Proposal and the material terms and conditions of any such Takeover Proposal (including any changes
to material terms of such Takeover Proposal) and the identity of the Person making any such
Takeover Proposal. The Company shall keep Parent fully informed of the status and material terms
(including any change to the material terms of such Takeover Proposal) of any Takeover Proposal,
and shall provide Parent with copies of all Takeover Proposals (and amendments or material
modifications of such Takeover Proposals) and related agreements, draft agreements exchanged by the
parties and modifications thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;For purposes of this Agreement:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Takeover Proposal</U>&#148; means any inquiry, proposal or offer from any Person (other
than Parent and its Subsidiaries) relating to any (A)&nbsp;direct or indirect acquisition or
purchase, in one transaction or a series of related transactions, of assets of the Company
and its Subsidiaries (including securities of Subsidiaries, but excluding sales of assets in
the ordinary course of business) equal to 25% or more of the Company&#146;s consolidated assets
or to which 25% or more of the Company&#146;s revenues, net income or earnings on a consolidated
basis are attributable, (B)&nbsp;acquisition of 25% or more of the outstanding Company Common
Stock (on a fully-diluted basis), (C)&nbsp;tender offer or exchange offer that if consummated
would result in any Person beneficially owning 25% or more of the outstanding Company Common
Stock (on a fully-diluted basis) or (D)&nbsp;merger, consolidation, share exchange, business
combination, recapitalization, liquidation, dissolution, joint venture or similar
transaction involving the Company or any of its Subsidiaries; in each case, other than the
Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Superior Proposal</U>&#148; means an unsolicited <I>bona fide </I>written Takeover Proposal
obtained not in breach of this <U>Section&nbsp;5.2</U> to acquire, directly or indirectly, for
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">consideration consisting of cash and/or securities, more than 75% of the outstanding Company
Common Stock (on a fully-diluted basis) or more than 75% of the assets of the Company and
its Subsidiaries on a consolidated basis, made by a third party, and which is otherwise on
terms and conditions which the Company Board determines in its good faith and reasonable
judgment (after receiving the advice of a financial advisor of national reputation and in
light of all relevant circumstances, including all the terms and conditions of such proposal
and this Agreement) to be (A)&nbsp;more favorable to the Company Stockholders than the Offer, the
Merger and the other Transactions, taken as a whole, (B)&nbsp;is reasonably likely to be
consummated on the terms so proposed, taking into account all relevant financial,
regulatory, legal and other aspects of such proposal, including any conditions; and (C)&nbsp;for
which financing, to the extent required, is then fully committed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;For purposes of this <U>Section&nbsp;5.2</U>, on a &#147;fully-diluted basis&#148; means the number of
Shares then issued and outstanding <I>plus </I>all shares of Company Common Stock which the Company may be
required to issue as of such date pursuant to options, warrants, convertible securities or similar
obligations regardless of the conversion or exercise price, the vesting schedule or other terms and
conditions thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Nothing in this <U>Section&nbsp;5.2</U> shall prohibit the Company Board from (i)&nbsp;taking and
disclosing to the Company Stockholders a position contemplated by Rule&nbsp;14e-2(a), Rule&nbsp;14d-9 or Item
1012(a) of Regulation&nbsp;M-A promulgated under the Exchange Act, or other applicable Law, if the
Company Board determines, after receiving the advice of its outside counsel, that failure to so
disclose such position could constitute a violation of applicable Law, or (ii)&nbsp;filing this
Agreement and any amendment hereto, together with a description of its terms, on a Form 8-K with
the SEC; <U>provided</U> that in no event shall the Company or the Company Board or any committee
of the Company Board take, or agree or resolve to take, any action prohibited by <U>Section
5.2(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.3 <U>Efforts to Consummate</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to the terms and conditions of this Agreement, each of the parties hereto shall
cooperate with the other party and use (and shall cause its respective Subsidiaries to use) its
respective reasonable best efforts, to the fullest extent permitted by applicable Law, to promptly
(i)&nbsp;take, or cause to be taken, all actions, and do, or cause to be done, all things, necessary,
proper or advisable to cause the conditions to the Offer and the Closing to be satisfied as
promptly as practicable and to consummate and make effective, in the most expeditious manner
practicable, the Transactions, including preparing and filing promptly and fully all documentation
to effect all necessary filings, notices, petitions, statements, registrations, submissions of
information, applications and other documents (including any required or recommended filings under
applicable Antitrust Laws), and (ii)&nbsp;obtain all approvals, consents, registrations, permits,
authorizations and other confirmations from any Governmental Authority or third party necessary,
proper or advisable to consummate the Transactions. For purposes hereof, &#147;<U>Antitrust Laws</U>&#148;
means the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade
Commission Act, as amended, and all other applicable Laws issued by a Governmental Authority that
are designed or intended to prohibit, restrict or regulate actions
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">having the purpose or effect of
monopolization or restraint of trade or lessening of competition
through merger or acquisition.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In furtherance and not in limitation of the foregoing, (i)&nbsp;each party hereto agrees to
make an appropriate filing of a Notification and Report Form pursuant to the HSR Act with respect
to the Transactions as promptly as practicable following the date of this Agreement (but in no
event later than ten (10)&nbsp;Business Days hereafter) and to supply as promptly as practicable any
additional information and documentary material that may be requested pursuant to the HSR Act and
to take, or cause to be taken, all other actions consistent with this <U>Section&nbsp;5.3</U> necessary
to cause the expiration or termination of the applicable waiting periods under the HSR Act as soon
as practicable; and (ii)&nbsp;the Company and Parent shall each use its reasonable best efforts to
(x)&nbsp;take all action necessary to ensure that no state takeover statute or similar Law is or becomes
applicable to the Transactions and (y)&nbsp;if any state takeover statute or similar Law becomes
applicable to the Transactions, take all action necessary to ensure that the Transactions
may be consummated as promptly as practicable on the terms contemplated by this Agreement and
otherwise minimize the effect of such Law on the Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of the parties hereto shall use its reasonable best efforts to (i)&nbsp;cooperate in all
respects with each other in connection with any filing or submission with a Governmental Authority
in connection with the Transactions and in connection with any investigation or other inquiry by or
before a Governmental Authority relating to the Transactions, including any proceeding initiated by
a private party, and (ii)&nbsp;keep the other party informed in all material respects and on a
reasonably timely basis of any material communication received by such party from, or given by such
party to, the Federal Trade Commission, the Antitrust Division of the Department of Justice, or any
other Governmental Authority and of any material communication received or given in connection with
any proceeding by a private party, in each case regarding the Transactions. Subject to applicable
Laws relating to the exchange of information, each of the parties hereto shall have the right to
review in advance, and to the extent practicable each will consult the other on, all the
information relating to the other parties and their respective Subsidiaries, as the case may be,
that appears in any filing made with, or written materials submitted to, any third party and/or any
Governmental Authority in connection with the Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;In furtherance and not in limitation of the covenants of the parties contained in this
<U>Section&nbsp;5.3</U>, each of the parties hereto shall use its reasonable best efforts to resolve
such objections, if any, as may be asserted by a Governmental Authority or other Person with
respect to the Transactions. Without limiting any other provision hereof, Parent shall take such
actions as shall be necessary to (i)&nbsp;avoid the entry of, or to have vacated or terminated, any
decree, order or judgment that would restrain, prevent or delay the consummation of the
Transactions on or before the Outside Date, including by defending through litigation on the merits
any claim asserted in any court by any Person, and (ii)&nbsp;avoid or eliminate each and every
impediment under any Antitrust Law that may be asserted by any Governmental Authority with respect
to the Transactions so as to enable the consummation of the Transactions to occur as soon as
reasonably possible (and in any event no later than the Outside Date) in each case, as may be
required in order to obtain any approvals from any Governmental Authority necessary to consummate
the Transactions or to avoid the entry of, or to effect the dissolution of, any injunction,
temporary restraining order, or other order in any Action or Proceeding, which would
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">otherwise have
the effect of preventing or materially delaying the consummation of the Transactions;
<U>provided</U>, <U>however</U>, that, notwithstanding anything to the contrary in this
Agreement, in connection with any filing or submission required or action to be taken by either
Parent or the Company to consummate the Transactions, in no event shall Parent or any of its
Subsidiaries or Affiliates be obligated to propose or agree to accept any undertaking or condition,
to enter into any consent decree, to make any divestiture or accept any operational restriction, or
take or commit to take any action (i)&nbsp;the effectiveness or consummation of which is not conditional
on the consummation of the Offer and the Merger or (ii)&nbsp;that individually or in the aggregate is or
would be reasonably expected to result in a material diminution of the benefits of the Transactions
to Parent (with materiality, for purposes of this provision, being measured in relation to the size
of the Company and its Subsidiaries taken as a whole) (any such action, undertaking, condition or
other restriction, a &#147;<U>Materially Burdensome Condition</U>&#148;). The Company shall agree, if
requested by Parent in writing, to commit to take any of the foregoing actions with respect to the
assets or business of
the Company in furtherance of this <U>Section&nbsp;5.3</U>; <U>provided</U>, <U>however</U>,
that any such action may be conditioned upon the consummation of the Offer and the Merger and the
other Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.4 <U>Public Announcements</U>. The initial press release with respect to the
execution of this Agreement shall be a joint press release to be reasonably agreed upon by Parent
and the Company. Thereafter, except as expressly permitted by <U>Section&nbsp;5.2</U>, neither the
Company nor Parent shall issue or cause the publication of any press release or other public
announcement (to the extent not previously issued or made in accordance with this Agreement) with
respect to this Agreement, the Offer, the Merger or the other Transactions without the prior
consent of the other party (which consent shall not be unreasonably withheld, conditioned or
delayed), except as may be required by Law or by any applicable listing agreement with or other
requirement of NASDAQ as determined in the good faith judgment of the party proposing to make such
release (in which case such party shall not issue or cause the publication of such press release or
other public announcement without prior consultation with the other party to the extent reasonably
practicable).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.5 <U>Access to Information; Confidentiality</U>. Subject to applicable Laws
relating to the exchange of information, the Company shall afford to Parent and Parent&#146;s
Representatives reasonable access during normal business hours to the officers, employees,
accountants, properties, books, Contracts and records of the Company and its Subsidiaries and the
Company shall furnish promptly to Parent (i)&nbsp;a copy of each report, schedule and other document
filed by it pursuant to the requirements of federal or state securities Laws and rules and
regulations promulgated thereunder and (ii)&nbsp;other information concerning the business and
properties of the Company and its Subsidiaries as Parent may reasonably request; <U>provided</U>,
<U>however</U>, that the Company shall not be required to provide access to any information or
documents which would, in the reasonable judgment of the Company, (i)&nbsp;breach any agreement of the
Company or any of its Subsidiaries with any third party, (ii)&nbsp;constitute a waiver of the
attorney-client or other privilege held by the Company or any of its Subsidiaries (iii)&nbsp;otherwise
violate any applicable Laws or (iv)&nbsp;which would result in a competitor of the Company or any of its
Subsidiaries receiving material information which is competitively sensitive; <U>provided</U>,
<U>further</U>, <U>however</U>, that the Company will use its reasonable best efforts to obtain
any required consents for the disclosure of such information or documents and take such other
action (such as the redaction of identifying or confidential information or entry into a joint
defense agreement or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other arrangement to avoid loss of attorney client privilege) with respect to
such information or documents as is necessary to permit disclosure to Parent and Parent&#146;s
Representatives. Until the Effective Time, the information provided pursuant to this Agreement
will be subject to the terms of the Confidentiality Agreement, dated as of December&nbsp;31, 2007,
between Parent, the record and beneficial owner of all of the outstanding capital stock of Parent,
and the Company (as it may be amended from time to time, the &#147;<U>Confidentiality Agreement</U>&#148;),
which shall survive the termination of this Agreement in accordance with the terms of the
Confidentiality Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.6 <U>Notification of Certain Matters</U>. The Company shall give reasonably prompt
notice to Parent, and Parent shall give reasonably prompt notice to the Company, of (i)&nbsp;any notice
or other communication received by such party from any Governmental Authority in connection with
the Transactions or from any Person alleging that the consent of such Person is or may be required
in connection with the Transactions, and (ii)&nbsp;any Actions or Proceedings
commenced or, to such party&#146;s Knowledge, threatened against, relating to or involving or
otherwise affecting such party or any of its Subsidiaries which, in the case of either clause
(i)&nbsp;or (ii), would, in the case of the Company, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect or, in the case of the Company or Parent,
prevent or materially delay consummation of the Transactions. Prior to the Acceptance Time, the
Company shall give reasonably prompt written notice to Parent of (a)&nbsp;the occurrence, or failure to
occur, after the date of this Agreement, of any fact or event which has caused or would be
reasonably likely (i)&nbsp;to cause any representation or warranty contained in this Agreement or in any
section of the Company Disclosure Letter to be untrue or inaccurate in any material respect or
(ii)&nbsp;to cause any covenant, condition or agreement (other than any covenant or agreement of Parent
or Purchaser) under this Agreement (including the conditions set forth in <U>Annex A</U> hereto)
not to be complied with or satisfied and (b)&nbsp;any failure by the Company to comply with or satisfy
in any material respect, any covenant, condition or agreement to be complied with or satisfied by
the Company hereunder (including the conditions set forth in <U>Annex A</U> hereto);
<U>provided</U> that no such notification shall affect the representations and warranties of the
Company contained in <U>Article&nbsp;III</U> or the conditions to the obligations of Parent or
Purchaser hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.7 <U>Indemnification and Insurance</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From the Acceptance Time until the Effective Time Parent shall cause (including by
providing adequate funding) the Company to, and after the Effective Time Parent shall cause
(including by providing adequate funding) the Surviving Corporation to, assume the obligations with
respect to all rights to indemnification and exculpation from liabilities, including advancement of
expenses, for acts or omissions occurring at or prior to the Effective Time now existing in favor
of the current or former directors or officers of the Company and its Subsidiaries (each, an
&#147;<U>Indemnitee</U>&#148; and, collectively, the &#147;<U>Indemnitees</U>&#148;) as provided in the Company
Charter Documents or any written indemnification Contract between such directors or officers and
the Company (in each case, as in effect on the date of this Agreement), without further action, and
such obligations shall survive the Merger and shall continue in full force and effect in accordance
with their terms. Without limiting the foregoing, Parent, for a period of at least six (6)&nbsp;years
after the Effective Time, shall cause the certificate of incorporation and by-laws of the Surviving
Corporation (or any successor) to contain provisions no less favorable to the Indemnitees with
respect to limitation of liabilities of directors and officers and indemnification than are set
forth as of the date of this Agreement in the Company Charter
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Documents, which provisions shall not
be amended, repealed or otherwise modified in a manner that would adversely affect the rights
thereunder of the Indemnitees. Parent shall cause (including by providing adequate funding to) the
Surviving Corporation to, honor all of its indemnification obligations existing as of the Effective
Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;For the six (6)&nbsp;year period commencing immediately after the Acceptance Time, Parent shall
maintain in effect directors&#146; and officers&#146; liability insurance covering acts or omissions
occurring at or prior to the Effective Time with respect to those persons who were or are currently
(and any additional persons who at or prior to the Effective Time become) covered by the Company&#146;s
directors&#146; and officers&#146; liability insurance policies on terms with respect to such coverage, and
in amount, not less favorable to such individuals than those of such policies in effect on the date
of this Agreement (or Parent may substitute therefor policies, issued by reputable insurers, of at
least the same coverage with respect to matters occurring prior to the
Effective Time; <U>provided</U> that any substitution or replacement of existing policies
shall not result in any gaps or lapses of coverage with respect to facts, events, acts or omissions
occurring at or prior to the Effective Time)); <U>provided</U>, <U>however</U>, that, if the
aggregate annual premiums for such insurance shall exceed 200% of the current aggregate annual
premiums, then Parent shall provide or cause to be provided a policy for the applicable individuals
with the best coverage as shall then be available at the sum of (i)&nbsp;an annual premium of 200% of
the current aggregate annual premiums plus (ii)&nbsp;the unearned portion of the premium paid by the
Company for the current year for such insurance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The provisions of this <U>Section&nbsp;5.7</U> are intended to be for the benefit of, and
shall be enforceable by, each Indemnitee, his or her heirs and his or her representatives and, in
addition to, and not in substitution for, and shall not impair any other rights to indemnification
or contribution that any such Person may have by contract, under the Company Charter Documents, or
the comparable organization documents of the Surviving Corporation or any of its subsidiaries,
under applicable Law, or otherwise. Parent shall ensure that the Surviving Corporation complies
with all of its obligations under this <U>Section&nbsp;5.7</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.8 <U>Fees and Expenses</U>. Except as provided in <U>Section&nbsp;7.3</U>, all fees
and expenses incurred in connection with this Agreement and the Transactions shall be paid by the
party incurring such fees or expenses, whether or not the Transactions are consummated<B>;</B>
<U>provided</U> that the fees and expenses of printing and mailing the Offer Documents, all filing
and other fees paid to the SEC in connection with the Offer and the Merger and all filing fees and
other out of pocket fees and expenses incurred by the Company or any of its Subsidiaries pursuant
to Section&nbsp;5.3, shall be reimbursed by Parent to the Company or such Subsidiary in the event that
this Agreement is terminated by (a)&nbsp;the Company or Parent pursuant to <U>Section&nbsp;7(b)(i)</U>,
<U>Section&nbsp;7(b)(ii)</U> or <U>Section&nbsp;7(b)(iii)</U> or (b)&nbsp;the Company pursuant to <U>Section
7(d)(i)</U> and, in any case, at the time of such termination any applicable period under the HSR
Act shall not have expired or been terminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.9 <U>Rule&nbsp;16b-3</U>. Prior to the Acceptance Time, the Company and Parent shall
take such steps as may be reasonably requested by any party hereto to cause dispositions of Company
equity securities (including derivative securities) pursuant to the Transactions by each individual
who is a director or officer of the Company to be exempt under Rule&nbsp;16b-3</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">promulgated under the
Exchange Act in accordance with that certain No-Action Letter dated January&nbsp;12, 1999 issued by the
SEC regarding such matters.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.10 <U>Employee Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Parent shall, for a period of one (1)&nbsp;year immediately following the later of the
Acceptance Time and the Effective Time, provide, or shall cause the Surviving Corporation and its
Subsidiaries to provide, employees who shall have been employees of the Company or any of its
Subsidiaries at the Acceptance Time who continue as employees of the Company, its Subsidiaries or
the Surviving Corporation following the Acceptance Time (the &#147;<U>Company Employees</U>&#148;) with
employee benefit plans, programs, policies and arrangements (other than equity-based plans and
severance arrangements) that are comparable, in the aggregate, to the employee benefit plans,
programs and arrangements (other than equity-based plans and severance arrangements) provided by
the Company and its Subsidiaries to
Company Employees immediately prior to the Acceptance Time. Parent shall recognize the
service of Company Employees with the Company and its Subsidiaries prior to the Acceptance Time as
service with Parent and its Affiliates in connection with any Parent Benefit Plan which is made
available to Company Employees following the Acceptance Time for purposes of any waiting period,
vesting, eligibility and benefit entitlement where length of service is relevant. Parent shall (i)
waive, or cause its insurance carriers to waive, all limitations as to pre-existing conditions, if
any, with respect to participation and coverage requirements applicable to Company Employees and
their dependents under any Parent Benefit Plan that is a welfare benefit plan (as defined in
Section&nbsp;3(1) of ERISA) which is made available to Company Employees following the Acceptance Time
(other than any limitations that were in effect with respect to such employees as of the Acceptance
Time under the analogous Company Plan), and (ii)&nbsp;provide credit to Company Employees and their
dependents for any co-payments, deductibles and out-of-pocket expenses paid by such employees under
the employee benefit plans, programs or arrangements of the Company and its Subsidiaries during the
portion of the relevant plan year, including the Purchase Date. Parent shall cause the Surviving
Corporation and its Subsidiaries to expressly assume and agree to perform any employment, severance
or change in control agreement listed in <U>Section&nbsp;3.11(h) of the Company Disclosure Letter</U>
in the same manner and to the same extent that the Company and its Subsidiaries would be required
to perform it if the Transactions had not taken place. Notwithstanding anything to the contrary
contained herein, Parent shall honor, and cause the Surviving Corporation and its Subsidiaries to
honor, in accordance with its terms as in effect immediately prior to the Acceptance Time, the 2008
Severance Pay Plan for the benefit of Company Employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This <U>Section&nbsp;5.10</U> shall be binding upon and inure solely to the benefit of each of
the parties to this Agreement, and nothing in this <U>Article&nbsp;V</U>, express or implied, is
intended to confer upon any other Person any rights or remedies of any nature whatsoever under or
by reason of this <U>Section&nbsp;5.10</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Nothing contained in this Agreement shall (i)&nbsp;constitute or be deemed to be an amendment
to any Company Plan or any other compensation or benefit plan, program or arrangement of the
Company or any of its Subsidiaries; (ii)&nbsp;prevent the amendment or termination of any Company Plan
in accordance with its terms, or interfere with the right or obligation of Parent or its Affiliates
to make such changes as are necessary to conform with
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">applicable Law (including without limitation
Section&nbsp;409A of the Code); or (iii)&nbsp;limit the right of Parent or any of its Affiliates to terminate
the employment of any employee at any time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If the Company or any of its Subsidiaries enters into, adopts, amends, modifies or
terminates any Company Compensation Arrangements for Covered Stockholders, the Company intends that
all such amounts payable under such Company Compensation Arrangements (i)&nbsp;shall be paid or granted
as compensation for past services performed, future services to be performed, or future services to
be refrained from performing, by the Covered Stockholders (and matters incidental thereto) and
(ii)&nbsp;shall not be calculated based on the number of shares tendered or to be tendered into the
Offer by the applicable Covered Stockholders. If there has been any adoption, approval, amendment
or modification of any Company Compensation Arrangement, either prior to or after the date of this
Agreement, the Company agrees that, upon the request of Parent, the Compensation Committee of the
Company Board, consisting solely of independent directors, shall approve resolutions approving such
adoption,
approval, amendment or modification as an employment compensation, severance or other employee
benefit arrangements, in accordance with the requirements of Rule&nbsp;14d-10(d)(2) under the Exchange
Act and the instructions thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.11 <u>Delisting</u>. Parent shall cause the Company Common Stock to be de-listed from NASDAQ and de-registered under the Exchange Act
as soon as practicable following the Effective Time. Prior to the Closing Date, the Company shall cooperate with Parent and use
reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper
or advisable on its part under applicable laws and rules and policies of the NASDAQ to enable the de-listing by the Surviving Corporation
of the Company Common Stock from the NASDAQ and the deregistration of the Company Common Stock under the Exchange Act as promptly as
practicable after the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.12 <u>Takeover Laws</u>. The Company and the Company Board shall (a)&nbsp;use reasonable best efforts to ensure that no state takeover
Law or similar Law is or becomes applicable to this Agreement, the Offer, the Merger or any of the other Transactions and (b)&nbsp;if any
state takeover Law or similar Law becomes applicable to this Agreement, the Offer, the Merger or any of the other Transactions, use
reasonable best efforts to ensure that the Offer, the Merger and the other Transactions may be consummated as promptly as practicable
on the terms contemplated by this Agreement and otherwise to minimize the effect of such Law on this Agreement, the Offer, the Merger
and the other Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.13 <u>Stockholder Litigation</u>. The Company shall give Parent the opportunity to participate in the defense or settlement of any
stockholder litigation against the Company and/or its directors relating to this Agreement, the Offer, the Merger or the other Transactions,
and no such settlement shall be agreed to without Parent&#146;s prior written consent, which prior to the Acceptance Time shall not be
unreasonably withheld, delayed or conditioned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.14 <u>Purchase of Shares of Series&nbsp;D-1 Preferred Stock</u>. Purchaser shall (and Parent shall cause Purchaser to) purchase,
subject to the terms and conditions of the Preferred Stockholder Agreement, the shares of Series&nbsp;D-1 Preferred Stock held by the
Company Preferred Stockholders.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Conditions to the Merger</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 6.1 <U>Conditions to Each Party&#146;s Obligation to Effect the Merger</U>. The
respective obligations of each party hereto to effect the Merger shall be subject to the
satisfaction (or waiver, if permissible under applicable Law) on or prior to the Closing Date of
the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company Stockholder Approval shall have been obtained, if and to the extent required
by applicable Law in order to consummate the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No Law, injunction, judgment or ruling enacted, promulgated, issued, entered, amended or
enforced by any Governmental Authority (collectively, &#147;<U>Restraints</U>&#148;) shall be in effect
enjoining, restraining, preventing or prohibiting consummation of the Merger or making the
consummation of the Merger illegal.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Purchaser shall have purchased all Shares validly tendered and not withdrawn pursuant to
the Offer; <U>provided</U>, <U>however</U>, that neither Parent nor Purchaser may invoke this
condition if Purchaser shall have failed to purchase Shares so tendered and not withdrawn in
violation of the terms of this Agreement or the Offer.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Termination</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7.1 <U>Termination</U>. This Agreement may be terminated and the Transactions
abandoned at any time prior to the Effective Time, whether before or after receipt of the Company
Stockholder Approval:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;by the mutual written consent of the Company and Parent duly authorized by the Company
Board (including, from and after the Acceptance Time, the Independent Director Approval
contemplated by <U>Section&nbsp;1.3(c)</U>) and the Board of Directors of Parent; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;by either the Company or Parent:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if the Merger shall not have been consummated on or before the Outside
Date; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement
under this <U>Section&nbsp;7.1(b)(i)</U> shall not be available to a party if the
failure of the Merger to have been consummated on or before the Outside Date was
primarily due to the failure of such party to perform any of its obligations under
this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if any Restraint enjoining, restraining, preventing or prohibiting
consummation of the Transactions or making the consummation of the Transactions
illegal shall be in effect and shall have become final and non appealable;
<U>provided</U> that the right to terminate this Agreement under this <U>Section
7.l(b)(ii)</U> shall not be available to a party if the issuance of such final, non
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">appealable Restraint was primarily due to the failure of such party to perform
any of its obligations under this Agreement; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if the Offer shall have expired or been terminated in accordance with the
terms of this Agreement without Parent or Purchaser having accepted for purchase any
shares of Company Common Stock pursuant to the Offer, other than due to a breach of
this Agreement by the terminating party; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(c)&nbsp;by Parent, prior to the Acceptance Time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if the Company shall have breached or failed to perform any of its
representations, warranties, covenants or agreements set forth in this Agreement,
which breach or failure to perform (A)&nbsp;would result in any of the events set forth
in clause (c)&nbsp;or (d)&nbsp;of <U>Annex A</U> to occur and (B)&nbsp;is not cured, or cannot be
cured, by the Company within thirty (30)&nbsp;calendar days following receipt of written
notice of such breach or failure to perform from Parent (or if the Outside Date is
less than thirty (30)&nbsp;calendar days from the notice by Parent, is not cured, or
cannot be cured, by the Company by the Outside Date); or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if a Company Adverse Recommendation Change shall have occurred; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(d)&nbsp;by the Company, prior to the Acceptance Time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if Parent or Purchaser shall have breached or failed to perform any of its
representations, warranties, covenants or agreements set forth in this Agreement,
which breach or failure to perform (A)&nbsp;would result in (x)&nbsp;any representation or any
representation or warranty of Parent and Purchaser contained in this Agreement not
being true and correct (without giving effect to any qualifications or limitations
as to materiality set forth therein) except, in the case of this clause (x), to the
extent that the facts or matters as to which such representation or warranty is not
so true and correct, individually or in the aggregate, have not had and could not
reasonably be expected to be materially adverse to the ability of Parent and
Purchaser to perform their obligations under this Agreement or to consummate the
Transactions by the Outside Date, or (y)&nbsp;a failure by Parent or Purchaser to perform
in all material respects its agreements, covenants and obligations required to be
performed by it under this Agreement at or prior to such time and (B)&nbsp;is not cured,
or is incapable of being cured, by Parent or Purchaser within thirty (30)&nbsp;calendar
days following receipt of written notice of such breach or failure to perform from
the Company (or, if the Outside Date is less than thirty (30)&nbsp;calendar days from the
notice by the Company, is not cured, or is incapable of being cured, by Parent or
Purchaser by the Outside Date); or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if concurrently it enters into a definitive Company Acquisition Agreement
providing for a Superior Proposal, but only after complying with the provisions of
<U>Section&nbsp;5.2(b)</U>, including paying to Parent the Termination Fee and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Expense Payment payable pursuant to <U>Section&nbsp;7.3</U> concurrently with such
termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7.2 <U>Effect of Termination</U>. In the event of the termination of this Agreement
as provided in <U>Section&nbsp;7.1</U>, written notice of such termination shall be given to the other
party or parties, specifying the provision of this Agreement pursuant to which such termination is
made, and this Agreement shall forthwith become null and void (other than <U>Sections&nbsp;5.8</U>,
<U>7.2</U> and <U>7.3</U>, <U>Article&nbsp;VIII</U>, the last sentence of <U>Section&nbsp;1.2(b)</U>, the
last sentence of <U>Section&nbsp;5.5</U> and the Confidentiality Agreement in accordance with its
terms, all of which shall survive termination of this Agreement in accordance with its terms, and
<U>Sections&nbsp;1.3</U> and <U>5.7</U>, which shall survive any termination of this Agreement
following the Acceptance Time but prior to the Effective Time) and there shall be no liability or
other obligation on the part of Parent, Purchaser or the Company or their respective Subsidiaries,
or its or their respective stockholders, controlling persons or Representatives, except (a)&nbsp;the
Company or Parent may have liability as provided in <U>Section&nbsp;7.3</U>, and (b)&nbsp;nothing shall
relieve Parent, Purchaser or the Company from liability for any willful and material breach by such
party of its covenants under this Agreement to be performed prior to the Closing Date. In the
event of termination of this Agreement pursuant to <U>Section&nbsp;7.1</U> prior to the expiration of
the Offer, Parent and Purchaser will promptly terminate the Offer upon such termination of this
Agreement without the purchase of any Shares thereunder. If the Offer is terminated, all tendered
Shares not theretofore accepted for payment shall forthwith be returned to the tendering
stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7.3 <U>Termination Fees</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event that this Agreement is terminated by Parent pursuant to <U>Section
7.1(c)(ii)</U> or the Company pursuant to <U>Section&nbsp;7.1(d)(ii),</U> then the Company shall pay to
Parent, no later than the second (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP>) Business Day following termination in the case of
<U>Section&nbsp;7.1(c)(ii)</U> and concurrently with termination in the case of <U>Section
7.1(d)(ii)</U>, by wire transfer of same-day funds (i)&nbsp;a termination fee of $12,600,000 (the
&#147;<U>Termination Fee</U>&#148;) and (ii)&nbsp;all out-of-pocket expenses, actually documented and incurred or
payable by or on behalf of Parent or Purchaser in connection with or in anticipation of the
Transactions (whether before or after the date of this Agreement), including all attorneys&#146; fees,
financial advisor&#146;s fees, accountants&#146; fees and filing fees (the &#147;<U>Expense Payment</U>&#148;);
provided that in no circumstance shall the Expense Payment exceed $1,000,000 in the aggregate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event that (i)&nbsp;Parent or the Company shall terminate this Agreement pursuant to
<U>Section&nbsp;7.1(b)(iii)</U>, or Parent shall terminate this Agreement pursuant to <U>Section
7.1(c)(i)</U> as a result of a breach of <U>Section&nbsp;5.2</U>, and (ii)&nbsp;in each case prior to the
time of such termination a <I>bona fide </I>Takeover Proposal or an intention (whether or not conditional)
to make a Takeover Proposal has been publicly made or otherwise made known to the Company Board or
generally to the Company Stockholders and not withdrawn at least five (5)&nbsp;Business Days prior to
termination, and (iii)&nbsp;if, within 12&nbsp;months after the date of such termination, a definitive
agreement is entered into by the Company or any of its Affiliates with respect to any Takeover
Proposal or any Takeover Proposal is consummated, then the Company shall pay to Parent, on the date
such agreement is entered into or on the date that such Takeover Proposal is consummated, whichever
is earlier, by wire transfer of same-day funds, an amount equal to the Termination Fee and the
Expense Payment; <U>provided</U>, <U>however</U>, that for the purpose of this
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Section&nbsp;7.3(b)</U>, all references in the definition of Takeover Proposal to &#147;25%&#148; shall
instead be deemed to refer to &#147;a majority&#148;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of the Company and Parent acknowledges that the agreements contained in this
<U>Section&nbsp;7.3</U> are an integral part of the Transactions and that, without these agreements,
Parent would not enter into this Agreement. Accordingly, in the event that the Company shall fail
to pay the Termination Fee or Expense Payment when due, the Company shall reimburse Parent for all
costs and expenses incurred or accrued by it (including reasonable fees and expenses of counsel) in
connection with the collection under and enforcement of this <U>Section&nbsp;7.3</U> with interest on
the amount of the Termination Fee and/or Expense Payment, as the case may be, from the date that
such payment was required to be made until the date of actual payment at the prime rate of
Citibank, N.A., in effect on the date that such payment was required to be made.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Miscellaneous</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.1 <U>Survival of Representations, Warranties and Agreements</U>. The
representations and warranties contained herein or in any other writing delivered pursuant hereto,
as well as any covenant or agreement of the parties that by its terms contemplates performance
exclusively prior to the Effective Time, shall survive until (but not beyond) the Effective Time.
Nothing in this paragraph shall limit any covenant or agreement of any of the parties that by its
terms contemplates performance in whole or in part after the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.2 <U>Amendment or Supplement</U>. At any time prior to the Effective Time, this
Agreement may be amended or supplemented in any and all respects, whether before or after the
Company Stockholder Approval, by written agreement of the parties hereto upon action taken by their
respective Boards of Directors (which in the case of the Company after the Acceptance Time shall
include the Independent Director Approval contemplated by <U>Section&nbsp;1.3</U>); <U>provided</U>,
<U>however</U>, that following receipt of the Company Stockholder Approval, there shall be no
amendment or change to the provisions hereof which by Law or in accordance with the rules of any
relevant stock exchange would require further approval by any of the stockholders of the Company
without such approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.3 <U>Extension of Time, Waiver, Etc</U>. At any time prior to the Effective Time,
either Parent or the Purchaser, on the one hand, or the Company, on the other, may, subject to
applicable Law, (a)&nbsp;waive any inaccuracies in the representations and warranties of the other, (b)
extend the time for the performance of any of the obligations or acts of the other or (c)&nbsp;waive
compliance by the other with any of the agreements contained herein or, except as otherwise
provided herein, waive any of such party&#146;s conditions; and <U>provided</U>, that in the case of
the Company following the Acceptance Time, the Independent Director Approval contemplated by
<U>Section&nbsp;1.3</U> is obtained; <U>provided</U>, <U>further</U>, that after the Company
Stockholder Approval is obtained, there may not be any extension or waiver of this Agreement or any
portion thereof which, by Law or in accordance with the rules of any relevant stock exchange would
require further approval by any of the stockholders of the Company. Notwithstanding the foregoing,
no failure or delay by the Company, Parent or Purchaser in exercising any right hereunder shall
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">operate as a waiver thereof nor shall any single or partial exercise thereof preclude any
other or further exercise thereof or the exercise of any other right hereunder. Any agreement on
the part of a party hereto to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.4 <U>Assignment</U>. Neither this Agreement nor any of the rights, interests or
obligations hereunder shall be assigned, in whole or in part, by operation of Law or otherwise, by
any of the parties without the prior written consent of the other parties; <U>provided</U> that
Parent and Purchaser may assign any of or all of its rights, interests and obligations under this
Agreement to Parent or to any direct or indirect wholly owned Subsidiary of Parent, but no such
assignment shall relieve Parent or Purchaser of any of its obligations under this Agreement.
Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of,
and be enforceable by, the parties hereto and their respective successors and permitted assigns.
Any purported assignment not permitted under this section shall be null and void.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.5 <U>Counterparts</U>. This Agreement may be executed in counterparts (each of
which shall be deemed to be an original but all of which taken together shall constitute one and
the same agreement) and shall become effective when one or more counterparts have been signed by
each of the parties and delivered to the other parties. Copies of executed counterparts
transmitted by telecopy, telefax or electronic transmission shall be considered original executed
counterparts for purposes of this <U>Section&nbsp;8.5</U> provided that receipt of copies of such
counterparts is confirmed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.6 <U>Entire Agreement; No Third-Party Beneficiaries</U>. This Agreement, together
with <U>Annex A</U> hereto, the Company Disclosure Letter and the Confidentiality Agreement, (a)
constitutes the entire agreement, and supersedes all other prior agreements and understandings,
both written and oral, among the parties, or any of them, with respect to the subject matter hereof
and thereof and (b)&nbsp;except for the provisions of <U>Section&nbsp;5.7</U>, is not intended to and shall
not confer upon any Person other than the parties hereto any rights or remedies hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.7 <U>Governing Law; Jurisdiction; Waiver of Jury Trial</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Agreement shall be governed by, and construed in accordance with, the Laws of the
State of Delaware applicable to Contracts executed in and to be performed entirely within that
State, regardless of the laws that might otherwise govern under applicable principles of conflicts
of laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All Actions or Proceedings arising out of or relating to this Agreement shall be heard and
determined in the Chancery Court of the State of Delaware, and the parties hereto hereby
irrevocably submit to the exclusive jurisdiction of such court (and, in the case of appeals,
appropriate appellate courts therefrom) in any such Action or Proceeding and irrevocably waive the
defense of an inconvenient forum to the maintenance of any such Action or Proceeding. The consents
to jurisdiction set forth in this paragraph shall not constitute general consents to service of
process in the State of Delaware and shall have no effect for any purpose except as provided in
this paragraph and shall not be deemed to confer rights on any Person other than the parties
hereto. The parties hereto agree that a final judgment in any such Action or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of the parties hereto hereby irrevocably waives any and all rights to trial by jury
in any legal proceeding arising out of or related to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.8 <U>Specific Enforcement; Remedies</U>. The parties agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. It is accordingly agreed that the
parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and
to enforce specifically the terms and provisions of this Agreement in the Chancery Court of the
State of Delaware, without bond or other security being required, this being in addition to any
other remedy to which they are entitled at Law or in equity. Parent and Purchaser agree and
acknowledge that none of the directors, officers or Affiliates of the Company shall have any
personal liability hereunder, including, without limitation, for any breach of this Agreement or
inaccuracy of any representation or warranty.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.9 <U>Notices</U>. All notices, requests and other communications to any party
hereunder shall be in writing and shall be deemed given if delivered either personally, by
facsimile transmission (with acknowledgment received), by electronic mail (with receipt confirmed)
or by overnight courier (providing proof of delivery) to the parties at the following addresses:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">If to Parent or Purchaser, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Galderma Laboratories, Inc.<BR>
c/o Galderma Laboratories, L.P.<BR>
14501 North Freeway<BR>
Fort Worth, TX 76177<BR>
Attention: Albert Draaijer, President<BR>
Facsimile: (817)&nbsp;961-0035<BR>
E-mail: albert.draaijer@galderma.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">with a copy (which shall not constitute notice) to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Galderma Laboratories, Inc.<BR>
c/o Galderma Laboratories, L.P.<BR>
14501 North Freeway<BR>
Fort Worth, TX 76177<BR>
Attention: Quintin Cassidy, General Counsel<BR>
Facsimile: (817)&nbsp;961-0034<BR>
E-mail: quintin.cassady@galderma.com
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">with a copy (which shall not constitute notice) to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Debevoise &#038; Plimpton LLP<BR>
919 Third Avenue<BR>
New York, New York 10022<BR>
Attention: Paul S. Bird, Esq.<BR>
Facsimile: (212)&nbsp;909-6836<BR>
E-mail: psbird@debevoise.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">If to the Company, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">CollaGenex Pharmaceuticals, Inc.<BR>
41 University Drive<BR>
Newton, PA 18940<BR>
Attention: Andrew K. W. Powell, General Counsel<BR>
Facsimile: (215)&nbsp;579-7388<BR>
E-mail: apowell@collagenex.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">with a copy (which shall not constitute notice) to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Milbank, Tweed, Hadley &#038; McCloy LLP<BR>
1 Chase Manhattan Plaza<BR>
New York, New York 10005<BR>
Attention: Robert S. Reder, Esq.<BR>
Facsimile: (212)&nbsp;822-5680<BR>
E-mail: rreder@milbank.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or such other address, facsimile number or email address as such party may hereafter specify by
notice to the other parties hereto. All such notices, requests and other communications shall be
deemed received on the date of receipt by the recipient thereof if received prior to 5 P.M. in the
place of receipt and such day is a Business Day in the place of receipt. Otherwise, any such
notice, request or communication shall be deemed not to have been received until the next
succeeding Business Day in the place of receipt.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.10 <U>Severability</U>. If any term or other provision of this Agreement is
determined by a court of competent jurisdiction to be invalid, illegal or incapable of being
enforced by any rule of Law or public policy, all other terms, provisions and conditions of this
Agreement shall nevertheless remain in full force and effect. Upon such determination that any
term or other provision is invalid, illegal or incapable of being enforced, the parties hereto
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible to the fullest extent permitted by applicable Law in an acceptable
manner to the end that the Transactions are fulfilled to the extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.11 <U>Definitions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As used in this Agreement, the following terms have the meanings ascribed thereto below:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Action or Proceeding</U>&#148; shall mean any action, suit, proceeding, hearing, charge,
complaint, grievance, arbitration or Governmental Authority investigation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Adverse Drug Reaction Report</U>&#148; shall mean an adverse drug experience reported to the
FDA or other corresponding Governmental Authority associated with the use of a drug, whether or not
considered drug related, including the following: an adverse event occurring in the course of the
use of a drug product in professional practice; an adverse event occurring from drug overdose
whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event
occurring from drug withdrawal; and any failure of expected pharmacological action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliate</U>&#148; shall mean, as to any Person, any other Person that directly or indirectly
controls, or is controlled by, or is under common control with, such Person. For this purpose,
&#147;control&#148; (including, with its correlative meanings, &#147;controlled by&#148; and &#147;under common control
with&#148;) shall mean the possession, directly or indirectly, of the power to direct or cause the
direction of management or policies of a Person, whether through the ownership of securities or
partnership or other ownership interests, by Contract or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Day</U>&#148; shall mean a day except a Saturday, a Sunday or other day on which the
SEC or banks in the City of New York are authorized or required by Law to be closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Board</U>&#148; shall mean the Board of Directors of the Company or any duly
constituted committee thereof which has been given the authority to act in the name, place and
stead of the Board of Directors of the Company with respect to this Agreement, the Offer, the
Merger and the other Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Option</U>&#148; shall mean any option to purchase shares of Company Common Stock
granted under any Company Stock Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Plan</U>&#148; shall mean each &#147;employee benefit plan,&#148; as defined in Section&nbsp;3(3) of
the Employee Retirement Income Security Act of 1974 (&#147;<U>ERISA</U>&#148;) , and any other (i)&nbsp;written
or oral employee benefit plan, scheme, program, policy, arrangement and contract (ii)&nbsp;bonus,
deferred compensation, stock bonus, stock purchase, restricted stock, stock option or other
equity-based arrangement, and (iii)&nbsp;employment, termination, retention, bonus, change in control or
severance agreement, plan, program, policy, arrangement or contract for the benefit of any current
or former director, officer, employee or consultant of the Company or any Subsidiary that, in each
case, is maintained, sponsored or contributed to, or required to be contributed to, by the Company
or any Subsidiary, or to which the Company or a Subsidiary is party, or with respect to which any
of them could incur liability under the Code or ERISA or any similar non-U.S. law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Rights Agreement</U>&#148; shall mean the Amended and Restated Shareholder Protection
Rights Agreement dated as of May&nbsp;29, 2002, between the Company and American Stock Transfer &#038; Trust
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stock Plan</U>&#148; shall mean any Company Plan pursuant to which shares of Company
Common Stock have been reserved for issuance.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>GAAP</U>&#148; shall mean generally accepted accounting principles in the United States.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Governmental Authority</U>&#148; shall mean any government, court, regulatory or
administrative agency, commission or authority or other governmental instrumentality, federal,
state or local, domestic, foreign or multinational.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Hazardous Material</U>&#148; means all substances or materials regulated as hazardous, toxic,
explosive, dangerous, flammable or radioactive under any Environmental Law, including (i)
petroleum, petroleum products and by-products, asbestos and asbestos-containing materials, urea
formaldehyde foam insulation, medical or infectious wastes, polychlorinated biphenyls, radon gas,
radioactive substances, chlorofluorocarbons and all other ozone-depleting substances, (ii)&nbsp;in the
United States, all substances defined as Hazardous Substances, Oils, Pollutants or Contaminants in
the National Oil and Hazardous Substances Pollution Contingency Plan, 40 C.F.R. Section&nbsp;300.5. and
(iii)&nbsp;any other chemical, material, substance, waste, pollutant, emission, discharge, release or
contaminant that could result in liability under, or that is prohibited, limited or regulated by or
pursuant to, any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>HSR Act</U>&#148; shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Knowledge</U>&#148; shall mean (i)&nbsp;in the case of Parent, the actual knowledge, after due
inquiry, of any officer of Parent and (ii)&nbsp;in the case of the Company, the actual knowledge, after
due inquiry, of any officer of the Company, including the President and Chief Executive Officer,
the Chief Financial Officer and Treasurer, the Senior Vice President, Sales and Marketing, the
Senior Vice President and Chief Medical Officer, the Vice President, Business Development and
Strategic Planning, and the Vice President, General Counsel and Secretary; <U>provided</U> that,
for the purposes of clause (ii), &#147;due inquiry&#148; shall not require inquiries of any Person who
provides goods or services of any nature to the Company or any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Outside Date</U>&#148; shall mean June&nbsp;30, 2008; <U>provided</U>, however, in the event that
the expiration or termination of the waiting periods applicable to the Transactions under the HSR
Act has not occurred prior to June&nbsp;30, 2008, either the Company or Parent may, upon written notice
to and without the consent of the other party, postpone the Outside Date on one or more occasions
for periods of not less than 20&nbsp;days but in no event beyond September&nbsp;30, 2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Benefit Plan</U>&#148; means any &#147;employee pension benefit plan&#148; (as defined in Section
3(2) of ERISA), any &#147;employee welfare benefit plan&#148; (as defined in Section&nbsp;3(1) of ERISA), and any
other written or oral plan, agreement or arrangement, including insurance coverage, severance
benefits, disability benefits, deferred compensation, bonuses, stock options, stock purchase,
phantom stock, stock appreciation or other forms of incentive compensation or post-retirement
compensation and all unexpired severance agreements, for the benefit of, or relating to, any
current or former employee of the Parent or any of its Subsidiaries or Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Person</U>&#148; shall mean an individual, a corporation, a limited liability company, a
partnership, an association, a trust or any other entity, including a Governmental Authority.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Purchase Date</U>&#148; shall mean the first date on which Purchaser accepts for payment
Shares tendered and not withdrawn pursuant to the Offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Release</U>&#148; means any actual or threatened spilling, leaking, pumping, pouring,
emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing or arranging for
disposal or migrating into or through the environment or any natural or man-made structure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subsidiary</U>&#148; when used with respect to any party, shall mean any corporation, limited
liability company, partnership, association, trust or other entity of which securities or other
ownership interests representing more than 50% of the equity and more than 50% of the ordinary
voting power (or, in the case of a partnership, more than 50% of the general partnership interests)
are, as of such date, owned by such party or one or more Subsidiaries of such party or by such
party and one or more Subsidiaries of such party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transactions</U>&#148; refers collectively to this Agreement, the transactions contemplated
hereby to take place on or before the Closing Date, including the Offer and the Merger, and the
transactions contemplated by the Preferred Stockholder Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following terms are defined on the page of this Agreement set forth opposite such term
below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">14d-10 Approvals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Acceptance Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alternative Transaction Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Antitrust Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Bankruptcy and Equity Exception</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Board Representation Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Certificate of Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Code</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Acquisition Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Adverse Recommendation Change</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Charter Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Common Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Compensation Arrangements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Current Reports</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Disclosure Letter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Leases</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Material Adverse Effect</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Preferred Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Preferred Stockholder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Recommendation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company SEC Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Stockholder Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Stockholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Stockholders Meeting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Confidentiality Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Contract</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Covered Stockholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CSA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">DGCL</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dissenting Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dissenting Stockholder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Environmental Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ERISA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exchange Act</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expense Payment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">FDA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">FDCA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Filed Company SEC Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnitee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnitees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Independent Director Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Independent Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">IP Licenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">IRS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Leased Real Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Licenses In</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Licenses Out</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Materially Burdensome Condition</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger Consideration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger Option</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger Option Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Minimum Condition</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">NASDAQ</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Offer Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Offer Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Option Consideration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Parent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Patents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Paying Agent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Permits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">PHSA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Preferred Stockholder Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proxy Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchaser</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Qualified Person</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Representatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Restraints</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Schedule&nbsp;14D-9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Schedule&nbsp;TO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SEC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Securities Act</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;D-1 Holders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;D-1 Preferred Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;D-1 Preferred Stock Certificate of Designation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;D-1 Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;D-1 Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Software</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SOX</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Superior Proposal</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Takeover Proposal</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Returns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Termination Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Trademarks</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8.12 <U>Interpretation</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The table of contents and headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the
words &#147;<U>include</U>&#148;, &#147;<U>includes</U>&#148; or &#147;<U>including</U>&#148; are used in this Agreement, they
shall be deemed to be followed by the words &#147;<U>without limitation</U>&#148;. Except as otherwise
specifically provided for in this Agreement, the words &#147;<U>hereof</U>&#148;, &#147;<U>herein</U>&#148; and
&#147;<U>hereunder</U>&#148; and words of similar import when used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this Agreement. All terms defined in
this Agreement shall have the defined meanings when used in any document made or delivered pursuant
hereto unless otherwise defined therein. The definitions contained in this Agreement are
applicable to the singular as well as the plural forms of such terms and to the masculine as well
as to the feminine and neuter genders of such terms. Any agreement, instrument or statute defined
or referred to herein or in any agreement or instrument that is referred to herein means such
agreement, instrument or statute as from time to time amended, modified or supplemented, including
(in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by
succession of comparable successor statutes and references to all attachments thereto and
instruments incorporated therein. References to a Person are also to its permitted successors and
assigns.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The parties hereto have participated jointly in the negotiation and drafting of this
Agreement and, in the event an ambiguity or question of intent or interpretation arises, this
Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision
of this Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed
and delivered as of the date first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GALDERMA LABORATORIES, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Albert Draaijer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GALDERMA ACQUISITION INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Albert Draaijer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Treasurer and Vice President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">COLLAGENEX PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Colin W. Stewart&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Agreement and Plan of Merger&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">ANNEX A
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Conditions to the Offer</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The capitalized terms used in this <U>Annex A</U> have the meanings set forth in the
Agreement to which this <U>Annex A</U> is attached, except that the term &#147;the Agreement&#148; shall be
deemed to refer to such Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of the Offer, Purchaser shall not be required to accept
for payment or, subject to any applicable rules and regulations of the SEC, including Rule&nbsp;14e-l(c)
under the Exchange Act (relating to Purchaser&#146;s obligation to pay for or return tendered Shares
promptly after termination or withdrawal of the Offer), pay for, and may delay the acceptance for
payment of or, subject to the restriction referred to above, the payment for, any tendered Shares,
and (subject to the provisions of the Agreement) may terminate the Offer and not accept for payment
any tendered Shares if (i)&nbsp;the Minimum Condition shall not have been satisfied at the expiration of
the Offer, (ii)&nbsp;any applicable waiting period under the HSR Act (and any extension thereof) shall
not have expired or been terminated prior to the expiration of the Offer, (iii)&nbsp;any Materially
Burdensome Condition shall have been imposed in connection with obtaining any approvals or
terminations described in clause (ii), or (iv)&nbsp;immediately prior to the expiration of the Offer,
any of the following conditions shall exist:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>there shall be any Restraint which enjoins, restrains, prevents or prohibits the making
or consummation of the Offer or the Merger or makes the making or consummation of the Offer
or the consummation of the Merger illegal or imposes a Materially Burdensome Condition;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>there shall be instituted or pending any Action or Proceeding brought by a Governmental
Authority challenging the acquisition by Parent or Purchaser of the Shares or otherwise
seeking to enjoin, restrain, prevent or prohibit the making or consummation of the Offer or
the Merger or impose a Materially Burdensome Condition;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(i)&nbsp;any representation or warranty of the Company contained in <U>Section&nbsp;3.2(a)</U>
and <U>Section&nbsp;3.2(b)</U> (other than clauses (B)&nbsp;and (C)&nbsp;of the first sentence of
<U>Section&nbsp;3.2(b)</U> and the last sentence of <U>Section&nbsp;3.2(b)</U>) shall not be true
and correct (except for any <I>de minimus inaccuracy</I>), (ii)&nbsp;any representation or warranty
contained in clauses (B)&nbsp;and (C)&nbsp;of the first sentence of <U>Section&nbsp;3.2(b)</U> or
<U>Section&nbsp;3.11(d)</U> shall not be true and correct in all material respects, and (iii)
any representation or warranty of the Company contained in any other section of the
Agreement shall not be true and correct (without giving effect to any qualifications or
limitations as to materiality, or Company Material Adverse Effect set forth therein), in
the case of each of clauses (i), (ii)&nbsp;and (iii), as of the date of determination as though
made on the date of determination (except to the extent that such representation or
warranty expressly relates to a specified date, in which case as of such specified date),
except, in the case of this clause (iii), where the failure of such representations and
warranties to be true and correct as of such dates, individually or in the aggregate, has
not had and could not reasonably be expected to have a Company Material Adverse Effect;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company shall not have performed in all material respects all agreements, covenants
and obligations required to be performed by it under the Agreement at or prior to the date
of determination;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company shall not have furnished Parent with a certificate dated as of the date of
determination signed on its behalf by its Chief Executive Officer or Chief Financial
Officer to the effect that the conditions set forth in paragraphs (c)&nbsp;and (d)&nbsp;of this Annex
A shall not have occurred and continue to exist;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>there shall have occurred any change, event, effect or occurrence arising since the
date of this Agreement that has had or would reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than filings pursuant to the HSR Act, any consent, approval or authorization of
any Governmental Entity required to consummate the Offer or the Merger shall not have been
obtained, unless the failure to obtain such consent, approval or authorization has not had
and could not reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Agreement shall have been terminated in accordance with its terms; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Preferred Stockholder Agreement shall have been terminated or any Company Preferred
Stockholder shall have failed to comply with the Preferred Stock Agreement in any material
respect and, as a result of such failure, Parent will not be able to cause the Merger to
become effective as soon as practicable after the Acceptance Time in accordance with
Section&nbsp;253 of the DGCL.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing conditions are for the sole benefit of Parent and Purchaser and, subject to the
terms and conditions of the Agreement, may be waived by Parent or Purchaser, in whole or in part,
at any time and from time to time in the sole discretion of Parent or Purchaser. The failure by
Parent or Purchaser at any time to exercise any of the foregoing rights shall not be deemed a
waiver of any such right and each such right shall be deemed an ongoing right which may be asserted
at any time and from time to time.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->A-2<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">ANNEX B
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PREFERRED STOCK PURCHASE AND VOTING AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS PREFERRED STOCK PURCHASE AND VOTING AGREEMENT (this &#147;<U>Agreement</U>&#148;), dated as of
February&nbsp;25, 2008, is made and entered into by and among Galderma Laboratories, Inc., a Delaware
corporation (&#147;<U>Parent</U>&#148;), Galderma Acquisition Inc., a Delaware corporation and a wholly
owned subsidiary of Parent (&#147;<U>Purchaser</U>&#148;), and the persons listed on <U>Schedule&nbsp;I</U>
hereto (collectively, the &#147;<U>Company Preferred Stockholders</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, concurrently with the execution and delivery of this Agreement, Parent, Purchaser and
CollaGenex Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), are entering into
an Agreement and Plan of Merger, dated as of the date hereof (as it exists on the date hereof, the
&#147;<U>Original Merger Agreement</U>&#148;, or as it may be amended from time to time, the &#147;<U>Merger
Agreement</U>&#148;; capitalized terms used herein without definition shall have the respective meanings
ascribed to them in the Merger Agreement), pursuant to which, among other things, (<U>a</U>)
Purchaser will commence a tender offer to purchase all of the outstanding shares of common stock,
par value $0.01, of the Company (&#147;<U>Company Common Stock</U>&#148;) (such offer as it may be amended
from time to time as permitted by the Merger Agreement, the &#147;<U>Offer</U>&#148;), and (<U>b</U>)
following the consummation of the Offer, Purchaser will be merged with and into the Company (the
&#147;<U>Merger</U>&#148;), with the Company being the surviving corporation, all upon the terms and subject
to the conditions set forth in the Merger Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as of the date hereof, each Company Preferred Stockholder is the record or
&#147;beneficial holder&#148; (as defined under Rule&nbsp;13d-3 under the Exchange Act) of the number of issued
and outstanding shares of Series&nbsp;D-1 Cumulative Convertible Preferred Stock, par value $0.01, of
the Company (the &#147;<U>Series&nbsp;D-1 Preferred Stock</U>&#148;), set forth opposite such Company Preferred
Stockholder&#146;s name on <U>Schedule&nbsp;I</U> hereto (all such shares of Series&nbsp;D-1 Preferred Stock, the
&#147;<U>Subject Shares</U>&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as a condition to their willingness to enter into the Merger Agreement, Parent and
Purchaser have requested that each Company Preferred Stockholder enter into this Agreement, and
each Company Preferred Stockholder has agreed to do so in order to induce Parent and Purchaser to
enter into, and in consideration of their entering into, the Merger Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and of the representations, warranties,
covenants and agreements herein contained, and intending to be legally bound hereby, the parties
hereto agree as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE I

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Purchase and Sale of Subject Shares</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.1. <U>Sale and Purchase of Subject Shares</U>. Upon the terms and subject to the
conditions contained herein, at the Closing (as defined below) each Company Preferred Stockholder
shall sell, convey, transfer, assign and deliver to Purchaser such Company Preferred Stockholder&#146;s
Subject Shares, free and clear of all liens, pursuant to this Agreement (the &#147;<U>Sale</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.2. <U>Consideration for the Subject Shares</U>. Upon the terms and subject to the
conditions contained herein, Purchaser shall (and Parent shall cause Purchaser to) pay to each
Company Preferred Stockholder an amount equal in cash to the product of the number of shares of
Company Common Stock into which such Company Preferred Stockholder&#146;s Subject Shares are convertible
pursuant to and in accordance with Section&nbsp;A.5 of the Certificate of Designation, Preferences and
Rights of the Series&nbsp;D-1 Cumulative Convertible Preferred Stock multiplied by the Offer Price (each
such amount, the &#147;<U>Purchase Price</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.3. <U>Delivery of Subject Shares</U>. At the Closing, each Company Preferred
Stockholder shall deliver to Purchaser one or more duly issued and executed stock certificates,
representing all of such Company Preferred Stockholder&#146;s Subject Shares, together with stock powers
duly executed in blank and all requisite stock transfer stamps.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.4. <U>Delivery of Purchase Price</U>. At the Closing, Purchaser shall (and Parent
shall cause Purchaser to) deliver to each Company Preferred Stockholder the Purchase Price for such
Company Preferred Stockholder&#146;s Subject Shares in immediately available funds payable to the
account designated by such Company Preferred Stockholder at least two Business Days prior to the
Closing Date (as defined below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.5. <U>Closing</U>. The closing of the sale and purchase of the Subject Shares (the
&#147;<U>Closing</U>&#148;) shall occur at the offices of Debevoise&nbsp;&#038; Plimpton LLP, 919&nbsp;Third Avenue, New
York, New York, on the first date that Purchaser becomes obligated, in accordance with the terms of
the Merger Agreement, to pay for Shares pursuant to the Offer (the date on which the Closing
occurs, the &#147;<U>Closing Date</U>&#148;).
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE II

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Voting of Subject Shares</U>.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.1. <U>Agreement to Vote</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From the date hereof until the termination of this Agreement in accordance with
<U>Section&nbsp;6.1</U>, except to the extent waived in writing by Parent in its sole and absolute
discretion, at any meeting of the stockholders of the Company, however called, or at any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">adjournment thereof, or in connection with any written consent of the stockholders of the
Company or in any other circumstances upon which a vote, consent or other approval of all or some
of the stockholders of the Company is sought, each Company Preferred Stockholder shall vote (or
cause to be voted) such Company Preferred Stockholder&#146;s Subject Shares and any other shares of
capital stock of the Company owned, beneficially or of record, by such Company Preferred
Stockholder during the term of this Agreement (such shares, together with the Subject Shares, the
&#147;<U>Voting Shares</U>&#148;): (<U>a</U>) against any action, transaction or agreement that would
result in a breach of any covenant, representation or warranty or any other obligation or agreement
of the Company under the Merger Agreement or of any of the parties hereto under this Agreement; and
(<U>b</U>) against the following actions (other than the Merger and the transactions contemplated
by the Merger Agreement): (<U>i</U>) any extraordinary corporate transaction, such as a merger,
consolidation or other business combination involving the Company or any of its Subsidiaries;
(<U>ii</U>) any sale, lease or transfer of a material amount of assets of the Company or any of
its Subsidiaries; (<U>iii</U>) any reorganization, recapitalization, dissolution, liquidation or
winding up of the Company or any of its Subsidiaries; (<U>iv</U>) any change in the majority of
the board of directors of the Company; (<U>v</U>) any change in the present capitalization of the
Company or any amendment of the Company&#146;s certificate of incorporation or by-laws; (<U>vi</U>) any
other material change in the Company&#146;s corporate structure or business; and (<U>vii</U>) any other
action, transaction or proposal involving the Company or any of its Subsidiaries that is intended
or would reasonably be expected to (<U>A</U>) prevent, nullify, impede, interfere with, frustrate,
delay, postpone, discourage or otherwise materially adversely affect the Offer, the Merger, the
Merger Agreement, any of the transactions contemplated by the Merger Agreement or this Agreement or
the contemplated economic benefits of any of the foregoing or (<U>B</U>) change in any manner the
voting rights of the Subject Shares. Each Company Preferred Stockholder further agrees not to
commit or agree to take any action inconsistent with the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event that a meeting of the stockholders of the Company is held, each Company
Preferred Stockholder shall, or shall cause the holder of record on any applicable record date to,
appear at such meeting or otherwise cause its Voting Shares to be counted as present thereat for
purposes of establishing a quorum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Company Preferred Stockholder shall not enter into any agreement or understanding
with any Person to vote or give instructions in any manner inconsistent with the terms of this
<U>Section&nbsp;2</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;EACH COMPANY PREFERRED STOCKHOLDER HEREBY IRREVOCABLY GRANTS TO AND APPOINTS QUINTIN
CASSADY AND ALBERT DRAAIJER, IN THEIR RESPECTIVE CAPACITIES AS OFFICERS OF PARENT, AND ANY
INDIVIDUAL WHO SHALL HEREAFTER SUCCEED TO ANY SUCH OFFICE OF PARENT, AND EACH OF THEM INDIVIDUALLY,
SUCH COMPANY PREFERRED STOCKHOLDER&#146;S PROXY AND ATTORNEY-IN-FACT (WITH FULL POWER OF SUBSTITUTION),
FOR AND IN THE NAME, PLACE AND STEAD OF SUCH
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">COMPANY PREFERRED STOCKHOLDER, TO REPRESENT, VOTE AND OTHERWISE ACT (BY VOTING AT ANY MEETING
OF STOCKHOLDERS OF THE COMPANY, BY WRITTEN CONSENT IN LIEU THEREOF OR OTHERWISE) WITH RESPECT TO
THE VOTING SHARES OWNED OR HELD BY SUCH COMPANY PREFERRED STOCKHOLDER REGARDING THE MATTERS
REFERRED TO IN <U>SECTION&nbsp;2.1(a)</U> HEREOF UNTIL THE TERMINATION OF THIS AGREEMENT, TO THE SAME
EXTENT AND WITH THE SAME EFFECT AS SUCH COMPANY PREFERRED STOCKHOLDER MIGHT OR COULD DO UNDER
APPLICABLE LAW, RULES AND REGULATIONS. THE PROXY GRANTED PURSUANT TO THIS <U>SECTION 2.1(d)</U>
IS COUPLED WITH AN INTEREST AND SHALL BE IRREVOCABLE. EACH COMPANY PREFERRED STOCKHOLDER WILL TAKE
SUCH FURTHER ACTION AND WILL EXECUTE SUCH OTHER INSTRUMENTS AS MAY BE NECESSARY TO EFFECTUATE THE
INTENT OF THIS PROXY. EACH COMPANY PREFERRED STOCKHOLDER HEREBY REVOKES ANY AND ALL PREVIOUS
PROXIES OR POWERS OF ATTORNEY GRANTED WITH RESPECT TO ANY OF THE VOTING SHARES OWNED OR HELD BY
SUCH COMPANY PREFERRED STOCKHOLDER REGARDING THE MATTERS REFERRED TO IN <U>SECTION&nbsp;2.1(a)</U>
HEREOF. THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER PARENT, NOR ANY OF ITS SUCCESSORS, ASSIGNS,
AFFILIATES, SUBSIDIARIES, EMPLOYEES, OFFICERS, DIRECTORS, STOCKHOLDERS, AGENTS OR OTHER
REPRESENTATIVES, SHALL INCUR ANY LIABILITY TO ANY STOCKHOLDER IN CONNECTION WITH OR AS A RESULT OF
ANY EXERCISE OF THE PROXY GRANTED TO PARENT PURSUANT TO THIS <U>SECTION 2.1(d)</U>, OTHER THAN FOR
A BREACH OF THIS <U>SECTION 2.1(d)</U>. NOTWITHSTANDING THE FOREGOING, THIS PROXY SHALL TERMINATE
UPON TERMINATION OF THIS AGREEMENT IN ACCORDANCE WITH ITS TERMS.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE III

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Representations and Warranties of Each Company Preferred Stockholder</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Preferred Stockholder hereby severally, and not jointly, represents and warrants
to Parent and Purchaser (as to such Company Preferred Stockholder) as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.1. <U>Authority</U>. Such Company Preferred Stockholder has all necessary legal
capacity, power, and authority to execute and deliver this Agreement and to consummate the
transactions contemplated by this Agreement. The execution and delivery of this Agreement by such
Company Preferred Stockholder and the consummation of the transactions contemplated by this
Agreement have been duly authorized by all necessary action on the part of such Company Preferred
Stockholder and, assuming the due authorization, execution, and delivery of this Agreement by
Parent, Purchaser and each other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company Preferred Stockholder, this Agreement constitutes a legal, valid, and binding
obligation of such Company Preferred Stockholder, enforceable against such Company Preferred
Stockholder in accordance with its terms, subject to the Bankruptcy and Equity Exception.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.2. <U>Ownership of Subject Shares; Total Shares</U>. Such Company Preferred
Stockholder is the record or beneficial owner (as defined in Rule&nbsp;13d-3 under the Exchange Act) of,
and has good title to, the Subject Shares listed beside such Company Preferred Stockholder&#146;s name
on <U>Schedule&nbsp;I</U> attached hereto, free and clear of all claims, liens, encumbrances and
security interests of any nature whatsoever (including any restriction on the right to vote or
otherwise transfer such Subject Shares), except as provided hereunder or pursuant to any applicable
restrictions on transfer under the Securities Act. As of the date hereof, such Company Preferred
Stockholder does not own, beneficially or otherwise, any Shares, Company Options or other
securities of the Company other than as set forth opposite such Company Preferred Stockholder&#146;s
name in <U>Schedule&nbsp;I</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.3. <U>Voting Power</U>. Such Company Preferred Stockholder has sole voting power
and sole power to issue instructions with respect to the matters set forth in this Agreement, sole
power of disposition with respect to dispositions contemplated by this Agreement, and sole power to
agree to all of the matters set forth in this Agreement, in each case with respect to all of such
Company Preferred Stockholder&#146;s Voting Shares, with no material limitations, qualifications, or
restrictions on such rights, subject only to applicable securities laws and the terms of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.4. <U>Consents and Approvals; No Violation</U>. (<U>i</U>) Except as may be set
forth in the Merger Agreement (including, without limitation, filings as may be required under
applicable securities laws), no filing with, and no permit, authorization, consent, or approval of,
any Governmental Authority is necessary for the execution of this Agreement by such Company
Preferred Stockholder and the consummation by such Company Preferred Stockholder of the
transactions contemplated by this Agreement, and (<U>ii</U>) none of the execution and delivery of
this Agreement by such Company Preferred Stockholder, the consummation by such Company Preferred
Stockholder of the transactions contemplated by this Agreement or compliance by such Company
Preferred Stockholder with any of the provisions of this Agreement shall (<U>A</U>) conflict with
or result in any breach of the organizational documents, if applicable, of such Company Preferred
Stockholder, (<U>B</U>) result in a material violation or material breach of, or constitute (with
or without notice or lapse of time, or both) a default (or give rise to any third party right of
termination, cancellation, amendment, or acceleration) under any of the terms, conditions, or
provisions of any material note, bond, mortgage, indenture, license, contract, commitment,
arrangement, understanding, agreement, or other instrument or obligation of any kind to which such
Company Preferred Stockholder is a party, or (<U>C</U>) subject to compliance with filing
requirements as may be required under applicable securities laws, violate any order, writ,
injunction, decree, judgment, statute, rule, or regulation applicable to such Company Preferred
Stockholder,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">except in each case under clauses (A), (B)&nbsp;and (C), where the absence of filing or
authorization, conflict, violation, breach, or default would not materially impair or materially
adversely affect the ability of such Company Preferred Stockholder to perform such Company
Preferred Stockholder&#146;s obligations hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.5. <U>No Finder&#146;s Fees</U>. Except as contemplated by the Merger Agreement, no
broker, investment banker, financial advisor, or other person is entitled to any broker&#146;s,
finder&#146;s, financial advisor&#146;s, or other similar fee or commission in connection with the
transactions contemplated by this Agreement based upon arrangements made by or on behalf of such
Company Preferred Stockholder.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE IV

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Representations and Warranties of Parent and Purchaser</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Purchaser hereby represent and warrant to the Company Preferred Stockholders as of
the date of this Agreement as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.1. <U>Organization</U>. Each of Parent and Purchaser is a corporation duly
organized, validly existing, and in good standing under the laws of the jurisdiction of its
incorporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.2. <U>Corporate Authorization; Validity of Agreement; Necessary Action</U>. Parent
and Purchaser have the corporate power and authority to execute and deliver this Agreement and to
consummate the transactions contemplated by this Agreement. The execution and delivery of this
Agreement by Parent and Purchaser and the consummation of the transactions contemplated by this
Agreement have been duly authorized by all necessary action on the part of Parent and Purchaser,
and, assuming the due authorization, execution and delivery thereof by the Company and each of the
Company Preferred Stockholders, constitutes a valid and legally binding agreement of Parent and
Purchaser enforceable against each of them in accordance with its terms, subject to the Bankruptcy
and Equity Exception.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.3. <U>Consents and Approvals; No Violation</U>. (<U>i</U>) Except as may be set
forth in the Merger Agreement (including, without limitation, filings as may be required under
applicable securities laws), no filing with, and no permit, authorization, consent, or approval of,
any Governmental Authority is necessary for the execution of this Agreement by each of Parent and
Purchaser and the consummation by each of Parent and Purchaser of the transactions contemplated by
this Agreement, and (<U>ii</U>) none of the execution and delivery of this Agreement by each of
Parent and Purchaser, the consummation by each of Parent and Purchaser of the transactions
contemplated by this Agreement or compliance by each of Parent and Purchaser with any of the
provisions of this Agreement shall (<U>A</U>) conflict with or result in any breach of the
organizational documents Parent or Purchaser, (<U>B</U>) result in a material violation or
material breach of, or constitute (with or without notice or lapse of time, or both) a default (or
give rise to any third party right of termination, cancellation,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">amendment, or acceleration) under any of the terms, conditions, or provisions of any material
note, bond, mortgage, indenture, license, contract, commitment, arrangement, understanding,
agreement, or other instrument or obligation of any kind to which Parent or Purchaser is a party,
or (<U>C</U>) subject to compliance with filing requirements as may be required under applicable
securities laws, violate any order, writ, injunction, decree, judgment, statute, rule, or
regulation applicable to Parent or Purchaser, except in each case under clauses (A), (B)&nbsp;or (C),
where the absence of filing or authorization, conflict, violation, breach, or default would not
materially impair or materially adversely effect the ability of each of Parent and Purchaser to
perform its obligations hereunder.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE V

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Covenants of Each Company Preferred Stockholder</U>

</DIV>

<DIV align="LEFT" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Preferred Stockholder severally covenants and agrees as follows:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.1. <U>Restriction on Transfer, Proxies, and Non-Interference</U>. Except as
contemplated by this Agreement or the Merger Agreement, during the period beginning from the
execution and delivery by the parties of this Agreement through the earlier of (<U>1</U>) the
Effective Time, (<U>2</U>) the termination of the Merger Agreement or (<U>3</U>) the termination
of this Agreement in accordance with <U>Section&nbsp;6.1</U>, each Company Preferred Stockholder shall
not (<U>i</U>) directly or indirectly, offer for sale, sell, transfer, tender, pledge, encumber,
assign, or otherwise dispose of (each, a &#147;<U>Transfer</U>&#148;), or enter into any contract, option,
or other arrangement or understanding (including any profit sharing arrangement) with respect to
the Transfer of, any or all of such Company Preferred Stockholder&#146;s Voting Shares or any other
securities of the Company or any interest therein to any Person, other than pursuant to the Merger
Agreement or the Offer, (<U>ii</U>) grant any proxies or powers of attorney, or any other
authorization or consent with respect to any or all of such Company Preferred Stockholder&#146;s Voting
Shares that could reasonably be expected to impede, interfere with or prevent the Merger,
(<U>iii</U>) deposit any of such Company Preferred Stockholder&#146;s Voting Shares into a voting trust
or enter into a voting agreement with respect to any of such Company Preferred Stockholder&#146;s Voting
Shares, other than pursuant to this Agreement or (<U>iv</U>) take any action that would make any
representation or warranty of such Company Preferred Stockholder contained in this Agreement untrue
or incorrect in any material respect or that would reasonably be expected to have the effect of
preventing or disabling or delaying such Company Preferred Stockholder from performing such Company
Preferred Stockholder&#146;s obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.2. <U>Stop Transfer; Changes in Voting Shares</U>. Each Company Preferred
Stockholder agrees with, and covenants to, Parent and Purchaser that (<U>i</U>) this Agreement and
the obligations hereunder shall attach to such Company Preferred Stockholder&#146;s Voting Shares and
shall be binding upon any person or entity to which legal or beneficial ownership
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall pass, whether by operation of law or otherwise, and (<U>ii</U>) such Company Preferred
Stockholder shall not request that the Company register the transfer (book-entry or otherwise) of
any certificate or uncertificated interest representing any or all of the Company Preferred
Stockholder&#146;s Voting Shares, unless such transfer is made in compliance with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.3. <U>Appraisal Rights</U>. Each Company Preferred Stockholder hereby waives any
rights of appraisal or rights to dissent from the Merger that such Company Preferred Stockholder
may have (including, without limitation, under Section&nbsp;262 of the DGCL).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.4. <U>Additional Securities; Certain Events</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event any Company Preferred Stockholder becomes the record or beneficial owner of
(<U>i</U>) any shares of Company Common Stock or any other securities of the Company, (<U>ii</U>)
any securities which may be converted into or exchanged for such shares or other securities or
(<U>iii</U>) any securities issued in replacement of, or as a dividend or distribution on, or
otherwise in respect of, such shares or other securities (collectively, &#147;<U>Additional
Securities</U>&#148;), then the terms of this Agreement shall apply to any of such Additional Securities
and such Additional Securities shall be considered Voting Shares for purposes hereof. Each Company
Preferred Stockholder agrees not to purchase or in any other manner acquire beneficial ownership of
any Additional Securities without Parent&#146;s prior written consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Company Preferred Stockholder agrees that this Agreement and the obligations
hereunder shall attach to the Voting Shares and shall be binding upon any Person to which legal or
beneficial ownership of the Voting Shares shall pass, whether by operation of law or otherwise,
including, without limitation, such Company Preferred Stockholder&#146;s successors or assigns.
Notwithstanding any Transfer of the Voting Shares, the transferor shall remain liable for the
performance of all of the obligations of the Company Preferred Stockholder under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.5. <U>Stockholder Capacity</U>. Each Company Preferred Stockholder enters into
this Agreement solely in its capacity as the record or beneficial owner of the Voting Shares.
Nothing contained in this Agreement shall limit the rights and obligations of any Company Preferred
Stockholder, any of its Affiliates, Representatives or any employee of any of its Affiliates in his
or her capacity as a director or officer of the Company, and the agreements set forth herein shall
in no way restrict any director or officer of the Company in the exercise of his or her fiduciary
duties as a director or officer of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.6. <U>Documentation and Information</U>. Each Company Preferred Stockholder
(<U>i</U>) consents to and authorizes the publication and disclosure by Parent and its affiliates
of its identity and holding of Subject Shares and the nature of its commitments and obligations
under this Agreement in any announcement or disclosure required by the SEC or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other Governmental Authority, the Offer Documents, or any other disclosure document in
connection with the Offer, the Merger or any of the other transactions contemplated by the Merger
Agreement or this Agreement, and (<U>ii</U>) agrees promptly to give to Parent any information it
may reasonably require for the preparation of any such disclosure documents. Each Company
Preferred Stockholder agrees to promptly notify Parent of any required corrections with respect to
any written information supplied by it specifically for use in any such disclosure document, if and
to the extent that any shall have become false or misleading in any material respect.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE VI

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Termination</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.1. This Agreement and the covenants and agreements set forth in this Agreement
(<U>a</U>) shall automatically (without any further action of the parties) terminate upon the
termination of the Original Merger Agreement or the Merger Agreement in accordance with its terms
and (<U>b</U>) shall be terminable by the Company Preferred Stockholders holding a majority of the
Series&nbsp;D-1 Preferred Stock upon (<U>i</U>) any modification or amendment of the Merger Agreement
that is adverse to the Company Preferred Stockholders in any material respect (including, without
limitation, any reduction in the Offer Price), (<U>ii</U>) any waiver by the Company of any
obligation of Parent or Purchaser under the Original Merger Agreement or the Merger Agreement,
including, without limitation, any of the Conditions of the Offer set forth in Annex A of the
Original Merger Agreement or the Merger Agreement, which such waiver is adverse to the Company
Preferred Stockholders in any material respect or (<U>iii</U>) the occurrence of a Company Adverse
Recommendation Change, <U>provided</U> that, in the case of clauses (i)&nbsp;and (ii), the Company
Preferred Stockholders holding a majority of the Series&nbsp;D-1 Preferred Stock have not consented in
writing to such modification, amendment or waiver, and except that any termination of this
Agreement pursuant to this <U>Section&nbsp;6.1</U> shall not relieve any party from liability for any
breach hereof prior to such termination. If this Agreement shall be terminated pursuant to this
<U>Section&nbsp;6.1</U>, no Sale shall occur.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ARTICLE VII

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Miscellanous</U>

</DIV>

<DIV align="LEFT" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.1. <U>Governing Law; Jurisdiction; Waiver of Jury Trial</U>.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Agreement shall be governed by, and construed in accordance with, the Laws of the
State of Delaware applicable to Contracts executed in and to be performed entirely within that
State, regardless of the laws that might otherwise govern under applicable principles of conflicts
of laws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All Actions or Proceedings arising out of or relating to this Agreement shall be heard and
determined in the Chancery Court of the State of Delaware, and the parties hereto hereby
irrevocably submit to the exclusive jurisdiction of such court (and, in the case of appeals,
appropriate appellate courts therefrom) in any such Action or Proceeding and irrevocably waive the
defense of an inconvenient forum to the maintenance of any such Action or Proceeding. The consents
to jurisdiction set forth in this paragraph shall not constitute general consents to service of
process in the State of Delaware and shall have no effect for any purpose except as provided in
this paragraph and shall not be deemed to confer rights on any Person other than the parties
hereto. The parties hereto agree that a final judgment in any such Action or Proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of the parties hereto hereby irrevocably waives any and all rights to trial by jury
in any legal proceeding arising out of or related to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.2. <U>Specific Performance</U>. Each Company Preferred Stockholder acknowledges
and agrees that (<U>a</U>) the covenants, obligations and agreements of such Company Preferred
Stockholder contained in this Agreement relate to special, unique and extraordinary matters,
(<U>b</U>) Parent is and will be relying on such covenants, obligations and agreements in
connection with entering into the Merger Agreement and the performance of Parent&#146;s obligations
under the Merger Agreement, and (<U>c</U>)&nbsp;a violation of any of the covenants, obligations or
agreements of such Company Preferred Stockholder contained in this Agreement will cause Parent
irreparable injury for which adequate remedies are not available at law. Therefore, each Company
Preferred Stockholder agrees that Parent shall be entitled to an injunction, restraining order or
such other equitable relief (without the requirement to post bond) as a court of competent
jurisdiction may deem necessary or appropriate to restrain such Company Preferred Stockholder, as
the case may be, from committing any violation of such covenants, obligations or agreements and to
specifically enforce the terms of this Agreement. These injunctive remedies are cumulative and in
addition to any other rights and remedies Parent may have under applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.3. <U>Assignment; No Third Party Beneficiaries</U>. This Agreement shall not be
assignable or otherwise transferable by a party without the prior consent of the other parties, and
any attempt to so assign or otherwise transfer this Agreement without such consent shall be void
and of no effect; <U>provided</U>, <U>however</U>, that Parent may, in its sole discretion,
assign or transfer all or any of its rights, interests and obligations under this Agreement to any
direct or indirect wholly owned subsidiary of Parent, but no such assignment shall relieve Parent
from its obligations under this Agreement. This Agreement shall be binding upon the respective
heirs, successors, legal representatives and permitted assigns of the parties hereto. Nothing in
this Agreement shall be construed as giving any Person, other than the parties hereto and their
heirs, successors, legal representatives and permitted assigns, any right, remedy or claim under or
in respect of this Agreement or any provision hereof; <U>provided</U>, <U>however</U>, that the
Company shall be a third party beneficiary of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the obligations of the parties to this Agreement and shall be entitled to enforce those
obligations as though a party hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.4. <U>Amendments, Waivers, etc</U>. Neither this Agreement nor any term hereof may
be amended other than by an instrument in writing signed by Parent, Purchaser and the Company
Preferred Stockholders. No provision of this Agreement may be waived, discharged or terminated
other than by an instrument in writing signed by the party against whom the enforcement of such
waiver, discharge or termination is sought, except that this Agreement may be terminated as set
forth in <U>Section&nbsp;6.1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.5. <U>Notices</U>. All notices, requests and other communications to any party
hereunder shall be in writing and shall be deemed given if delivered either personally, by
facsimile transmission (with acknowledgment received), by electronic mail (with receipt confirmed)
or by overnight courier (providing proof of delivery) to the parties at the following addresses:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to the Company Preferred Stockholders: At the address set forth beside each Company
Preferred Stockholder&#146;s name listed on <U>Schedule&nbsp;I</U>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">If to Parent or Purchaser, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Galderma Laboratories, Inc.<BR>
c/o Galderma Laboratories, L.P.<BR>
14501 North Freeway<BR>
Fort Worth, TX 76177<BR>
Attention: Albert Draaijer, President<BR>
Facsimile: (817)&nbsp;961-0035<BR>
E-mail: albert.draaijer@galderma.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">with a copy (which shall not constitute notice) to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Galderma Laboratories, Inc.<BR>
c/o Galderma Laboratories, L.P.<BR>
14501 North Freeway<BR>
Fort Worth, TX 76177<BR>
Attention: Quintin Cassidy, General Counsel<BR>
Facsimile: (817)&nbsp;961-0034<BR>
E-mail: quintin.cassady@galderma.com
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">with a copy (which shall not constitute notice) to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Debevoise &#038; Plimpton LLP<BR>
919 Third Avenue<BR>
New York, New York 10022<BR>
Attention: Paul S. Bird, Esq.<BR>
Facsimile: (212)&nbsp;909-6836<BR>
E-mail: psbird@debevoise.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or such other address, facsimile number or email address as such party may hereafter specify by
notice to the other parties hereto. All such notices, requests and other communications shall be
deemed received on the date of receipt by the recipient thereof if received prior to 5 P.M. in the
place of receipt and such day is a Business Day in the place of receipt. Otherwise, any such
notice, request or communication shall be deemed not to have been received until the next
succeeding Business Day in the place of receipt.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.6. <U>Expenses</U>. Except as otherwise provided herein, all costs and expenses
incurred in connection with the transactions contemplated by this Agreement shall be paid by the
party incurring such costs and expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.7. <U>Remedies</U>. No failure or delay by any party in exercising any right,
power or privilege under this Agreement shall operate as a waiver thereof nor shall any single or
partial exercise thereof preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. The rights and remedies provided herein shall be cumulative and
not exclusive of any rights or remedies provided by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.8. <U>Severability</U>. If any term or provision of this Agreement is held to be
invalid, illegal, incapable of being enforced by any rule of law, or public policy, or
unenforceable for any reason, it shall be adjusted rather than voided, if possible, in order to
achieve the intent of the parties hereto to the maximum extent possible. In any event, the
invalidity or unenforceability of any provision of this Agreement in any jurisdiction shall not
affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or
the validity or enforceability of this Agreement, including that provision, in any other
jurisdiction. Upon such determination that any term or other provision is invalid, illegal or
incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in a mutually
acceptable manner in order that the terms of this Agreement remain as originally contemplated to
the fullest extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.9. <U>Entire Agreement</U>. This Agreement constitutes the entire agreement among
the parties with respect to the subject matter of this Agreement and supersedes all other prior
agreements and understandings, both written and oral, between the parties with respect to the
subject matter of this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.10. <U>Further Assurances</U>. From time to time at the request of Parent, and
without further consideration, each Company Preferred Stockholder shall execute and deliver or
cause to be executed and delivered such additional documents and instruments and take all such
further action as may be reasonably necessary or desirable to effect the matters contemplated by
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.11. <U>Section&nbsp;Headings</U>. The article and section headings used in this
Agreement are inserted for convenience of reference only and are not intended to be part of or to
affect the meaning or interpretation of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.12. <U>Public Announcements</U>. No Company Preferred Stockholder shall issue any
press release or make any other public statement with respect to the transactions contemplated by
this Agreement and the Merger Agreement without the prior written consent of Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.13. <U>Counterparts</U>. This Agreement may be executed in two or more
counterparts, each of which when executed shall be deemed to be an original but all of which taken
together shall constitute one and the same agreement. Delivery of an executed counterpart of a
signature page to this Agreement by telecopier shall be effective as delivery of a manually
executed counterpart of this Agreement.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;SIGNATURE PAGES FOLLOW&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">GALDERMA LABORATORIES, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Albert Draaijer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: President</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">GALDERMA ACQUISITION INC.</TD>
</TR>
<TR><TD style="font-size: 10pt">&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Albert Draaijer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Treasurer and Vice President</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;Signature Page to Preferred Stock Purchase Agreement&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert J. Easton</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;Signature Page to Preferred Stock Purchase Agreement&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Cutchogue
Point&nbsp;AP,&nbsp;LLC</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD nowrap align="left" valign="top">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR></TD>
</TR>



<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Richard&nbsp;A. Horstmann,
as Managing Member</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;Signature Page to Preferred Stock Purchase Agreement&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">OCM PRINCIPAL OPPORTUNITIES FUND, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">OCM Principal Opportunities Fund GP, LLC</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Oaktree Capital Management, L.P.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Managing Member</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;Signature Page to Preferred Stock Purchase Agreement&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">PEBBLEBROOK PARTNERS, LTD.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Stuart Schube</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: General Partner</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;Signature Page to Preferred Stock Purchase Agreement&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>SCHEDULE I</U>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Company Preferred Stockholder</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares of Series D-1</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>(Name and Address)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OCM Principal Opportunities Fund, L.P.<br>
c/o Oaktree Capital Management, LLC<br>
333 South Grand Avenue, 28<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor<br>
Los Angeles, California 90071<br>
Attention: Stephen A. Kaplan<br>
Facsimile: (213)&nbsp;830-6395<br>
E-mail: skaplan@oaktreecap.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">177,000</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">With a copy (which shall not constitute notice)
to:<br>
Skadden, Arps, Slate, Meagher &#038; Flom LLP<br>
300 South Grand Avenue, Suite&nbsp;3400<br>
Los Angeles, California 90071-3144<br>
Attention: Jeffrey H. Cohen<br>
Facsimile: (213)&nbsp;621-5288<br>
E-Mail: jcohen@skadden.com</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cutchogue
Point&nbsp;AP,&nbsp;LLC<br>
XXXXX<br>
Bernardsville, NJ&nbsp; 07924<br>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10,000</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert J. Easton<br>
XXXXX<br>
New York, NY 10021
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2,000</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Pebblebrook Partners Ltd.<br>
XXXXX<br>
Houston, TX 77005
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1,000</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;I-1

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
